<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5â€‰years after the initial analysis</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":2.835205,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpYAwYIBVoNAR9SSkYMVgoHEkkZTAJdVlwcVwVUVk9XB1tUCQcPHQNACg4=","queueTime":0,"ttGuid":"719d43e90bdf974b"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/full">
<meta property="description" name="description" content="Background: Approximately half of hypertrophic cardiomyopathy (HCM) patients lack a precise genetic diagnosis. The likelihood of identifying clinically relev...">
<meta property="og:title" name="title" content="Frontiers | Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5â€‰years after the initial analysis">
<meta property="og:description" name="description" content="Background: Approximately half of hypertrophic cardiomyopathy (HCM) patients lack a precise genetic diagnosis. The likelihood of identifying clinically relev...">
<meta name="keywords" content="HCM,Exome reanalysis,Sarcomeric Genes,non-sarcomeric genes,novelassociated genes,FHOD3,trim63,SVIL">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="11">
<meta name="citation_journal_title" content="Frontiers in Medicine">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Med.">
<meta name="citation_issn" content="2296-858X">
<meta name="citation_doi" content="10.3389/fmed.2024.1480947">
<meta name="citation_firstpage" content="1480947">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5â€‰years after the initial analysis">
<meta name="citation_keywords" content="HCM; Exome reanalysis; Sarcomeric Genes; non-sarcomeric genes; novelassociated genes; FHOD3; trim63; SVIL">
<meta name="citation_abstract" content="Background: Approximately half of hypertrophic cardiomyopathy (HCM) patients lack a precise genetic diagnosis. The likelihood of identifying clinically relevant variants increased over time.Methods: Herein, we conducted a gene-centric reanalysis of exome data of 200 HCM cases 5 years after the initial analysis. In this reanalysis, priority was given to genes with a matched HCM entry in OMIM database and recently emerging HCM-associated genes gathered using text mining-based literature review. Further classification of the identified genes and variants was performed using ClinGen resource and ACMG guidelines to assess the robustness of gene-disease association and the clinical actionability of the prioritized variants.Results: As expected, the majority of patients carried variants in MYBPC3 and MYH7 genes 26% (n=51) and 8% (n=16) respectively, in accordance with the initial analysis. The vast majority of pathogenic and likely pathogenic variants were found in MYBPC3 (22 out of 40 variants) and MYH7 (8 out of 16 variants) genes. Three genes, not included in the initial analysis, were identified: SVIL, FHOD3, and TRIM63. Considering only patients with unique variants in the last three genes, there was a 9% enhancement in variant identification.Importantly, SVIL variants carriers presented apical and septal HCM, aortopathies, and severe scoliosis for one patient. Ten patients (5%) carried variants in FHOD3 gene, six of them in hotspot regions (Exons 12 and 15). We identified seven variants within the TRIM63 gene in 12 patients (6%). Homozygous variants were detected in 2.5% of the cohort in MYBPC3 (n=1), MYL3 (n=1), and TRIM63 (n=3) genes.No variants were found in the ACTC1, TPM1, and TNNI3 genes in the HYPERGEN cohort. Thus, variants were identified in five out of the eight HCM core genes with high prevalence in young patients. We identified variants in three recent HCMassociated genes (SVIL, FHOD3, and TRIM63) in 35 patients, with 18 patients carrying unique variants (9%). Our results further emphasize the usefulness of exome data reanalysis particularly in genotype-negative patients.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2024/10/09">
<meta name="citation_publication_date" content="2024/10/31">
<meta name="citation_author" content="Jaouadi, Hager ">
<meta name="citation_author_institution" content="Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France">
<meta name="citation_author" content="Morel, Victor ">
<meta name="citation_author_institution" content="Department of Medical Genetics, La Timone Hospital, AP-HM, La Timone Childrenâ€™s Hospital, France">
<meta name="citation_author" content="Martel, Helene ">
<meta name="citation_author_institution" content="Department of Cardiology, La Timone Hospital, AP-HM, France">
<meta name="citation_author" content="Lindenbaum, Pierre ">
<meta name="citation_author_institution" content="Nantes UniversitÃ©, CHU Nantes, CNRS, INSERM, lâ€™institut du Thorax, France">
<meta name="citation_author" content="Lamy de la Chapelle, Lorcan ">
<meta name="citation_author_institution" content="Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France">
<meta name="citation_author" content="Herbane, Marine ">
<meta name="citation_author_institution" content="Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France">
<meta name="citation_author" content="Lucas, Claire ">
<meta name="citation_author_institution" content="Department of Cardiology, La Timone Hospital, AP-HM, France">
<meta name="citation_author" content="Magdinier, FrÃ©dÃ©rique ">
<meta name="citation_author_institution" content="Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France">
<meta name="citation_author" content="Habib, Gilbert ">
<meta name="citation_author_institution" content="Department of Cardiology, La Timone Hospital, AP-HM, France">
<meta name="citation_author" content="Schott, Jean-Jacques ">
<meta name="citation_author_institution" content="Nantes UniversitÃ©, CHU Nantes, CNRS, INSERM, lâ€™institut du Thorax, France">
<meta name="citation_author" content="Zaffran, StÃ©phane ">
<meta name="citation_author_institution" content="Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France">
<meta name="citation_author" content="Nguyen, Karine ">
<meta name="citation_author_institution" content="Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France">
<meta name="dc.identifier" content="doi:10.3389/fmed.2024.1480947">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5â€‰years after the initial analysis","author":[{"@type":"Person","name":"Hager Jaouadi","affiliation":["Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France"]},{"@type":"Person","name":"Victor Morel","affiliation":["Department of Medical Genetics, La Timone Hospital, AP-HM, La Timone Childrenâ€™s Hospital, France"]},{"@type":"Person","name":"Helene Martel","affiliation":["Department of Cardiology, La Timone Hospital, AP-HM, France"]},{"@type":"Person","name":"Pierre Lindenbaum","affiliation":["Nantes UniversitÃ©, CHU Nantes, CNRS, INSERM, lâ€™institut du Thorax, France"]},{"@type":"Person","name":"Lorcan Lamy de la Chapelle","affiliation":["Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France"]},{"@type":"Person","name":"Marine Herbane","affiliation":["Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France"]},{"@type":"Person","name":"Claire Lucas","affiliation":["Department of Cardiology, La Timone Hospital, AP-HM, France"]},{"@type":"Person","name":"FrÃ©dÃ©rique Magdinier","affiliation":["Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France"]},{"@type":"Person","name":"Gilbert Habib","affiliation":["Department of Cardiology, La Timone Hospital, AP-HM, France"]},{"@type":"Person","name":"Jean-Jacques Schott","affiliation":["Nantes UniversitÃ©, CHU Nantes, CNRS, INSERM, lâ€™institut du Thorax, France"]},{"@type":"Person","name":"StÃ©phane Zaffran","affiliation":["Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France"]},{"@type":"Person","name":"Karine Nguyen","affiliation":["Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France","Department of Medical Genetics, La Timone Hospital, AP-HM, La Timone Childrenâ€™s Hospital, France"]}],"datePublished":"2024-10-31","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2024","isPartOf":{"@type":"PublicationVolume","volumeNumber":"11","isPartOf":{"@type":"Periodical","name":"Frontiers in Medicine"}}},"citation":["https://doi.org/10.3389/fmed.2024.1480947"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/medicine" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Medicine</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIRÂ² Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=39&amp;specialtyid=0&amp;entitytype=2&amp;entityid=602" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/medicine" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Medicine</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/dermatology" data-event="iBarJournal-sections-a_id_797">Dermatology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/family-medicine-and-primary-care" data-event="iBarJournal-sections-a_id_842">Family Medicine and Primary Care</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/gastroenterology" data-event="iBarJournal-sections-a_id_681">Gastroenterology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/gene-and-cell-therapy" data-event="iBarJournal-sections-a_id_1321">Gene and Cell Therapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/geriatric-medicine" data-event="iBarJournal-sections-a_id_790">Geriatric Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/healthcare-professions-education" data-event="iBarJournal-sections-a_id_1969">Healthcare Professions Education</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/hematology" data-event="iBarJournal-sections-a_id_752">Hematology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/hepatobiliary-diseases" data-event="iBarJournal-sections-a_id_3648">Hepatobiliary Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/infectious-diseases-pathogenesis-and-therapy" data-event="iBarJournal-sections-a_id_3379">Infectious Diseases: Pathogenesis and Therapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/intensive-care-medicine-and-anesthesiology" data-event="iBarJournal-sections-a_id_1139">Intensive Care Medicine and Anesthesiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/nephrology" data-event="iBarJournal-sections-a_id_768">Nephrology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/nuclear-medicine" data-event="iBarJournal-sections-a_id_815">Nuclear Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/obstetrics-and-gynecology" data-event="iBarJournal-sections-a_id_2526">Obstetrics and Gynecology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/ophthalmology" data-event="iBarJournal-sections-a_id_1635">Ophthalmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/pathology" data-event="iBarJournal-sections-a_id_618">Pathology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/precision-medicine" data-event="iBarJournal-sections-a_id_1307">Precision Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/pulmonary-medicine" data-event="iBarJournal-sections-a_id_678">Pulmonary Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/regulatory-science" data-event="iBarJournal-sections-a_id_1306">Regulatory Science</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/rheumatology" data-event="iBarJournal-sections-a_id_662">Rheumatology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/translational-medicine" data-event="iBarJournal-sections-a_id_1318">Translational Medicine</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/medicine/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/medicine/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/medicine/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIRÂ² Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=39&amp;specialtyid=0&amp;entitytype=2&amp;entityid=602" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/medicine" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Medicine</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/dermatology" data-event="iBarJournal-sections-a_id_797">Dermatology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/family-medicine-and-primary-care" data-event="iBarJournal-sections-a_id_842">Family Medicine and Primary Care</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/gastroenterology" data-event="iBarJournal-sections-a_id_681">Gastroenterology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/gene-and-cell-therapy" data-event="iBarJournal-sections-a_id_1321">Gene and Cell Therapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/geriatric-medicine" data-event="iBarJournal-sections-a_id_790">Geriatric Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/healthcare-professions-education" data-event="iBarJournal-sections-a_id_1969">Healthcare Professions Education</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/hematology" data-event="iBarJournal-sections-a_id_752">Hematology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/hepatobiliary-diseases" data-event="iBarJournal-sections-a_id_3648">Hepatobiliary Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/infectious-diseases-pathogenesis-and-therapy" data-event="iBarJournal-sections-a_id_3379">Infectious Diseases: Pathogenesis and Therapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/intensive-care-medicine-and-anesthesiology" data-event="iBarJournal-sections-a_id_1139">Intensive Care Medicine and Anesthesiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/nephrology" data-event="iBarJournal-sections-a_id_768">Nephrology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/nuclear-medicine" data-event="iBarJournal-sections-a_id_815">Nuclear Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/obstetrics-and-gynecology" data-event="iBarJournal-sections-a_id_2526">Obstetrics and Gynecology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/ophthalmology" data-event="iBarJournal-sections-a_id_1635">Ophthalmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/pathology" data-event="iBarJournal-sections-a_id_618">Pathology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/precision-medicine" data-event="iBarJournal-sections-a_id_1307">Precision Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/pulmonary-medicine" data-event="iBarJournal-sections-a_id_678">Pulmonary Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/regulatory-science" data-event="iBarJournal-sections-a_id_1306">Regulatory Science</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/rheumatology" data-event="iBarJournal-sections-a_id_662">Rheumatology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/translational-medicine" data-event="iBarJournal-sections-a_id_1318">Translational Medicine</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/medicine/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/medicine/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/medicine/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/medicine" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Medicine</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/dermatology" data-event="iBarJournal-sections-a_id_797">Dermatology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/family-medicine-and-primary-care" data-event="iBarJournal-sections-a_id_842">Family Medicine and Primary Care</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/gastroenterology" data-event="iBarJournal-sections-a_id_681">Gastroenterology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/gene-and-cell-therapy" data-event="iBarJournal-sections-a_id_1321">Gene and Cell Therapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/geriatric-medicine" data-event="iBarJournal-sections-a_id_790">Geriatric Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/healthcare-professions-education" data-event="iBarJournal-sections-a_id_1969">Healthcare Professions Education</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/hematology" data-event="iBarJournal-sections-a_id_752">Hematology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/hepatobiliary-diseases" data-event="iBarJournal-sections-a_id_3648">Hepatobiliary Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/infectious-diseases-pathogenesis-and-therapy" data-event="iBarJournal-sections-a_id_3379">Infectious Diseases: Pathogenesis and Therapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/intensive-care-medicine-and-anesthesiology" data-event="iBarJournal-sections-a_id_1139">Intensive Care Medicine and Anesthesiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/nephrology" data-event="iBarJournal-sections-a_id_768">Nephrology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/nuclear-medicine" data-event="iBarJournal-sections-a_id_815">Nuclear Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/obstetrics-and-gynecology" data-event="iBarJournal-sections-a_id_2526">Obstetrics and Gynecology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/ophthalmology" data-event="iBarJournal-sections-a_id_1635">Ophthalmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/pathology" data-event="iBarJournal-sections-a_id_618">Pathology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/precision-medicine" data-event="iBarJournal-sections-a_id_1307">Precision Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/pulmonary-medicine" data-event="iBarJournal-sections-a_id_678">Pulmonary Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/regulatory-science" data-event="iBarJournal-sections-a_id_1306">Regulatory Science</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/rheumatology" data-event="iBarJournal-sections-a_id_662">Rheumatology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/medicine/sections/translational-medicine" data-event="iBarJournal-sections-a_id_1318">Translational Medicine</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/medicine/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/medicine/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/medicine/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/medicine/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=39&amp;specialtyid=0&amp;entitytype=2&amp;entityid=602" data-event="iBarJournal-a-submit"><span>Submit</span><span>Â your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Med.</span><span>, 31 October 2024</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Precision Medicine</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 11 - 2024 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fmed.2024.1480947">https://doi.org/10.3389/fmed.2024.1480947</a></p><!----></div><!----><p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span><span class="ArticleLayoutHeader__isPartOfRT__title">Precision Medicine: Biomarker Testing for Diagnosis and Treatment of Cardiovascular Disease</span><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View all 6 articles" href="https://www.frontiersin.org/research-topics/48823/precision-medicine-biomarker-testing-for-diagnosis-and-treatment-of-cardiovascular-disease/magazine" target="_self" data-event="customLink-linkType-a_viewAll6Articles"><span>View all 6 articles</span></a></span></p></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5&#x2009;years after the initial analysis</h1><span class="JournalAbstract__titleWrapper__titleLabel">Updated</span></div><div class="RelatedArticles"><div class="Alert Alert--warning"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M12 10h24v28H12z"></path><path fill="var(--orange50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24Zm1.92 31.73a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92Zm0-7.68a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.49a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v13.44Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">A correction has been applied to this article in:</p><!--[--><!--]--><!----></div><ol class="Alert__info"><!--[--><li class="Alert__infoItem"><p class="Alert__infoItem__text">Corrigendum: Exome Sequencing Data Reanalysis of 200 Hypertrophic Cardiomyopathy patients: The HYPERGEN French Cohort 5 years after the initial analysis</p><ol class="Alert__infoItem__links"><!--[--><li><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--small Link--icon Link--chevronRight Link--right" aria-label="Read correction" href="/journals/medicine/articles/10.3389/fmed.2025.1595049/full" data-event="customLink-linkType-a_readCorrection"><span>Read correction</span></a></span></li><!--]--></ol></li><!--]--></ol></div></div></div><div class="JournalFullText"><div class="JournalAbstract"> <a id="h1" name="h1"></a>
 <div class="authors"><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2817503" class="user-id-2817503"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2817503/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Hager Jaouadi&#xA;">Hager Jaouadi</a><sup>1</sup><sup>&#x0002A;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2355955" class="user-id-2355955"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2355955/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Victor Morel">Victor Morel</a><sup>2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Helene Martel" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Helene Martel<sup>3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2817593" class="user-id-2817593"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2817593/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Pierre Lindenbaum">Pierre Lindenbaum</a><sup>4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Lorcan Lamy de la Chapelle" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Lorcan Lamy de la Chapelle<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Marine Herbane" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Marine Herbane<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Claire Lucas" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Claire Lucas<sup>3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/351861" class="user-id-351861"><img class="pr5" src="https://loop.frontiersin.org/images/profile/351861/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Fr&#xE;d&#xE;rique Magdinier">Fr&#x000E9;d&#x000E9;rique Magdinier</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1073045" class="user-id-1073045"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1073045/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Gilbert Habib">Gilbert Habib</a><sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jean-Jacques Schott" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jean-Jacques Schott<sup>4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1012177" class="user-id-1012177"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1012177/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="St&#xE;phane Zaffran&#xA;&#x;">St&#x000E9;phane Zaffran</a><sup>1</sup><sup>&#x0002A;</sup><sup>&#x2020;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Karine Nguyen,&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Karine Nguyen<sup>1,2</sup><sup>&#x2020;</sup></span></div> <ul class="notes"> <li><span><sup>1</sup></span>Aix Marseille Universit&#x00E9;, INSERM, Marseille Medical Genetics (MMG), U1251, Marseille, France</li> <li><span><sup>2</sup></span>Department of Medical Genetics, La Timone Hospital, AP-HM, La Timone Children&#x2019;s Hospital, Marseille, France</li> <li><span><sup>3</sup></span>Department of Cardiology, La Timone Hospital, AP-HM, Marseille, France</li> <li><span><sup>4</sup></span>Nantes Universit&#x000E9;, CHU Nantes, CNRS, INSERM, l&#x2019;institut du Thorax, Nantes, France</li> </ul>
<p class="mb15"><b>Background:</b> Approximately half of hypertrophic cardiomyopathy (HCM) patients lack a precise genetic diagnosis. The likelihood of identifying clinically relevant variants increased over time.</p>
<p class="mb15"><b>Methods:</b> In this study, we conducted a gene-centric reanalysis of exome data of 200 HCM cases 5&#x2009;years after the initial analysis. This reanalysis prioritized genes with a matched HCM entry in the OMIM database and recently emerging HCM-associated genes gathered using a text mining-based literature review. Further classification of the identified genes and variants was performed using the Clinical Genome Resource (ClinGen) resource and American College of Medical Genetics and Genomics (ACMG) guidelines to assess the robustness of gene&#x2013;disease association and the clinical actionability of the prioritized variants.</p>
<p class="mb15"><b>Results:</b> As expected, the majority of patients carried variants in <i>MYBPC3</i> and M<i>YH7</i> genes, 26% (<i>n</i>&#x2009;=&#x2009;51) and 8% (<i>n</i>&#x2009;=&#x2009;16), respectively, in accordance with the initial analysis. The vast majority of pathogenic (P) and likely pathogenic (LP) variants were found in <i>MYBPC3</i> (22 out of 40 variants) and <i>MYH7</i> (8 out of 16 variants) genes. Three genes&#x2014;not included in the initial analysis&#x2014;were identified: <i>SVIL</i>, <i>FHOD3</i>, and <i>TRIM63</i>. Considering only patients with unique variants in the last three genes, there was a 9% enhancement in variant identification. Importantly, <i>SVIL</i> variant carriers presented apical and septal HCM, aortopathies, and severe scoliosis for one patient. Ten patients (5%) carried variants in the <i>FHOD3</i> gene, six in hotspot regions (exons 12 and 15). We identified seven variants within the <i>TRIM63</i> gene in 12 patients (6%). Homozygous variants were detected in 2.5% of the cohort in <i>MYBPC3</i> (<i>n</i>&#x2009;=&#x2009;1), <i>MYL3</i> (<i>n</i>&#x2009;=&#x2009;1), and <i>TRIM63</i> (<i>n</i>&#x2009;=&#x2009;3) genes.</p>
<p class="mb0"><b>Conclusion:</b> Our study revealed that no variants were found in the <i>ACTC1</i>, <i>TPM1</i>, and <i>TNNI3</i> genes in the HYPERGEN cohort. However, we identified variants in five out of the eight HCM core genes, with a high prevalence in young patients. We identified variants in three recent HCM-associated genes (<i>SVIL</i>, <i>FHOD3</i>, and <i>TRIM63</i>) in 35 patients, with 18 patients carrying unique variants (9%). Our results further emphasize the usefulness of exome data reanalysis, particularly in genotype-negative patients.</p> <div class="clear"></div> </div> <div class="JournalFullText"> <a id="h2" name="h2"></a>
<h2>Introduction</h2>
<p class="mb15">Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease, defined by left ventricular (LV) wall thickness greater than 15&#x2009;mm, in the absence of other loading conditions that could explain the hypertrophy (<a href="#ref1">1</a>). The degree, localization, and distribution of the hypertrophy are variable (<a href="#ref2">2</a>). The LV systolic function can be preserved, increased, or reduced (<a href="#ref2">2</a>). Consequently, HCM is characterized by a phenotypic heterogeneity that could be partly explained by the heterogeneity of the genetic underlying etiology.</p>
<p class="mb15">The estimated prevalence of HCM is 1:500 in the general population based on the recognition of the disease phenotype (<a href="#ref3">3</a>&#x2013;<a href="#ref5">5</a>). However, considering familial transmission, genotype-positive cases for sarcomeric genes, and subclinical cases, a higher prevalence (1:200) is reported (<a href="#ref6">6</a>).</p>
<p class="mb15">The clinical manifestations of HCM typically occur between the ages of 20 and 40, although they can develop at any age (<a href="#ref7">7</a>). It is noteworthy that 50&#x2013;60% of cases are diagnosed after the age of 30, reflecting the variable penetrance and expressivity of the disease (<a href="#ref3">3</a>). The average life expectancy for HCM patients is typically favorable, approaching 70&#x2009;years in effectively managed cases (<a href="#ref6">6</a>), although outcomes are greatly dependent on the presence of risk factors for complications such as early onset of the disease, arrhythmias, and heart failure. The annual risk of sudden cardiac death (SCD) in high-risk patients is estimated to range from 0.5 to 1%, with the highest risk observed in young cases under 30&#x2009;years of age (<a href="#ref8">8</a>).</p>
<p class="mb15">HCM is widely recognized as a sarcomeric disease since the vast majority of patients carry variants within the eight core genes encoding sarcomeric proteins (<a href="#ref9">9</a>). Indeed, the myosin-binding protein C (<i>MYBPC3</i>) and the <i>&#x03B2;</i>-myosin heavy chain (<i>MYH7</i>) genes account for 50&#x2013;70% of HCM cases that undergo genetic testing (<a href="#ref1">1</a>&#x2013;<a href="#ref3">3</a>, <a href="#ref10">10</a>, <a href="#ref11">11</a>). The remaining patients harbor variants in other sarcomeric genes, such as myosin light chain (MLC) genes (<i>MYL2</i> and <i>MYL3</i>), troponin encoding genes (<i>TNNT2</i> and <i>TNNI3</i>), tropomyosin 1 (<i>TPM1</i>), and actin <i>&#x03B1;</i>-cardiac muscle 1 (<i>ACTC1</i>) (<a href="#ref4">4</a>, <a href="#ref11">11</a>, <a href="#ref12">12</a>). Collectively, actionable variants in sarcomeric-positive (sarc+) patients account for &#x0003E;90% of the totality of pathogenic (P) variants in HCM patients (<a href="#ref12">12</a>). Of note, these percentages vary widely depending on the studied populations, the clinical profiling, the sequencing method used (panel, whole-exome sequencing [WES], etc.), and variant prioritization criteria.</p>
<p class="mb15">Several additional genes have been linked to HCM encoding non-sarcomeric proteins, including, but not restricted to, proteins of the Z-disk (<i>ACTN2</i>, <i>TCAP</i>, and <i>VCL</i>), calcium handling genes (<i>TNNC1</i>, <i>RYR2</i>, <i>JPH2</i>, <i>PLN</i>), and the proteasome (<i>TRIM63</i>) (<a href="#ref4">4</a>). Similarly to the sarcomeric genes, both inheritance models are reported in these genes with a predominance of the autosomal dominant pattern (<a href="#ref12">12</a>, <a href="#ref13">13</a>). However, the contribution of these genes is minor, ranging from 0.06 to 8.7% based on combined published data involving genes with strong, moderate, and weak evidence of causality and HCM-associated genes supported only by functional data (<a href="#ref13">13</a>). These findings reinforce the fact that sarcomeric genes predominantly cause HCM and emphasize the significant proportion of the missing heritability in HCM (<a href="#ref13">13</a>). Therefore, up to 50% of HCM patients do not have an identifiable pathogenic disease-causing variant (<a href="#ref14">14</a>, <a href="#ref15">15</a>). So far, this missing heritability is increasingly explained by the fact that sarcomeric-negative (Sarc-) and genotype-negative patients have a non-Mendelian or near-Mendelian disease caused by a joint effect of genetic and non-genetic factors (<a href="#ref13">13</a>, <a href="#ref16">16</a>). Thus, the additive effect of allelic heterogeneity and additional genetic variants, along with variants in cis causing allelic imbalance, could also partially explain the missing heritability, the phenotypic variability, and the incomplete penetrance. In this line, many studies have suggested the oligogenic inheritance model in HCM patients lacking an identifiable highly penetrant variant (<a href="#ref16">16</a>&#x2013;<a href="#ref20">20</a>). Furthermore, rare variants are broadly acknowledged among the plausible sources of missing heritability and the likely contributors to the oligogenic inheritance rather than common variants. Indeed, variants with strong effects are expected to be kept under selective pressure and remain at low to extremely low frequencies in the population (<a href="#ref21">21</a>, <a href="#ref22">22</a>). Altogether, incomplete penetrance, variable expressivity, and missing heritability in HCM make the genetic diagnosis and clinical prognosis challenging.</p>
<p class="mb15">The efficiency of WES reanalysis has been demonstrated to improve genetic testing yield, especially by adding the newly associated genes previously unrecognized as clinically relevant. It is estimated that the genetic diagnostic yield could be enhanced by approximately 15% when including new disease-gene associations, up-to-date software, variant frequency databases, and text mining for genetic and clinical re-evaluation (<a href="#ref23">23</a>). Moreover, it is recommended that the dataset initially analyzed over 2&#x2009;years ago should be prioritized for reanalysis (<a href="#ref24">24</a>).</p>
<p class="mb0">In this study, we sought to refine the initial Hypertension Genetic Epidemiology Network (HYPERGEN) analysis by focusing on HCM-causing genes (that are known and recently associated). Additionally, we assessed the usefulness of our reanalysis regarding the clinical actionability of the identified variants by applying the American College of Medical Genetics and Genomics/Association of Molecular Pathologists (ACMG/AMP) criteria.</p> <a id="h3" name="h3"></a>
<h2>Methods</h2>
<p class="mb0">This study was approved by an institutional review committee. All subjects gave informed consent for genetic studies. WES was performed on the NGS Illumina HiSeq2500 platform using Agilent SureSelect V6 technology (Genwiz, United States) (<a href="#ref25">25</a>).</p>
<h3>The HYPERGEN cohort</h3>
<p class="mb15">The HYPERGEN cohort included 132 men and 68 women (mean age, 55&#x2009;years; range, 19&#x2013;91&#x2009;years; 86.5% above 40; 34% familial cases). The patients were enrolled in five French centers: Marseille, Bordeaux, Paris, Dijon, and Rennes.</p>
<p class="mb15">A definite echocardiographic evidence of HCM was considered based on the measurements of maximal wall thickness&#x2009;&#x02265;&#x2009;15&#x2009;mm in sporadic and&#x2009;&#x0003E;&#x2009;13&#x2009;mm in familial cases without dilatation or any cardiovascular comorbidities or systemic disease.</p>
<p class="mb0">None of the patients was reported by the clinicians as syndromic or likely syndromic. However, the first HYPERGEN study identified one novel variant in the <i>GLA</i> gene (p.Leu311Profs&#x0002A;4), and the clinical re-evaluation of the patient confirmed a Fabry disease diagnosis. A second case with the disease-causing variant <i>TTR</i>: p.Val50Met has been reported with transthyretin cardiac amyloidosis (<a href="#ref25">25</a>). Of note, this study&#x2019;s variant prioritization strategy is different from the first HYPERGEN analysis. Thus, an important caveat to our reanalysis is that an accurate comparison of the genetic diagnosis yield cannot be assessed as the initial analysis pipeline differs from this reanalysis. Additionally, since we do not have access to the variant coordinates identified in the first analysis, it is impossible to determine whether any variants have been downgraded or upgraded. The significant differences are detailed in the following.</p>
<h3>Initial HYPERGEN analysis vs. the 5&#x2009;years interval analysis</h3>
<p class="mb15">In the initial HYPERGEN study, bioinformatic analyses were performed by retaining exonic and intronic variants with a minor allele frequency (MAF) lower than 1% and predicted as P or likely pathogenic LP mainly according to the Universal Mutation Database (UMD) predictor. The first step of WES data analysis consisted of searching for variants in a virtual panel of 167 genes involved in cardiomyopathies and other various cardiac hereditary diseases (<a href="#ref25">25</a>).</p>
<p class="mb0">In contrast, in this reanalysis, priority was given to genes with a matched HCM entry in Mendelian disease in the Online Mendelian Inheritance in Man (OMIM) database and the ClinGen<sup id="footnotesuper1"><a id="xfn0001"></a><a class="footnoteanchor" href="#fn0001">1</a></sup> as well as recently emerging HCM-associated genes gathered using text mining-based literature review from 2016 to 2023 (<a href="#fig1">Figure 1</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 1</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg" name="figure1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg" alt="www.frontiersin.org" id="fig1" loading="lazy">
  </picture>
</a>
<p><b>Figure 1</b>. Venn diagram visualization of genes across initial and 5-year analyses. The &#x201C;previously analyzed genes&#x201D; section includes genes from the 167-gene panel used in the original HYPERGEN study; the &#x201C;overlapping genes&#x201D; section contains genes identified in both the initial and current analyses; the &#x201C;newly identified genes&#x201D; section consists of genes associated with HCM between 2019 and 2024.</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb15">More importantly, variant pathogenicity was assessed according to ACMG/AMP guidelines, and the consistency of a predicted deleterious effect by at least 3 prediction tools and a high combined annotation-dependent depletion (CADD) score.</p>
<p class="mb15">As aforementioned, the initial HYPERGEN analysis showed two HCM phenocopies. In this study, a preanalysis included the significant syndromic genes and genes yielding known HCM phenocopies. None of the variants identified within these genes were classified as P or LP according to ACMG or reported in ClinVar database (data not shown). Moreover, all these variants were found along with other HCM-relevant variants. Thus, in this reanalysis, variants in genes causing syndromic HCM and phenocopies are not included. The <i>TTN</i> gene is not included as well.</p>
<p class="mb0">The Venn diagram shown in <a href="#fig1">Figure 1</a> illustrates the relationship between the genes previously prioritized in the first analysis and those reanalyzed in this study. The overlapping section represents genes shared between both analyses.</p>
<h3>Variant filtering, prioritization, and sanger validation</h3>
<p class="mb15">The first criterion of this reanalysis is variant rarity. Thus, a filtering allele frequency of &#x0003C;1% in gnomAD database was applied. Subsequently, intergenic, intronic, and synonymous variants were removed. The remaining variants were prioritized based on their <i>in silico</i> predicted impact on protein function. This analysis&#x2019;s primary scoring tool is the CADD (<a href="#ref26">26</a>). Indeed, variants predicted as damaging or probably damaging, deleterious, disease-causing by PolyPhen-2 and SIFT, and/or MutationTaster while also having a CADD score&#x2009;&#x0003E;&#x2009;15 were considered as variants of high confidence of pathogenicity (<a href="#ref27">27</a>&#x2013;<a href="#ref29">29</a>). Of note, up to two-thirds of the variants of uncertain significance (VUS) in confirmed sarcomeric genes are considered causal of HCM (<a href="#ref30">30</a>). Thus, suspicious VUS with some evidence of causality (a rarity, VUS within well-established HCM genes, mutational hotspots&#x2026;) is reported in this reanalysis.</p>
<p class="mb15">Finally, to gauge the clinical actionability of the detected variants, a subsequent classification according to ACMG criteria was performed (<a href="#ref31">31</a>).</p>
<p class="mb0">All the prioritized variants within the core and minor HCM genes were validated by Sanger sequencing when DNA samples were available (<a href="#SM1">Supplementary File 1</a>).</p>
<h3>Biological pathway and gene ontology analyses</h3>
<p class="mb0">Given a large number of variants, even after the filtering steps, variants within HCM-minor genes could be missed. To facilitate and ensure the identification of these variants, a biological pathway analysis including Reactome and KEGG databases as well as gene (GO) and human phenotype (HPO) ontologies terms was carried out using VarAFT software (<a href="#ref32">32</a>&#x2013;<a href="#ref36">36</a>). For example, querying the HPO and GO databases with the keywords &#x201C;cardiomyopathy phenotype&#x201D; and &#x201C;cardiac hypertrophy&#x201D; results in 3 HPO term identifiers (HP:0001639, HP:0005157, HP:0031992), 27 disease terms (matching all the OMIM phenotypes) and 83 additional genes. VarAFT software allowed us to query each variant call format (VCF) file for all the possible combinations.</p>
<h3>French control cohort</h3>
<p class="mb0">French healthy controls (<i>n</i>&#x2009;=&#x2009;960) were queried to compare variants allele frequencies. Exons coordinate on GRCh37 were extracted for the genes of interest and extended by 50 bases. Those regions were called using GATK (4.3.0.0) with a set of Binary Alignment Map (BAM) files using a nextflow-based pipeline for joint-genotyping.<sup id="footnotesuper2"><a id="xfn0002"></a><a class="footnoteanchor" href="#fn0002">2</a></sup> Resulting VCF was annotated with snpEff (<a href="#ref37">37</a>) and jvarkit/GnomAD.<sup id="footnotesuper3"><a id="xfn0003"></a><a class="footnoteanchor" href="#fn0003">3</a></sup> Variants known to be filtered in gnomAD or having an allele frequency greater than 1% in the non-finish population were excluded. Protein truncating and splice site variants were kept using jvarkit/vcffilterso.</p> <a id="h4" name="h4"></a>
<h2>Results</h2>
<h3>Variant identification among the definitive HCM genes</h3>
<h4><i>MYBPC3</i> and <i>MYH7</i> genes: the permanently significant HCM genes</h4>
<p class="mb15">Definitive HCM genes with a well-established disease association are mainly the eight sarcomeric genes with strong evidence of causality (<i>MYBPC3</i>, <i>MYH7</i>, <i>TNNT2</i>, <i>TNNI3</i>, <i>TPM1</i>, <i>ACTC1</i>, <i>MYL3</i>, and <i>MYL2</i>) (<a href="#ref38">38</a>, <a href="#ref39">39</a>). In our analysis, variants were found in five out of these eight well-established genes.</p>
<p class="mb0">Not surprisingly, the most prevalent genes in our case cohort are <i>MYBPC3</i> and <i>MYH7</i> genes, which is in accordance with the initial HYPERGEN study (<a href="#fig2">Figure 2</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 2</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg" name="figure2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg" alt="www.frontiersin.org" id="fig2" loading="lazy">
  </picture>
</a>
<p><b>Figure 2</b>. Variant distribution within HCM well-established genes. The number of patients harboring variants in each HCM core gene is dark purple. The number of variants within each gene is indicated in light purple.</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb0">Variants coordinates are detailed in <a href="#tab1">Tables 1</a>&#x2013;<a href="#tab4">4</a>.</p>
<div class="DottedLine"></div> <div class="Imageheaders">Table 1</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg" name="table1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg" alt="www.frontiersin.org" id="tab1" loading="lazy">
  </picture>
</a>
<p><b>Table 1</b>. Variants identified in the <i>MYBPC3</i> gene (transcript NM_000256, MANE select).
</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Table 2</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg" name="table2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg" alt="www.frontiersin.org" id="tab2" loading="lazy">
  </picture>
</a>
<p><b>Table 2</b>. Variants identified in the <i>MYH7</i> gene (transcript NM_000257, MANE select).
</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Table 3</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg" name="table3" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg" alt="www.frontiersin.org" id="tab3" loading="lazy">
  </picture>
</a>
<p><b>Table 3</b>. Variants identified in the <i>TNNT2</i> gene (transcript NM_001276345, MANE select).
</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Table 4</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg" name="table4" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg" alt="www.frontiersin.org" id="tab4" loading="lazy">
  </picture>
</a>
<p><b>Table 4</b>. Variants identified in myosin light chain (MLC) genes.
</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb0">We identified 24 missense variants and 16 protein-truncating variants (PTV) in <i>MYBPC3</i> gene (<a href="#fig2">Figure 2</a>). The vast majority of the identified <i>MYBPC3</i> variants are unique (42 out of 51 patients; 82%), 3 patients are double heterozygous (HCM-5, HCM-6, and HCM-14) harboring each a missense variant classified as a VUS and a second PTV or splice-site variant reported in ClinVar database and classified as P according to ACMG. Six patients with variants in the <i>MYBPC3</i> carrying one or more additional variants in minor HCM genes (<i>ACTN2</i> and <i>MYH6</i>) and in recent HCM-associated genes (<i>FHOD3</i>, <i>TRIM63</i>, and <i>SVIL</i>) (<a href="#tab1">Table 1</a>; see <a href="#fig3">Figure 3</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 3</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg" name="figure3" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg" alt="www.frontiersin.org" id="fig3" loading="lazy">
  </picture>
</a>
<p><b>Figure 3</b>. Variant type distribution of <i>MYBPC3</i> gene.</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb0">We identified 16 distinct variants in the <i>MYH7</i> gene, suggesting that these variants are more likely private. Importantly, in our case cohort, no PTV <i>MYH7</i> variant has been identified, and 8 out of the 16 missense variants are classified P and reported P or LP according to ACMG rules and ClinVar Database, respectively (<a href="#tab2">Table 2</a>). It should be noted that <i>MYBPC3</i> and <i>MYH7</i> are not only the most prevalent genes but also the most genes with P/LP classified variants following ACMG/AMP criteria (<a href="#fig4">Figure 4</a>). The remaining variants in this study are predicted to be deleterious through several tools. Each variant&#x2019;s detailed <i>in silico</i> prediction is available in <a href="#SM1">Supplementary File 2</a>.</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 4</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg" name="figure4" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg" alt="www.frontiersin.org" id="fig4" loading="lazy">
  </picture>
</a>
<p><b>Figure 4</b>. Proportion of <i>MYBPC3</i> and <i>MYH7</i> variants with P/LP ACMG classification. B, Benign; P, Pathogenic; LP, Likely Pathogenic; VUS, Variant of Uncertain Significance.</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<h4>Troponin T2 and MLC genes: the minor sarcomeric genes</h4>
<p class="mb15">We identified a small proportion of patients carrying variants in <i>TNNT2</i>, <i>MYL2</i>, and <i>MYL3</i> genes (<i>n</i>&#x2009;=&#x2009;6; 3%) (<a href="#tab3">Table 3</a>). Two patients carried missense variants in <i>TNNT2</i> (p.Val95Met and p.Lys283Glu), reported in ClinVar as LP and P, respectively. Furthermore, we identified four variants in <i>MYL2</i> (<i>n</i>&#x2009;=&#x2009;1) and <i>MYL3</i> (<i>n</i>&#x2009;=&#x2009;3) genes, one of which is at a homozygous state (<i>MYL3</i> p.Ala57Asp) with the conflicting interpretation of pathogenicity in ClinVar (<a href="#tab4">Table 4</a>).</p>
<p class="mb0">All the variants in troponin T2 and MLC genes are unique.</p>
<h3>Variant identification among minor HCM genes</h3>
<p class="mb0">Several additional genes are consistently reported as HCM-causing genes encoding sarcomeric and non-sarcomeric proteins and contributing to a small proportion of HCM genetic etiology (<a href="#ref13">13</a>). In our reanalysis, we identified variants in 12 HCM minor genes. Rare and deleterious variants in <i>FLNC</i>, <i>MYH6</i>, <i>MYPN</i>, and <i>ACTN2</i> genes accounted for the majority of the prioritized variants among these genes (<a href="#tab5">Table 5</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Table 5</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg" name="table5" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg" alt="www.frontiersin.org" id="tab5" loading="lazy">
  </picture>
</a>
<p><b>Table 5</b>. Variants identified in minor HCM genes.
</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb15">Ten patients were found to carry unique variants in the <i>FLNC</i> gene, and three were digenic (HCM-67, HCM-66, and HCM-100) harboring an additional variant in the <i>MYH6</i>, <i>MYH7</i>, and <i>MYPN</i> genes, respectively. Unique variants in the <i>MYH6</i> gene were identified in five patients. Three out of six patients with <i>MYPN</i> variants carried the same p.Pro1112Leu variant.</p>
<p class="mb0">Less unique variants were detected in the remaining minor genes <i>ALPK3</i>, <i>CSRP3</i>, <i>MYLK2</i>, <i>CAV3</i>, <i>VCL</i>, and <i>JPH2</i> genes. Of note, variants in <i>NEXN</i> (p.Glu332Ala) and <i>TCAP</i> (p.Met71Thr) are unique.</p>
<h4>Emerging HCM genes: <i>TRIM63</i>, <i>FHOD3</i>, and <i>SVIL</i></h4>
<p class="mb0">The main goal of this reanalysis was to identify variants within the recently associated genes not included in the initial HYPERGEN analysis. Three genes were identified toward this goal<i>TRIM63</i>, <i>FHOD3</i>, and <i>SVIL</i>.</p>
<h5><i>TRIM63</i> gene</h5>
<p class="mb0">The <i>TRIM63</i> gene was associated with an autosomal recessive form of HCM (<a href="#ref40">40</a>, <a href="#ref41">41</a>). In this study, we identified variants within the <i>TRIM63</i> gene in 12 patients. Three patients presented homozygous variants for <i>TRIM63</i> gene, and 6 variants were unique (<a href="#tab6">Table 6</a>). Indeed, the missense variants (p.Cys23Tyr and p.Cys75Tyr) were identified in patients at the heterozygous and homozygous states. Similarly, the stop variant (p.Gln247&#x0002A;) was found at the homozygous state in one patient and heterozygous for two other patients. According to ACMG/AMP classification, the missense variants Cys23Tyr and Cys75Tyr are LP. The <i>TRIM63</i> p.Gln247&#x0002A; stop variant is reported in ClinVar with conflicting interpretations of pathogenicity. A second stopgain variant (p.Glu261&#x0002A;) was found in a single patient (<a href="#fig5">Figure 5</a>). Of note, PTVs were identified only in <i>MYBPC3</i> and <i>TRIM63</i> genes.</p>
<div class="DottedLine"></div> <div class="Imageheaders">Table 6</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg" name="table6" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg" alt="www.frontiersin.org" id="tab6" loading="lazy">
  </picture>
</a>
<p><b>Table 6</b>. Variants identified in the <i>TRIM63</i> gene (transcript NM_032588, MANE select).
</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Figure 5</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg" name="figure5" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg" alt="www.frontiersin.org" id="fig5" loading="lazy">
  </picture>
</a>
<p><b>Figure 5</b>. Schematic representation of the <i>TRIM63</i> gene. Upside: Rare variants identified in HYPERGEN cohort: Green: B/LB; Yellow: VUS; Red: LP/P; Downside: Variants reported in Clinvar database (clinical significance at last reviewed): Grey: VUS and conflicting interpretations of pathogenicity; Black: LP/P; Protein domains: Red = RING-finger domain (Zn-finger of 40 to 60 residue); Blue = B-Box-type zinc finger; Green = Zn2+ binding site; Yellow&#x2009;= Inter-Src homology 2 (iSH2) helical domain of Class IA Phosphoinositide 3-kinase Regulatory subunits. Figure created with ProteinPaint (<a href="https://proteinpaint.stjude.org/">https://proteinpaint.stjude.org/</a>).</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb0">Clinical data were gathered for some patients with <i>TRIM63</i> variants. Two patients have septal hypertrophy and normal left ventricular ejection fraction (LVEF) (HCM-44 and HCM-113). Two patients with homozygous <i>TRIM63</i> variants (HCM-112 and HCM-114) have apical hypertrophy. The patient (HCM-117) with the stop variant p.Glu261&#x0002A; has a severe biventricular HCM with LVEF&#x2009;=&#x2009;49% and mild aortic regurgitation.</p>
<h5><i>FHOD3</i> gene</h5>
<p class="mb0">The <i>FHOD3</i> locus is one of the most vital signals for HCM in genome-wide association study (GWAS) studies (<a href="#ref42">42</a>). Pathogenic variants are mainly located in two regions in the FHOD3 diaphanous inhibitory domain (exon 12) and the coiled&#x2013;coil domain (exons 15 and 16). Moreover, it has been demonstrated that exons 11 and 12 are crucial for MybpC-mediated localization of the FHOD3 protein to the sarcomeric C-zone (<a href="#ref12">12</a>, <a href="#ref43">43</a>&#x2013;<a href="#ref45">45</a>). Our reanalysis further strengthens these associations by the identification of 3 missense variants in exon 12 and 15 in 6 patients of the HYPERGEN cohort. In total, 7 rare variants were prioritized in the <i>FHOD3</i> gene in 10 patients (<a href="#fig6">Figure 6</a>). The majority of variants are unique except for two patients (HCM-48 and HCM-27) with the recurrent <i>FHOD3</i> p.Arg637Gln variant. Both patients carried <i>MYBPC3</i> variants, p.(Cys1202Leufs&#x0002A;35) and p.(Arg597Gln), respectively (<a href="#tab7">Table 7</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 6</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg" name="figure6" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg" alt="www.frontiersin.org" id="fig6" loading="lazy">
  </picture>
</a>
<p><b>Figure 6</b>. Schematic representation of the <i>FHOD3</i> gene. Upside: Rare variants identified in HYPERGEN cohort: Green&#x2009;=&#x2009;B/LB; Yellow&#x2009;=&#x2009;VUS; Red&#x2009;=&#x2009;LP/P; Downside: Variants reported in ClinVar database (clinical significance at last reviewed): Gray&#x2009;=&#x2009;VUS and conflicting interpretations of pathogenicity; Black&#x2009;=&#x2009;LP/P; protein domain: Green&#x2009;=&#x2009;Formin Homology 2 Domain. Figure was created with ProteinPaint (<a href="https://proteinpaint.stjude.org/">https://proteinpaint.stjude.org/</a>).</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Table 7</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg" name="table7" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg" alt="www.frontiersin.org" id="tab7" loading="lazy">
  </picture>
</a>
<p><b>Table 7</b>. Variants identified in the <i>FHOD3</i> gene (transcript NM_001281740, MANE select).
</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb0">We had access to the clinical description of one patient (HCM-104) with <i>FHOD3</i> variant (p.Leu177Phe). A definite HCM diagnosis was made at the age of 13&#x2009;years. The patient had a concentric HCM with biventricular dilation. At the age of 31&#x2009;years, his LVEF&#x2009;=&#x2009;71% and RVEF&#x2009;=&#x2009;53%.</p>
<h5><i>SVIL</i> gene</h5>
<p class="mb0">Recently, the <i>SVIL</i> gene was associated with HCM (<a href="#ref46">46</a>, <a href="#ref47">47</a>). Thus, we performed a gene-targeted analysis for the <i>SVIL</i> gene. No PTV or homozygous variants were found in patients of the HYPERGEN cohort. Nevertheless, we identified 10 missense <i>SVIL</i> variants in 13 patients (<a href="#tab8">Table 8</a>; <a href="#fig7">Figure 7</a>). The prioritized variants are absent in 1920 control alleles. Five variants are unique. To better characterize the clinical presentation of <i>SVIL</i> variant carriers, cardiac and extracardiac features were gathered for 7 patients, two women and 5 men (<a href="#tab9">Table 9</a>). The age at onset of women patients was 29 and 27&#x2009;years, one of them in the postpartum period. Moreover, the patient with <i>SVIL</i>: p.(Arg215Trp) had severe scoliosis with permanent bracing and muscle fasciculations. Three patients had aortopathies including a bicuspid aortic valve with severe regurgitation, isolated ectasia of the Valsalva sinus, and degenerative aortic insufficiency. A consistent pattern of fibrosis localization was noted in these patients in the septum and LV apex. Magnetic resonance imaging (MRI) findings showed significant myocardial fibrosis for the majority of patients with intramyocardial delayed contrast in the inferior and lateral walls (<a href="#tab9">Table 9</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Table 8</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg" name="table8" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg" alt="www.frontiersin.org" id="tab8" loading="lazy">
  </picture>
</a>
<p><b>Table 8</b>. Variants identified in the <i>SVIL</i> gene (transcript NM_021738, MANE select).
</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Figure 7</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg" name="figure7" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg" alt="www.frontiersin.org" id="fig7" loading="lazy">
  </picture>
</a>
<p><b>Figure 7</b>. Schematic representation of the <i>SVIL</i> gene. Upside: Rare variants identified in HYPERGEN cohort: Green&#x2009;=&#x2009;B/LB; Yellow&#x2009;=&#x2009;VUS; Downside: Variants reported in ClinVar database (clinical significance at last reviewed): Gray&#x2009;=&#x2009;VUS and conflicting interpretations of pathogenicity; Black&#x2009;=&#x2009;LP/P; Protein domains: Green, blue, yellow, gray, and brown&#x2009;=&#x2009;gelsolin-like domains. Figure was created with ProteinPaint (<a href="https://proteinpaint.stjude.org/">https://proteinpaint.stjude.org/</a>).</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Table 9</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg" name="table9" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg" alt="www.frontiersin.org" id="tab9" loading="lazy">
  </picture>
</a>
<p><b>Table 9</b>. Clinical findings of <i>SVIL</i> variant carriers.
</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb0">Only seven variants of the HYPERGEN cohort were present in the control cohort with low allele frequencies (<a href="#tab10">Table 10</a>). Moreover, four out of these seven variants were found to have the highest allele frequencies in the European non-Finnish population in gnomAD.</p>
<div class="DottedLine"></div> <div class="Imageheaders">Table 10</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg" name="table10" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg" alt="www.frontiersin.org" id="tab10" loading="lazy">
  </picture>
</a>
<p><b>Table 10</b>. HYPERGEN variants found in the control cohort.
</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<h4>The genetic landscape of young HYPERGEN patients</h4>
<p class="mb0">The HYPERGEN cohort included 27 patients with HCM occurring at a very young age or in early adulthood (13.5%). The HCM clinical diagnosis of the patients was definite before the age of 40&#x2009;years. We sought to determine the genetic architecture of this young proportion. Indeed, sarcomeric genes were the most involved genes, as 50% of the identified variants are within the <i>MYBPC3</i> gene. Interestingly, variants in <i>SVIL</i> and <i>FHOD3</i> genes accounted for 10 and 7% of young HYPERGEN patients, respectively (<a href="#fig8">Figure 8</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 8</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg" name="figure8" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg" alt="www.frontiersin.org" id="fig8" loading="lazy">
  </picture>
</a>
<p><b>Figure 8</b>. Percentages of gene variants distribution among young patients.</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb0">In summary, a total of 20 genes have been identified in the HYPERGEN cohort, with a significant implication of the <i>MYBPC3</i> gene, followed by <i>MYH7</i> and <i>SVIL</i> genes (<a href="#fig9">Figure 9</a>). According to ClinGen, 8 out of the 20 identified genes are classified with a robust association with HCM, 7 with disputed/limited evidence, and the <i>JPH2</i> gene with a moderate gene&#x2013;disease validity. The <i>FLNC</i>, <i>CAV</i>, and <i>SVIL</i> are not curated for HCM, and the <i>FHOD3</i> gene is under curation (<a href="#tab11">Table 11</a>). However, those genes are reported in the literature and in the OMIM database in association with HCM.</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 9</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg" name="figure9" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg" alt="www.frontiersin.org" id="fig9" loading="lazy">
  </picture>
</a>
<p><b>Figure 9</b>. Genes implicated in the HYPERGEN cohort. The number of variants is indicated in dark purple, and the number of patients is indicated in light purple.</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Table 11</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg" name="table11" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg" alt="www.frontiersin.org" id="tab11" loading="lazy">
  </picture>
</a>
<p><b>Table 11</b>. List of the identified genes in the HYPERGEN cohort and their matched ClinGen classification.
</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<p class="mb15">Our reanalysis yielded 16 novel variants, including four in the <i>MYBPC3</i> gene, three in <i>MYH7</i>, two variants were found in each of <i>MYH6</i> and <i>FLNC</i> genes, and one novel variant in <i>TNNT2</i>, <i>MYL2</i>, <i>MYPN</i>, <i>ALPK3</i>, and <i>CSRP3</i>, respectively.</p>
<p class="mb15">Of note, considering only patients with unique variants in <i>TRIM63</i>, <i>FHOD3</i>, and <i>SVIL</i> genes, there was a 9% enhancement in variant identification following this reanalysis.</p>
<p class="mb0">All the identified genes and their matched phenotypes in the OMIM database are summarized in <a href="#SM1">Supplementary File 3</a>.</p> <a id="h5" name="h5"></a>
<h2>Discussion</h2>
<p class="mb15">Despite the advent of next-generation sequencing, approximately 50% of cases remain genotype-elusive. In this study, a reanalysis of exome data from 200 HCM patients was carried out 5&#x2009;years after the initial analysis with the goal of refining the initial analysis, reporting all the relevant, prioritized variants, and particularly identifying rare variants within the novel HCM-associated genes.</p>
<p class="mb15">In the present reanalysis, nearly 34% of patients were found to carry variants in <i>MYBPC3</i> and <i>MYH7</i> genes. This yield of sarc+ patients reached 37% when including patients with <i>TNNT2</i>, <i>MYL2</i>, and <i>MYL3</i> variants.</p>
<p class="mb15">Haploinsufficiency is the primary mechanism driving HCM linked to <i>MYBPC3</i> (myosin binding protein C3) gene (<a href="#ref38">38</a>, <a href="#ref48">48</a>). Thus, non-truncating variants (missense, in-frame indels, PTV predicted to escape non-sense mediated decay [NMD], and stop-loss) are prioritized whether they are predicted as pathogenic with high or low confidence. Our reanalysis yielded a total of 40 <i>MYBPC3</i> variants, including 24 missense, 4 splice-site, 6 stopgain, and 6 frameshift variants. The most recurrent and common HCM causal variant <i>MYBPC3</i>, p.Arg502Trp, was identified in only three patients (1.5%). This variant was found in 2.4% of the European-descent patients (<a href="#ref15">15</a>, <a href="#ref49">49</a>&#x2013;<a href="#ref51">51</a>). However, the pathogenic <i>MYBPC3</i>: c1928-2A&#x2009;&#x0003E;&#x2009;G variant was the most commonly identified variant in the HYPERGEN cohort (<i>n</i>&#x2009;=&#x2009;7; 3.5%). Notably, these variants are unique except for one patient (HCM-5) harboring a second <i>MYBPC3</i> variant (p.Leu183Ile) (<a href="#tab1">Table 1</a>). Contrary to the <i>MYBPC3</i> gene, mostly known with haploinsufficiency and allelic imbalance as the underlying mechanism of the disease, the pathophysiology mechanism of <i>MYH7</i> (myosin heavy chain 7) missense variants is the dominant negative effect, which implies that the <i>MYH7</i> gene is tolerant to loss of function (LoF) variants (<a href="#ref10">10</a>, <a href="#ref38">38</a>, <a href="#ref39">39</a>, <a href="#ref52">52</a>, <a href="#ref53">53</a>). Thus, prioritizing the <i>MYH7</i> missense variant with a predicted deleterious impact according to different <i>in silico</i> algorithms may increase the identification rate of actionable variants. Moreover, gene regions in which rare and likely causal variants are significantly clustered; therefore, a new etiological fraction-based ACMG rule on rare missense <i>MYH7</i> variants was proposed to improve genetic testing yield in HCM (<a href="#ref30">30</a>). All the identified <i>MYH7</i> variants in this study are missense (<i>n</i>&#x2009;=&#x2009;16) with 8 P/LP variants. Of note, variants in the <i>MYH7</i> gene were associated with significant LV hypertrophy, which is the hallmark of HCM and an unfavorable prognosis compared to patients carrying variants in the other HCM genes (<a href="#ref54">54</a>).</p>
<p class="mb15">We identified a small proportion of patients (3%) carrying variants in <i>TNNT2</i>, <i>MYL2</i>, and <i>MYL3</i> genes. Only two variants in the <i>TNNT2</i> gene were identified. The <i>TNNT2</i> gene encodes the cardiac troponin T2 which is a regulatory protein of the thin filament troponin complex in the sarcomere playing a crucial role in contractility function (<a href="#ref39">39</a>, <a href="#ref55">55</a>). More than 30 <i>TNNT2</i> P/LP variants have been linked to HCM, with individual variants being unique and private to distinct families (<a href="#ref55">55</a>). Moreover, phenotypic variability was reported among patients carrying the same <i>TNNT2</i> variant (<a href="#ref55">55</a>). The MLCs are composed of a regulatory light chain (<i>MYL2</i>) and an essential light chain (<i>MYL3</i>). These genes contribute to the stability of myosin head and the regulation of cardiac contraction by phosphorylation and Ca<sup>2+</sup> binding (<a href="#ref52">52</a>). Despite these genes being considered well-established HCM genes, their contribution to HCM etiology is limited. A study by Borrelli et al. estimated that the contribution of genes encoding sarcomere thin filaments does not exceed 5% (<a href="#ref11">11</a>). In our cohort, no high or moderate confidence variants were found in <i>ACTC1</i>, <i>TPM1</i>, <i>TNNC1</i>, or <i>TNNI3</i> genes. A recent study by Allouba et al. (<a href="#ref56">56</a>) showed that homozygous variants are more prevalent within <i>MYL2</i> and <i>MYL3</i> genes than within major sarcomeric HCM genes. In the HYPERGEN cohort, only one homozygous variant was identified (<i>MYL3</i>: p.Ala57Asp) in a patient with a family history of HCM.</p>
<p class="mb15">Although HCM has been recognized as a monogenic disease for a long time, the wide utilization of high-throughput sequencing has demonstrated that it may be caused by the occurrence of more than one variant, particularly for sarc&#x02212;patients. In this reanalysis, considering sarc+patients, we identified three patients with two variants within the <i>MYBPC3</i> gene, seven cases carrying digenic variants, and five patients carrying more than two variants (<a href="#tab1">Tables 1</a>, <a href="#tab2">2</a>). In some sarc&#x02212;cases, unique variants were found in genes encoding proteins located in the Z-disc, namely, <i>FLNC</i>, <i>ACTN2</i>, <i>CSRP3</i>, <i>TRIM63</i>, and <i>SVIL</i> (<a href="#tab5">Tables 5</a>&#x2013;<a href="#tab8">8</a>). Of note, variants within <i>CAV3</i>, <i>VCL</i>, and <i>JPH2</i> genes were found along with additional sarcomeric and non-sarcomeric variants.</p>
<p class="mb15">We identified three <i>CSRP3</i> variants, including the known p.Trp4Arg variant. The <i>CSRP3</i> gene, encoding cysteine and glycine-rich protein 3, is one of the non-sarcomeric HCM-associated genes with strong evidence for a primary pathogenic role in HCM (<a href="#ref13">13</a>). It plays different roles in mechanosensory functions and actin cytoskeleton assembly (<a href="#ref12">12</a>, <a href="#ref57">57</a>). Functional analysis of <i>Csrp3</i> knock-in animals (<i>Csrp3<sup>Trp4Arg/+</sup></i>) and (<i>Csrp3<sup>Trp4Arg/Trp4Arg</sup></i>) showed an age-and gene dosage-dependent HCM and heart failure, characterized by a nearly complete loss of contractile function under catecholamine-induced stress. Moreover, <i>Cspr3</i> mRNA and protein levels were significantly decreased in the hearts of heterozygous and homozygous <i>Cspr3<sup>Trp4Arg</sup></i> knock-in animals (<a href="#ref57">57</a>).</p>
<p class="mb15">We identified five variants in the <i>ACTN2</i> gene, three of which were unique, and two patients were digenic and were carrying additional variants in <i>MYBPC3</i> and <i>TRIM63</i> genes. The <i>ACTN2</i> gene (major Z-disc cross-linking protein) is of particular interest as variants within this gene have been linked to diverse cardiac phenotypes such as HCM, dilated cardiomyopathy (DCM), LV non-compaction (LVNC), and SCD (<a href="#SM1">Supplementary File 3</a>) (<a href="#ref58">58</a>&#x2013;<a href="#ref61">61</a>). Patients with <i>ACTN2</i> pathogenic variants showed no specific hypertrophy pattern, as septal, apical, concentric, and biventricular hypertrophy were reported. More importantly, patients with mild hypertrophy had severe complications such as resuscitated cardiac arrest and heart failure (<a href="#ref12">12</a>, <a href="#ref61">61</a>&#x2013;<a href="#ref64">64</a>).</p>
<p class="mb15">A small number of variants was identified within the <i>ALPK3</i> gene (<i>n</i>&#x2009;=&#x2009;4), 3 out of the 4 variants were unique. Of note, the <i>ALPK3</i> gene (<i>&#x03B1;</i>-protein kinase 3) was initially linked to an autosomal recessive form of severe pediatric mixed cardiomyopathy (HCM/DCM phenotype) (<a href="#ref65">65</a>&#x2013;<a href="#ref67">67</a>). In 2020, the <i>ALPK3</i> gene reached a definitive classification of strong evidence for an autosomal recessive form of HCM with an infant onset (<a href="#ref46">46</a>). However, cases harboring heterozygous LoF variants were reported with mild-to-moderate phenotypes, and an autosomal dominant pattern of inheritance was subsequently associated with an adult-onset HCM (<a href="#ref12">12</a>, <a href="#ref46">46</a>, <a href="#ref68">68</a>, <a href="#ref69">69</a>). Recently, rare missense <i>ALPK3</i> variants have been identified in Asian HCM patients (<a href="#ref46">46</a>, <a href="#ref70">70</a>).</p>
<p class="mb15">Three genes were recently associated with HCM and identified in this reanalysis: <i>TRIM63</i>, <i>FHOD3</i>, and <i>SVIL</i>. <i>TRIM63</i> is one of the rare genes recently described as a cause of HCM with autosomal-recessive inheritance. <i>TRIM63</i> encodes muscle-specific RING-finger protein 1 (MuRF1), a member of the ubiquitin ligases subfamily, such as MuRF-2 and MuRF-3 (<a href="#ref71">71</a>, <a href="#ref72">72</a>). It is an E3 ubiquitin&#x02212;protein that regulates the degradation of sarcomeric proteins such as Mybpc3 and Myh6 through ubiquitylation (<a href="#ref12">12</a>, <a href="#ref72">72</a>). Homozygous and compound heterozygous rare variants in the <i>TRIM63</i> gene were linked to HCM. <i>TRIM63</i> variant carriers showed concentric LV hypertrophy, significant cardiac fibrosis, LV systolic dysfunction, and arrhythmias (<a href="#ref12">12</a>, <a href="#ref40">40</a>, <a href="#ref41">41</a>). Furthermore, systolic dysfunction and late gadolinium enhancement have been reported as characteristic features of <i>TRIM63</i>-associated cardiomyopathies (<a href="#ref41">41</a>). Rare missense variants in <i>TRIM63</i> at the heterozygous state were reported as genetic modifiers of HCM. Although the <i>TRIM63</i> missense variants had limited evidence of disease causality, <i>TRIM63</i> knockouts are likely to be associated with HCM, given their enrichment in HCM patients and their absence in gnomAD (<a href="#ref12">12</a>, <a href="#ref41">41</a>). In our reanalysis, the two LP missense variants (p.Cys23Tyr and p.Cys75Tyr) were identified in 5 patients of the HYPERGEN cohort. The <i>TRIM63</i>: (p.Gln247&#x0002A;) stop variant was identified in three patients, one at the homozygous state and two patients were heterozygous. The p.Gln247&#x0002A; variant is reported in the ClinVar database with a conflicting interpretation of pathogenicity. Nevertheless, <i>in vitro</i> and <i>in vivo</i> functional studies showed near complete loss of auto-ubiquitination in cells transduced with the TRIM63Q247&#x0002A; lentiviral construct (<a href="#ref12">12</a>, <a href="#ref41">41</a>). Several other <i>TRIM63</i> variants impair the ubiquitination of Trim63 substrates in adult cardiomyocytes. These findings implicate the impaired protein degradation as a pathophysiology mechanism of HCM (<a href="#ref40">40</a>, <a href="#ref41">41</a>).</p>
<p class="mb15">Of note, in the HYPERGEN cohort, five patients (2.5%) carried homozygous variants in <i>MYBPC3</i> (<i>n</i> =&#x2009;1), <i>MYL3</i> (<i>n</i> =&#x2009;1), and <i>TRIM63</i> (<i>n</i> =&#x2009;3) genes.</p>
<p class="mb15">The second recent gene identified in this reanalysis is the <i>FHOD3</i> gene. <i>FHOD3</i> encodes the cardiac formin homology 2 domain containing three proteins that localize in the thin filament of the sarcomere and promote actin filament polymerization in cardiomyocytes (<a href="#ref44">44</a>).</p>
<p class="mb15">Rare pathogenic <i>FHOD3</i> variants were linked to HCM etiology through association analysis of 3,189 HCM patients and familial segregation studies (<a href="#ref43">43</a>). <i>FHOD3</i> variants associated with HCM are mostly non-truncating and disturb the diaphanous inhibitory domain of the protein. Patients carrying likely causative <i>FHOD3</i> variants showed mild-to-moderate LV hypertrophy and a 1% annual incidence of cardiovascular mortality (<a href="#ref43">43</a>). Additionally, <i>FHOD3</i>-HCM patients were diagnosed in adulthood (mean age 46.1&#x2009;years), and two-thirds (66%) were men. The majority of patients (82%) had asymmetric septal hypertrophy (mean 18.8&#x2009;&#x000B1;&#x2009;5&#x2009;mm). LV ejection fraction &#x0003C;50% was present in 14% of the cohort and hypertrabeculation in 16% (<a href="#ref43">43</a>). Moreover, the cardiomyopathic phenotype of <i>cMyBP-C</i> null mice was aggravated by Fhod3 overexpression with a sarcomere integrity disruption. This phenotype was partially improved by a reduction in the Fhod3 protein levels, suggesting that Fhod3 has a damaging impact on cardiac function under <i>cMyBP-C</i> null conditions where Fhod3 is mis-localized (<a href="#ref44">44</a>). These findings suggest the likely contribution of Fhod3 to the pathogenesis of cMyBP-C-related cardiomyopathy and that Fhod3 is implicated in cardiac cMyBP-C-mediated regulation via direct interaction (<a href="#ref44">44</a>). In this study, rare missense <i>FHOD3</i> variants were identified in the hotspot exons (12 and 15), and two patients with the recurrent <i>FHOD3</i> p.Arg637Gln variant were digenic, carrying additional variants in the <i>MYBPC3</i> gene (p.Cys1202Leufs&#x0002A;35 and p.Arg597Gln).</p>
<p class="mb15">More recently, the <i>SVIL</i> gene was associated with HCM (<a href="#ref46">46</a>, <a href="#ref47">47</a>). The <i>SVIL</i> (Supervillin) encodes a multidomain actin and myosin-binding protein in the Z-disc (<a href="#ref73">73</a>, <a href="#ref74">74</a>). Biallelic LoF <i>SVIL</i> variants were identified in patients with skeletal myopathy, mild LV hypertrophy, and smaller descending aortic diameter (<a href="#ref75">75</a>). Indeed, a 10.5-fold excess burden of <i>SVIL</i> rare PTV variants in HCM cases has been demonstrated in a recent GWAS (<a href="#ref47">47</a>). Patients harboring rare truncating <i>SVIL</i> variants were found to have an increased LV contractility in both obstructive and non-obstructive forms of HCM, as demonstrated by Mendelian randomization analyses (<a href="#ref47">47</a>). In one family, the <i>SVIL</i>: p.(Gln255&#x0002A;) variant was found in two affected cousins, providing some evidence of familial segregation (<a href="#ref47">47</a>). In this reanalysis, clinical data were gathered for 7 out of the 13 patients with <i>SVIL</i> variants (<a href="#tab9">Table 9</a>). Three patients harboring the <i>SVIL</i>: p.(Ser1414Thr), p.(Glu1286Lys), and p.(Lys1960Arg) variants presented an aortic phenotype including bicuspid aortic valve disease, isolated ectasia of Valsalva sinus, and mild aortic insufficiency. Overall, the majority of <i>SVIL</i> patients showed severe intramyocardial late gadolinium enhancement. One patient (HCM-108) experienced SCD, and another patient (HCM-139) had a history of syncopes during physical effort. Of note, the patient (HCM-108) carried an additional variant in the <i>FHOD3</i> gene (p.Arg638Trp). A severe scoliosis was diagnosed in one patient (HCM-129).</p>
<p class="mb15">Interestingly, variants in <i>SVIL</i> and <i>FHOD3</i> genes accounted for 10 and 7%, respectively, of patients with early HCM onset. Patients with sarcomere mutations have been reported to show earlier adverse complications and a worse prognosis (<a href="#ref76">76</a>). Several published HCM cohorts, studies, and data provided by the Sarcomeric Human Cardiomyopathy Registry (SHaRe) have shown that cases with sarcomeric variants had an early onset of the disease and a more severe phenotype with malignant complications. Thus, patients diagnosed in early adulthood (&#x0003C;40&#x2009;years) had more severe outcomes with many adverse complications compared to patients with late-onset HCM. Moreover, HCM young patients (20&#x2013;29&#x2009;years) had a 4-fold increase in the risk of death compared to the general population (<a href="#ref76">76</a>&#x2013;<a href="#ref78">78</a>).</p>
<p class="mb15">All the identified variants in this reanalysis were searched in a French control cohort, gathering 960 healthy individuals. Only seven variants were present (<a href="#tab10">Table 10</a>). Of note, <i>TCAP</i>: p.(Met71Thr), <i>ALPK3</i>: p.(Arg1483Trp), <i>FLNC</i>: p.(Arg1860Cys) and <i>MYPN</i>: p.(Pro1112Leu) variants were unique in HYPERGEN carriers. The <i>VCL</i>: p.(His636Arg) and <i>MYPN</i>: p.P (ro1112Leu) variants were found in Finnish and Ashkenazi Jewish populations, respectively, suggesting that these variants could be more prevalent in these bottleneck populations.</p>
<p class="mb15">Although the identification of variants in genes lacking strong evidence for disease causality and/or VUS in minor HCM genes does not increase the clinically actionable genes/variants discovery, it sheds light on the possibility of a combinatorial joint effect where VUS variants may act as a small risk increasing genetic factor.</p>
<p class="mb15">Gathering strong proof of disease causality remains challenging for many reasons, such as the unavailability of family members to undergo co-segregation and funding constraints for functional studies. Indeed, genes such as <i>ALPK3</i> and <i>FHOD3</i> have been considered disease-causing by large gene-centric case&#x2013;control studies. This strategy is an effective approach to reaching the needed statistical power supporting gene&#x2013;disease association (<a href="#ref46">46</a>). Furthermore, the publication of cases with variants of low to moderate evidence was recommended, as the identical variants may be detected in extended families with similar phenotypes by researchers interested in functional validation (<a href="#ref46">46</a>).</p>
<p class="mb15">Presently, we aimed to reanalyze a cohort of 200 HCM patients by focusing on genes strongly associated with HCM while also investigating newly linked genes with limited or insufficient evidence of causality to determine their potential involvement in our cohort. Overall, our results strengthen the implication of <i>FHOD3</i>, <i>TRIM63</i>, and <i>SVIL</i> genes in HCM as minor genes. Variants in the <i>SVIL</i> gene, recently linked to HCM, were found in 13 HYPERGEN patients. More importantly, patients harboring <i>SVIL</i> variants presented a similar hypertrophic pattern (significant myocardial fibrosis for six out of the seven patients/apical for three patients), and aortopathy was reported for three patients. The findings from our study extend the clinical and genetic spectrum of <i>SVIL</i> gene carriers. While Tadros et al. (<a href="#ref47">47</a>) identified <i>SVIL</i> variants in HCM patients, our study reveals additional cases, underscoring the need for expanded genetic screening. This broader understanding can facilitate future investigations into the pathophysiological mechanisms associated with <i>SVIL</i> variants, potentially leading to improved risk stratification and management strategies for patients.</p>
<p class="mb15">The assessing and reporting of the identified variants&#x2014;particularly within the novel associated genes&#x2014;may provide additional strength to the previously reported variants and identify novel variants that help an accurate classification and interpretation. This study contributes to defining the genetic landscape of French HCM patients, which facilitates cascade genetic testing in familial cases and ultimately could guide personalized treatment.</p>
<p class="mb0">The main goal of this study was to assess and report actionable and high-confidence variants in known and emerging HCM genes. However, there are several limitations in our study, making an accurate estimation of the increased diagnostic yield challenging. This is mainly due to the absence of detailed genetic results from the initial analysis. In addition, detailed patient phenotyping and clinical data are lacking. Thus, genotype&#x2013;phenotype correlations and risk stratification were difficult to achieve.</p> <a id="h6" name="h6"></a>
<h2>Data availability statement</h2>
<p class="mb0">The data presented in the study are deposited in the ClinVar database under the following link: <a href="https://www.ncbi.nlm.nih.gov/clinvar/submitters/508840/">https://www.ncbi.nlm.nih.gov/clinvar/submitters/508840/</a>.</p> <a id="h7" name="h7"></a>
<h2>Ethics statement</h2>
<p class="mb0">The studies involving humans were approved by Comit&#x000E9; d&#x2019;&#x000E9;thique de la Recherche d&#x2019;Aix-Marseille Universit&#x000E9;. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p> <a id="h8" name="h8"></a>
<h2>Author contributions</h2>
<p class="mb0">HJ: Conceptualization, Data curation, Formal analysis, Investigation, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. VM: Data curation, Formal analysis, Writing &#x2013; review &#x0026; editing. HM: Data curation, Investigation, Writing &#x2013; review &#x0026; editing. PL: Data curation, Formal analysis, Methodology, Writing &#x2013; review &#x0026; editing. LL: Formal analysis, Investigation, Writing &#x2013; review &#x0026; editing. MH: Formal analysis, Investigation, Writing &#x2013; review &#x0026; editing. CL: Data curation, Writing &#x2013; review &#x0026; editing. FM: Resources, Supervision, Validation, Writing &#x2013; review &#x0026; editing. GH: Data curation, Investigation, Resources, Supervision, Validation, Writing &#x2013; review &#x0026; editing. J-JS: Data curation, Resources, Validation, Writing &#x2013; review &#x0026; editing. SZ: Conceptualization, Data curation, Investigation, Resources, Supervision, Validation, Writing &#x2013; review &#x0026; editing. KN: Data curation, Formal analysis, Investigation, Resources, Validation, Writing &#x2013; review &#x0026; editing.</p> <a id="h9" name="h9"></a>
<h2>Funding</h2>
<p class="mb0">The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by SANOFI GENZYME SA (contract number C01550), the "Association Fran&#x000E7;aise contre les Myopathies" (NMH-Decrypt Project), and the "Institut National de la Sant&#x000E9; et de la Recherche M&#x000E9;dicale" to SZ. HJ received a postdoctoral fellowship from the "Fondation Lefoulon Delalande".</p> <a id="h10" name="h10"></a>
<h2>Conflict of interest</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p> <a id="h11" name="h11"></a>
<h2>Publisher&#x2019;s note</h2>
<p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p> <a id="h12" name="h12"></a>
<h2>Supplementary material</h2>
<p class="mb0" id="SM1">The Supplementary material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fmed.2024.1480947/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmed.2024.1480947/full#supplementary-material</a></p> <a id="h13" name="h13"></a>
<h2>Footnotes</h2> <div id="footnotetext" class="fulltextdescription">
<p style="margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;" id="fn0001">1. <a class="footnotetextanchor" href="#xfn0001" title="">^</a><a href="https://www.clinicalgenome.org/">https://www.clinicalgenome.org/</a></p>
<p style="margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;" id="fn0002">2. <a class="footnotetextanchor" href="#xfn0002" title="">^</a><a href="https://github.com/lindenb/gazoduc-nf/tree/aab8c83f47267e64a24a37bed686ec4f041003e6/workflows/gatk/gatk4gvcfs">https://github.com/lindenb/gazoduc-nf/tree/aab8c83f47267e64a24a37bed686ec4f041003e6/workflows/gatk/gatk4gvcfs</a></p>
<p style="margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;" id="fn0003">3. <a class="footnotetextanchor" href="#xfn0003" title="">^</a><a href="https://doi.org/10.6084/m9.figshare.1425030.v1">https://doi.org/10.6084/m9.figshare.1425030.v1</a></p>
</div> <a id="h14" name="h14"></a>
<h2>References</h2>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref1" id="ref1"></a>1. Richard, P, Charron, P, Carrier, L, Ledeuil, C, Cheav, T, Pichereau, C, et al. Hypertrophic cardiomyopathy: distribution of disease genes, Spectrum of mutations, and implications for a molecular diagnosis strategy. <i>Circulation</i>. (2003) 107:2227&#x2013;32. doi: 10.1161/01.CIR.0000066323.15244.54</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1161/01.CIR.0000066323.15244.54" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Richard&#x00026;author=P+Charron&#x00026;author=L+Carrier&#x00026;author=C+Ledeuil&#x00026;author=T+Cheav&#x00026;author=C+Pichereau&#x00026;publication_year=2003&#x00026;title=Hypertrophic+cardiomyopathy:+distribution+of+disease+genes+Spectrum+of+mutations+and+implications+for+a+molecular+diagnosis+strategy&#x00026;journal=Circulation&#x00026;volume=107&#x00026;pages=2227-32" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref2" id="ref2"></a>2. Muresan, ID, and Agoston-Coldea, L. Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging. <i>Heart Fail Rev</i>. (2021) 26:1023&#x2013;36. doi: 10.1007/s10741-020-09931-1 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32040801" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10741-020-09931-1" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=ID+Muresan&#x00026;author=L+Agoston-Coldea&#x00026;publication_year=2021&#x00026;title=Phenotypes+of+hypertrophic+cardiomyopathy:+genetics+clinics+and+modular+imaging&#x00026;journal=Heart+Fail+Rev&#x00026;volume=26&#x00026;pages=1023-36" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref3" id="ref3"></a>3. Maron, BJ, Desai, MY, Nishimura, RA, Spirito, P, Rakowski, H, Towbin, JA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. <i>J Am Coll Cardiol</i>. (2022) 79:372&#x2013;89. doi: 10.1016/j.jacc.2021.12.002</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/j.jacc.2021.12.002" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BJ+Maron&#x00026;author=MY+Desai&#x00026;author=RA+Nishimura&#x00026;author=P+Spirito&#x00026;author=H+Rakowski&#x00026;author=JA+Towbin&#x00026;publication_year=2022&#x00026;title=Diagnosis+and+evaluation+of+hypertrophic+cardiomyopathy:+JACC+state-of-the-art+review&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=79&#x00026;pages=372-89" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref4" id="ref4"></a>4. Litt, MJ, Ali, A, and Reza, N. Familial hypertrophic cardiomyopathy: diagnosis and management. <i>Vasc Health Risk Manag</i>. (2023) 19:211&#x2013;21. doi: 10.2147/VHRM.S365001 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/37050929" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.2147/VHRM.S365001" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MJ+Litt&#x00026;author=A+Ali&#x00026;author=N+Reza&#x00026;publication_year=2023&#x00026;title=Familial+hypertrophic+cardiomyopathy:+diagnosis+and+management&#x00026;journal=Vasc+Health+Risk+Manag&#x00026;volume=19&#x00026;pages=211-21" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref5" id="ref5"></a>5. Bourfiss, M, van Vugt, M, Alasiri, AI, Ruijsink, B, van Setten, J, Schmidt, AF, et al. Prevalence and disease expression of pathogenic and likely pathogenic variants associated with inherited cardiomyopathies in the general population. <i>Circ Genomic Precis Med</i>. (2022) 15:e003704. doi: 10.1161/CIRCGEN.122.003704</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1161/CIRCGEN.122.003704" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Bourfiss&#x00026;author=M+van+Vugt&#x00026;author=AI+Alasiri&#x00026;author=B+Ruijsink&#x00026;author=J+van+Setten&#x00026;author=AF+Schmidt&#x00026;publication_year=2022&#x00026;title=Prevalence+and+disease+expression+of+pathogenic+and+likely+pathogenic+variants+associated+with+inherited+cardiomyopathies+in+the+general+population&#x00026;journal=Circ+Genomic+Precis+Med&#x00026;volume=15&#x00026;pages=e003704" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref6" id="ref6"></a>6. Maron, BJ, Desai, MY, Nishimura, RA, Spirito, P, Rakowski, H, Towbin, JA, et al. Management of Hypertrophic Cardiomyopathy: JACC state-of-the-art review. <i>J Am Coll Cardiol</i>. (2022) 79:390&#x2013;414. doi: 10.1016/j.jacc.2021.11.021</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/j.jacc.2021.11.021" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BJ+Maron&#x00026;author=MY+Desai&#x00026;author=RA+Nishimura&#x00026;author=P+Spirito&#x00026;author=H+Rakowski&#x00026;author=JA+Towbin&#x00026;publication_year=2022&#x00026;title=Management+of+Hypertrophic+Cardiomyopathy:+JACC+state-of-the-art+review&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=79&#x00026;pages=390-414" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref7" id="ref7"></a>7. Semsarian, C, Ingles, J, Maron, MS, and Maron, BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. <i>J Am Coll Cardiol</i>. (2015) 65:1249&#x2013;54. doi: 10.1016/j.jacc.2015.01.019 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25814232" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2015.01.019" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Semsarian&#x00026;author=J+Ingles&#x00026;author=MS+Maron&#x00026;author=BJ+Maron&#x00026;publication_year=2015&#x00026;title=New+perspectives+on+the+prevalence+of+hypertrophic+cardiomyopathy&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=65&#x00026;pages=1249-54" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref8" id="ref8"></a>8. Members, WC, Ommen, SR, Mital, S, Burke, MA, Day, SM, Deswal, A, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>Circulation</i>. (2020) 142:e533&#x2013;57. doi: 10.1161/CIR.0000000000000938</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1161/CIR.0000000000000938" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WC+Members&#x00026;author=SR+Ommen&#x00026;author=S+Mital&#x00026;author=MA+Burke&#x00026;author=SM+Day&#x00026;author=A+Deswal&#x00026;publication_year=2020&#x00026;title=2020+AHA/ACC+guideline+for+the+diagnosis+and+treatment+of+patients+with+hypertrophic+cardiomyopathy:+Executive+summary:+A+report+of+the+American+College+of+Cardiology/American+Heart+Association+joint+committee+on+clinical+practice+guidelines&#x00026;journal=Circulation&#x00026;volume=142&#x00026;pages=e533-57" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref9" id="ref9"></a>9. Morimoto, S. Sarcomeric proteins and inherited cardiomyopathies. <i>Cardiovasc Res</i>. (2008) 77:659&#x2013;66. doi: 10.1093/cvr/cvm084 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18056765" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/cvr/cvm084" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Morimoto&#x00026;publication_year=2008&#x00026;title=Sarcomeric+proteins+and+inherited+cardiomyopathies&#x00026;journal=Cardiovasc+Res&#x00026;volume=77&#x00026;pages=659-66" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref10" id="ref10"></a>10. Sabater-Molina, M, P&#x000E9;rez-S&#x000E1;nchez, I, JPH, R, and Gimeno, JR. Genetics of hypertrophic cardiomyopathy: a review of current state. <i>Clin Genet</i>. (2018) 93:3&#x2013;14. doi: 10.1111/cge.13027</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1111/cge.13027" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Sabater-Molina&#x00026;author=I+P&#x000E9;rez-S&#x000E1;nchez&#x00026;author=R+JPH&#x00026;author=JR+Gimeno&#x00026;publication_year=2018&#x00026;title=Genetics+of+hypertrophic+cardiomyopathy:+a+review+of+current+state&#x00026;journal=Clin+Genet&#x00026;volume=93&#x00026;pages=3-14" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref11" id="ref11"></a>11. Borrelli, F, Losi, MA, Canciello, G, Todde, G, Perillo, EF, Ordine, L, et al. Sarcomeric versus non-Sarcomeric HCM. <i>Cardiogenetics</i>. (2023) 13:92&#x2013;105. doi: 10.3390/cardiogenetics13020009</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.3390/cardiogenetics13020009" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Borrelli&#x00026;author=MA+Losi&#x00026;author=G+Canciello&#x00026;author=G+Todde&#x00026;author=EF+Perillo&#x00026;author=L+Ordine&#x00026;publication_year=2023&#x00026;title=Sarcomeric+versus+non-Sarcomeric+HCM&#x00026;journal=Cardiogenetics&#x00026;volume=13&#x00026;pages=92-105" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref12" id="ref12"></a>12. Walsh, R, Offerhaus, JA, Tadros, R, and Bezzina, CR. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. <i>Nat Rev Cardiol</i>. (2022) 19:151&#x2013;67. doi: 10.1038/s41569-021-00608-2 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34526680" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41569-021-00608-2" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=JA+Offerhaus&#x00026;author=R+Tadros&#x00026;author=CR+Bezzina&#x00026;publication_year=2022&#x00026;title=Minor+hypertrophic+cardiomyopathy+genes+major+insights+into+the+genetics+of+cardiomyopathies&#x00026;journal=Nat+Rev+Cardiol&#x00026;volume=19&#x00026;pages=151-67" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref13" id="ref13"></a>13. Walsh, R, Buchan, R, Wilk, A, John, S, Felkin, LE, Thomson, KL, et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. <i>Eur Heart J</i>. (2017) 38:3461&#x2013;8. doi: 10.1093/eurheartj/ehw603 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28082330" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/eurheartj/ehw603" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=R+Buchan&#x00026;author=A+Wilk&#x00026;author=S+John&#x00026;author=LE+Felkin&#x00026;author=KL+Thomson&#x00026;publication_year=2017&#x00026;title=Defining+the+genetic+architecture+of+hypertrophic+cardiomyopathy:+re-evaluating+the+role+of+non-sarcomeric+genes&#x00026;journal=Eur+Heart+J&#x00026;volume=38&#x00026;pages=3461-8" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref14" id="ref14"></a>14. Lopes, LR, Syrris, P, Guttmann, OP, O&#x2019;Mahony, C, Tang, HC, Dalageorgou, C, et al. Novel genotype&#x2013;phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. <i>Heart</i>. (2015) 101:294&#x2013;301. doi: 10.1136/heartjnl-2014-306387 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25351510" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/heartjnl-2014-306387" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=LR+Lopes&#x00026;author=P+Syrris&#x00026;author=OP+Guttmann&#x00026;author=C+O&#x2019;Mahony&#x00026;author=HC+Tang&#x00026;author=C+Dalageorgou&#x00026;publication_year=2015&#x00026;title=Novel+genotype&#x2013;phenotype+associations+demonstrated+by+high-throughput+sequencing+in+patients+with+hypertrophic+cardiomyopathy&#x00026;journal=Heart&#x00026;volume=101&#x00026;pages=294-301" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref15" id="ref15"></a>15. Lopes, LR, Zekavati, A, Syrris, P, Hubank, M, Giambartolomei, C, Dalageorgou, C, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. <i>J Med Genet</i>. (2013) 50:228&#x2013;39. doi: 10.1136/jmedgenet-2012-101270 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23396983" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jmedgenet-2012-101270" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=LR+Lopes&#x00026;author=A+Zekavati&#x00026;author=P+Syrris&#x00026;author=M+Hubank&#x00026;author=C+Giambartolomei&#x00026;author=C+Dalageorgou&#x00026;publication_year=2013&#x00026;title=Genetic+complexity+in+hypertrophic+cardiomyopathy+revealed+by+high-throughput+sequencing&#x00026;journal=J+Med+Genet&#x00026;volume=50&#x00026;pages=228-39" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref16" id="ref16"></a>16. Maron, BJ, Maron, MS, Maron, BA, and Loscalzo, J. Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy. <i>J Am Coll Cardiol</i>. (2019) 73:1978&#x2013;86. doi: 10.1016/j.jacc.2019.01.061 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31000001" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2019.01.061" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BJ+Maron&#x00026;author=MS+Maron&#x00026;author=BA+Maron&#x00026;author=J+Loscalzo&#x00026;publication_year=2019&#x00026;title=Moving+beyond+the+sarcomere+to+explain+heterogeneity+in+hypertrophic+cardiomyopathy&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=73&#x00026;pages=1978-86" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref17" id="ref17"></a>17. Marian, AJ. Oligogenic cardiomyopathy. J Cardiovasc. <i>Aging</i>. (2022) 2:3. doi: 10.20517/jca.2021.27</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.20517/jca.2021.27" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AJ+Marian&#x00026;publication_year=2022&#x00026;title=Oligogenic+cardiomyopathy.+J+Cardiovasc&#x00026;journal=Aging&#x00026;volume=2&#x00026;pages=3" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref18" id="ref18"></a>18. Baulina, NM, Kiselev, IS, Chumakova, OS, and Favorova, OO. Hypertrophic cardiomyopathy as an Oligogenic disease: transcriptomic arguments. <i>Mol Biol</i>. (2020) 54:840&#x2013;50. doi: 10.1134/S0026893320060023</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1134/S0026893320060023" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=NM+Baulina&#x00026;author=IS+Kiselev&#x00026;author=OS+Chumakova&#x00026;author=OO+Favorova&#x00026;publication_year=2020&#x00026;title=Hypertrophic+cardiomyopathy+as+an+Oligogenic+disease:+transcriptomic+arguments&#x00026;journal=Mol+Biol&#x00026;volume=54&#x00026;pages=840-50" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref19" id="ref19"></a>19. Helms, AS, and Day, SM. Other side of the coin: the missing heritability in hypertrophic cardiomyopathy. <i>Eur Heart J</i>. (2017) 38:3469&#x2013;71. doi: 10.1093/eurheartj/ehx024 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28201496" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/eurheartj/ehx024" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AS+Helms&#x00026;author=SM+Day&#x00026;publication_year=2017&#x00026;title=Other+side+of+the+coin:+the+missing+heritability+in+hypertrophic+cardiomyopathy&#x00026;journal=Eur+Heart+J&#x00026;volume=38&#x00026;pages=3469-71" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref20" id="ref20"></a>20. Li, L, Bainbridge, MN, Tan, Y, Willerson, JT, and Marian, AJ. A potential Oligogenic etiology of hypertrophic cardiomyopathy novelty and significance: a classic single-gene disorder. <i>Circ Res</i>. (2017) 120:1084&#x2013;90. doi: 10.1161/CIRCRESAHA.116.310559 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28223422" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCRESAHA.116.310559" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Li&#x00026;author=MN+Bainbridge&#x00026;author=Y+Tan&#x00026;author=JT+Willerson&#x00026;author=AJ+Marian&#x00026;publication_year=2017&#x00026;title=A+potential+Oligogenic+etiology+of+hypertrophic+cardiomyopathy+novelty+and+significance:+a+classic+single-gene+disorder&#x00026;journal=Circ+Res&#x00026;volume=120&#x00026;pages=1084-90" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref21" id="ref21"></a>21. Gorlov, I, Gorlova, O, Frazier, M, Spitz, M, and Amos, C. Evolutionary evidence of the effect of rare variants on disease etiology. <i>Clin Genet</i>. (2011) 79:199&#x2013;206. doi: 10.1111/j.1399-0004.2010.01535.x </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20831747" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/j.1399-0004.2010.01535.x" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I+Gorlov&#x00026;author=O+Gorlova&#x00026;author=M+Frazier&#x00026;author=M+Spitz&#x00026;author=C+Amos&#x00026;publication_year=2011&#x00026;title=Evolutionary+evidence+of+the+effect+of+rare+variants+on+disease+etiology&#x00026;journal=Clin+Genet&#x00026;volume=79&#x00026;pages=199-206" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref22" id="ref22"></a>22. Zuk, O, Schaffner, SF, Samocha, K, Do, R, Hechter, E, Kathiresan, S, et al. Searching for missing heritability: designing rare variant association studies. <i>Proc Natl Acad Sci</i>. (2014) 111:E455&#x2013;64. doi: 10.1073/pnas.1322563111</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1073/pnas.1322563111" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=O+Zuk&#x00026;author=SF+Schaffner&#x00026;author=K+Samocha&#x00026;author=R+Do&#x00026;author=E+Hechter&#x00026;author=S+Kathiresan&#x00026;publication_year=2014&#x00026;title=Searching+for+missing+heritability:+designing+rare+variant+association+studies&#x00026;journal=Proc+Natl+Acad+Sci&#x00026;volume=111&#x00026;pages=E455-64" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref23" id="ref23"></a>23. Schobers, G, Schieving, JH, Yntema, HG, Pennings, M, Pfundt, R, Derks, R, et al. Reanalysis of exome negative patients with rare disease: a pragmatic workflow for diagnostic applications. <i>Genome Med</i>. (2022) 14:66. doi: 10.1186/s13073-022-01069-z </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/35710456" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13073-022-01069-z" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Schobers&#x00026;author=JH+Schieving&#x00026;author=HG+Yntema&#x00026;author=M+Pennings&#x00026;author=R+Pfundt&#x00026;author=R+Derks&#x00026;publication_year=2022&#x00026;title=Reanalysis+of+exome+negative+patients+with+rare+disease:+a+pragmatic+workflow+for+diagnostic+applications&#x00026;journal=Genome+Med&#x00026;volume=14&#x00026;pages=66" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref24" id="ref24"></a>24. Hiatt, SM, Amaral, MD, Bowling, KM, Finnila, CR, Thompson, ML, Gray, DE, et al. Systematic reanalysis of genomic data improves quality of variant interpretation. <i>Clin Genet</i>. (2018) 94:174&#x2013;8. doi: 10.1111/cge.13259 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29652076" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cge.13259" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SM+Hiatt&#x00026;author=MD+Amaral&#x00026;author=KM+Bowling&#x00026;author=CR+Finnila&#x00026;author=ML+Thompson&#x00026;author=DE+Gray&#x00026;publication_year=2018&#x00026;title=Systematic+reanalysis+of+genomic+data+improves+quality+of+variant+interpretation&#x00026;journal=Clin+Genet&#x00026;volume=94&#x00026;pages=174-8" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref25" id="ref25"></a>25. Nguyen, K, Roche, S, Donal, E, Odent, S, Eicher, J-C, Faivre, L, et al. Whole exome sequencing reveals a large genetic heterogeneity and revisits the causes of hypertrophic cardiomyopathy. <i>Circ Genomic Precis Med</i>. (2019) 12:e002500. doi: 10.1161/CIRCGEN.119.002500 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31112424" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCGEN.119.002500" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Nguyen&#x00026;author=S+Roche&#x00026;author=E+Donal&#x00026;author=S+Odent&#x00026;author=J-C+Eicher&#x00026;author=L+Faivre&#x00026;publication_year=2019&#x00026;title=Whole+exome+sequencing+reveals+a+large+genetic+heterogeneity+and+revisits+the+causes+of+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Genomic+Precis+Med&#x00026;volume=12&#x00026;pages=e002500" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref26" id="ref26"></a>26. Rentzsch, P, Witten, D, Cooper, GM, Shendure, J, and Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. <i>Nucleic Acids Res</i>. (2019) 47:D886&#x2013;94. doi: 10.1093/nar/gky1016</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1093/nar/gky1016" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Rentzsch&#x00026;author=D+Witten&#x00026;author=GM+Cooper&#x00026;author=J+Shendure&#x00026;author=M+Kircher&#x00026;publication_year=2019&#x00026;title=CADD:+predicting+the+deleteriousness+of+variants+throughout+the+human+genome&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=47&#x00026;pages=D886-94" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref27" id="ref27"></a>27. Adzhubei, I, Jordan, DM, and Sunyaev, SR. Predicting functional effect of human missense mutations using poly Phen-2. <i>Curr Protoc Hum Genet</i>. (2013) Chapter 7: Unit 7.20 doi: 10.1002/0471142905.hg0720s76</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1002/0471142905.hg0720s76" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I+Adzhubei&#x00026;author=DM+Jordan&#x00026;author=SR+Sunyaev&#x00026;publication_year=2013&#x00026;title=Predicting+functional+effect+of+human+missense+mutations+using+poly+Phen-2&#x00026;journal=Curr+Protoc+Hum+Genet&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref28" id="ref28"></a>28. Ng, PC, and Henikoff, S. SIFT: predicting amino acid changes that affect protein function. <i>Nucleic Acids Res</i>. (2003) 31:3812&#x2013;4. doi: 10.1093/nar/gkg509 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/12824425" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkg509" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=PC+Ng&#x00026;author=S+Henikoff&#x00026;publication_year=2003&#x00026;title=SIFT:+predicting+amino+acid+changes+that+affect+protein+function&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=31&#x00026;pages=3812-4" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref29" id="ref29"></a>29. Schwarz, JM, Cooper, DN, Schuelke, M, and Seelow, D. Mutation taster 2: mutation prediction for the deep-sequencing age. <i>Nat Methods</i>. (2014) 11:361&#x2013;2. doi: 10.1038/nmeth.2890 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24681721" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nmeth.2890" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JM+Schwarz&#x00026;author=DN+Cooper&#x00026;author=M+Schuelke&#x00026;author=D+Seelow&#x00026;publication_year=2014&#x00026;title=Mutation+taster+2:+mutation+prediction+for+the+deep-sequencing+age&#x00026;journal=Nat+Methods&#x00026;volume=11&#x00026;pages=361-2" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref30" id="ref30"></a>30. Walsh, R, Mazzarotto, F, Whiffin, N, Buchan, R, Midwinter, W, Wilk, A, et al. Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. <i>Genome Med</i>. (2019) 11:5. doi: 10.1186/s13073-019-0616-z </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30696458" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13073-019-0616-z" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=F+Mazzarotto&#x00026;author=N+Whiffin&#x00026;author=R+Buchan&#x00026;author=W+Midwinter&#x00026;author=A+Wilk&#x00026;publication_year=2019&#x00026;title=Quantitative+approaches+to+variant+classification+increase+the+yield+and+precision+of+genetic+testing+in+Mendelian+diseases:+the+case+of+hypertrophic+cardiomyopathy&#x00026;journal=Genome+Med&#x00026;volume=11&#x00026;pages=5" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref31" id="ref31"></a>31. Richards, S, Aziz, N, Bale, S, Bick, D, Das, S, Gastier-Foster, J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <i>Genet Med Off J Am Coll Med Genet</i>. (2015) 17:405&#x2013;24. doi: 10.1038/gim.2015.30</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1038/gim.2015.30" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Richards&#x00026;author=N+Aziz&#x00026;author=S+Bale&#x00026;author=D+Bick&#x00026;author=S+Das&#x00026;author=J+Gastier-Foster&#x00026;publication_year=2015&#x00026;title=Standards+and+guidelines+for+the+interpretation+of+sequence+variants:+a+joint+consensus+recommendation+of+the+American+College+of+Medical+Genetics+and+Genomics+and+the+Association+for+Molecular+Pathology&#x00026;journal=Genet+Med+Off+J+Am+Coll+Med+Genet&#x00026;volume=17&#x00026;pages=405-24" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref32" id="ref32"></a>32. Kanehisa, M, Sato, Y, Kawashima, M, Furumichi, M, and Tanabe, M. KEGG as a reference resource for gene and protein annotation. <i>Nucleic Acids Res</i>. (2016) 44:D457&#x2013;62. doi: 10.1093/nar/gkv1070</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1093/nar/gkv1070" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Kanehisa&#x00026;author=Y+Sato&#x00026;author=M+Kawashima&#x00026;author=M+Furumichi&#x00026;author=M+Tanabe&#x00026;publication_year=2016&#x00026;title=KEGG+as+a+reference+resource+for+gene+and+protein+annotation&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=44&#x00026;pages=D457-62" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref33" id="ref33"></a>33. Jassal, B, Matthews, L, Viteri, G, Gong, C, Lorente, P, Fabregat, A, et al. The reactome pathway knowledgebase. <i>Nucleic Acids Res</i>. (2020) 48:D498&#x2013;503. doi: 10.1093/nar/gkz1031 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31691815" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkz1031" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B+Jassal&#x00026;author=L+Matthews&#x00026;author=G+Viteri&#x00026;author=C+Gong&#x00026;author=P+Lorente&#x00026;author=A+Fabregat&#x00026;publication_year=2020&#x00026;title=The+reactome+pathway+knowledgebase&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=48&#x00026;pages=D498-503" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref34" id="ref34"></a>34. K&#x000F6;hler, S, Gargano, M, Matentzoglu, N, Carmody, LC, Lewis-Smith, D, Vasilevsky, NA, et al. The human phenotype ontology in 2021. <i>Nucleic Acids Res</i>. (2021) 49:D1207&#x2013;17. doi: 10.1093/nar/gkaa1043 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33264411" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkaa1043" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+K&#x000F6;hler&#x00026;author=M+Gargano&#x00026;author=N+Matentzoglu&#x00026;author=LC+Carmody&#x00026;author=D+Lewis-Smith&#x00026;author=NA+Vasilevsky&#x00026;publication_year=2021&#x00026;title=The+human+phenotype+ontology+in+2021&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=49&#x00026;pages=D1207-17" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref35" id="ref35"></a>35. Gene Ontology Consortium. Gene ontology consortium: going forward. <i>Nucleic Acids Res</i>. (2015) 43:D1049&#x2013;56. doi: 10.1093/nar/gku1179 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25428369" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gku1179" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?publication_year=2015&#x00026;title=Gene+ontology+consortium:+going+forward&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=43&#x00026;pages=D1049-56" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref36" id="ref36"></a>36. Desvignes, J-P, Bartoli, M, Delague, V, Krahn, M, Miltgen, M, B&#x000E9;roud, C, et al. Var AFT: a variant annotation and filtration system for human next generation sequencing data. <i>Nucleic Acids Res</i>. (2018) 46:W545&#x2013;53. doi: 10.1093/nar/gky471 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29860484" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gky471" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J-P+Desvignes&#x00026;author=M+Bartoli&#x00026;author=V+Delague&#x00026;author=M+Krahn&#x00026;author=M+Miltgen&#x00026;author=C+B&#x000E9;roud&#x00026;publication_year=2018&#x00026;title=Var+AFT:+a+variant+annotation+and+filtration+system+for+human+next+generation+sequencing+data&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=46&#x00026;pages=W545-53" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref37" id="ref37"></a>37. Cingolani, P, Platts, A, Wang, LL, Coon, M, Nguyen, T, Wang, L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of <i>Drosophila melanogaster</i> strain w1118; iso-2; iso-3. <i>Fly (Austin)</i>. (2012) 6:80&#x2013;92. doi: 10.4161/fly.19695 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22728672" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4161/fly.19695" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Cingolani&#x00026;author=A+Platts&#x00026;author=LL+Wang&#x00026;author=M+Coon&#x00026;author=T+Nguyen&#x00026;author=L+Wang&#x00026;publication_year=2012&#x00026;title=A+program+for+annotating+and+predicting+the+effects+of+single+nucleotide+polymorphisms+SnpEff:+SNPs+in+the+genome+of+Drosophila+melanogaster+strain+w1118;+iso-2;+iso-3&#x00026;journal=Fly+(Austin)&#x00026;volume=6&#x00026;pages=80-92" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref38" id="ref38"></a>38. Park, J, Packard, EA, Levin, MG, Judy, RL, Damrauer, SM, Day, SM, et al. A genome-first approach to rare variants in hypertrophic cardiomyopathy genes MYBPC3 and MYH7 in a medical biobank. <i>Hum Mol Genet</i>. (2021) 31:827&#x2013;37. doi: 10.1093/hmg/ddab249</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1093/hmg/ddab249" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Park&#x00026;author=EA+Packard&#x00026;author=MG+Levin&#x00026;author=RL+Judy&#x00026;author=SM+Damrauer&#x00026;author=SM+Day&#x00026;publication_year=2021&#x00026;title=A+genome-first+approach+to+rare+variants+in+hypertrophic+cardiomyopathy+genes+MYBPC3+and+MYH7+in+a+medical+biobank&#x00026;journal=Hum+Mol+Genet&#x00026;volume=31&#x00026;pages=827-37" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref39" id="ref39"></a>39. Ingles, J, Goldstein, J, Thaxton, C, Caleshu, C, Corty, EW, Crowley, SB, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. <i>Circ Genomic Precis Med</i>. (2019) 12:e002460. doi: 10.1161/CIRCGEN.119.002460 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30681346" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCGEN.119.002460" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Ingles&#x00026;author=J+Goldstein&#x00026;author=C+Thaxton&#x00026;author=C+Caleshu&#x00026;author=EW+Corty&#x00026;author=SB+Crowley&#x00026;publication_year=2019&#x00026;title=Evaluating+the+clinical+validity+of+hypertrophic+cardiomyopathy+genes&#x00026;journal=Circ+Genomic+Precis+Med&#x00026;volume=12&#x00026;pages=e002460" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref40" id="ref40"></a>40. Andreeva, S, Chumakova, O, Karelkina, E, Lebedeva, V, Lubimtseva, T, Semenov, A, et al. Case report: two new cases of autosomal-recessive hypertrophic cardiomyopathy associated with TRIM63-compound heterozygous variant. <i>Front Genet</i>. (2022) 13:743472. doi: 10.3389/fgene.2022.743472 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/35273634" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fgene.2022.743472" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Andreeva&#x00026;author=O+Chumakova&#x00026;author=E+Karelkina&#x00026;author=V+Lebedeva&#x00026;author=T+Lubimtseva&#x00026;author=A+Semenov&#x00026;publication_year=2022&#x00026;title=Case+report:+two+new+cases+of+autosomal-recessive+hypertrophic+cardiomyopathy+associated+with+TRIM63-compound+heterozygous+variant&#x00026;journal=Front+Genet&#x00026;volume=13&#x00026;pages=743472" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref41" id="ref41"></a>41. Salazar-Mendiguch&#x000ED;a, J, Ochoa, JP, Palomino-Doza, J, Dom&#x000ED;nguez, F, D&#x000ED;ez-L&#x000F3;pez, C, Akhtar, M, et al. Mutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy. <i>Heart</i>. (2020) 106:1342&#x2013;8. doi: 10.1136/heartjnl-2020-316913 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32451364" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/heartjnl-2020-316913" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Salazar-Mendiguch&#x000ED;a&#x00026;author=JP+Ochoa&#x00026;author=J+Palomino-Doza&#x00026;author=F+Dom&#x000ED;nguez&#x00026;author=C+D&#x000ED;ez-L&#x000F3;pez&#x00026;author=M+Akhtar&#x00026;publication_year=2020&#x00026;title=Mutations+in+TRIM63+cause+an+autosomal-recessive+form+of+hypertrophic+cardiomyopathy&#x00026;journal=Heart&#x00026;volume=106&#x00026;pages=1342-8" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref42" id="ref42"></a>42. Harper, AR, Goel, A, Grace, C, Thomson, KL, Petersen, SE, Xu, X, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. <i>Nat Genet</i>. (2021) 53:135&#x2013;42. doi: 10.1038/s41588-020-00764-0 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33495597" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41588-020-00764-0" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AR+Harper&#x00026;author=A+Goel&#x00026;author=C+Grace&#x00026;author=KL+Thomson&#x00026;author=SE+Petersen&#x00026;author=X+Xu&#x00026;publication_year=2021&#x00026;title=Common+genetic+variants+and+modifiable+risk+factors+underpin+hypertrophic+cardiomyopathy+susceptibility+and+expressivity&#x00026;journal=Nat+Genet&#x00026;volume=53&#x00026;pages=135-42" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref43" id="ref43"></a>43. Ochoa, JP, Sabater-Molina, M, Garc&#x000ED;a-Pinilla, JM, Mogensen, J, Restrepo-C&#x000F3;rdoba, A, Palomino-Doza, J, et al. Formin homology 2 domain containing 3 (FHOD3) is a genetic basis for hypertrophic cardiomyopathy. <i>J Am Coll Cardiol</i>. (2018) 72:2457&#x2013;67. doi: 10.1016/j.jacc.2018.10.001 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30442288" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2018.10.001" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JP+Ochoa&#x00026;author=M+Sabater-Molina&#x00026;author=JM+Garc&#x000ED;a-Pinilla&#x00026;author=J+Mogensen&#x00026;author=A+Restrepo-C&#x000F3;rdoba&#x00026;author=J+Palomino-Doza&#x00026;publication_year=2018&#x00026;title=Formin+homology+2+domain+containing+3+(FHOD3)+is+a+genetic+basis+for+hypertrophic+cardiomyopathy&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=72&#x00026;pages=2457-67" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref44" id="ref44"></a>44. Matsuyama, S, Kage, Y, Fujimoto, N, Ushijima, T, Tsuruda, T, Kitamura, K, et al. Interaction between cardiac myosin-binding protein C and formin Fhod 3. <i>Proc Natl Acad Sci USA</i>. (2018) 115:E4386&#x2013;95. doi: 10.1073/pnas.1716498115 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29686099" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1073/pnas.1716498115" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Matsuyama&#x00026;author=Y+Kage&#x00026;author=N+Fujimoto&#x00026;author=T+Ushijima&#x00026;author=T+Tsuruda&#x00026;author=K+Kitamura&#x00026;publication_year=2018&#x00026;title=Interaction+between+cardiac+myosin-binding+protein+C+and+formin+Fhod+3&#x00026;journal=Proc+Natl+Acad+Sci+USA&#x00026;volume=115&#x00026;pages=E4386-95" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref45" id="ref45"></a>45. Wooten, EC, Hebl, VB, Wolf, MJ, Greytak, SR, Orr, NM, Draper, I, et al. Formin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy. <i>Circ Cardiovasc Genet</i>. (2013) 6:10&#x2013;8. doi: 10.1161/CIRCGENETICS.112.965277 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23255317" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCGENETICS.112.965277" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EC+Wooten&#x00026;author=VB+Hebl&#x00026;author=MJ+Wolf&#x00026;author=SR+Greytak&#x00026;author=NM+Orr&#x00026;author=I+Draper&#x00026;publication_year=2013&#x00026;title=Formin+homology+2+domain+containing+3+variants+associated+with+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Cardiovasc+Genet&#x00026;volume=6&#x00026;pages=10-8" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref46" id="ref46"></a>46. Chumakova, OS, and Baulina, NM. Advanced searching for hypertrophic cardiomyopathy heritability in real practice tomorrow. <i>Front Cardiovasc Med</i>. (2023) 10:1236539. doi: 10.3389/fcvm.2023.1236539 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/37583586" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fcvm.2023.1236539" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=OS+Chumakova&#x00026;author=NM+Baulina&#x00026;publication_year=2023&#x00026;title=Advanced+searching+for+hypertrophic+cardiomyopathy+heritability+in+real+practice+tomorrow&#x00026;journal=Front+Cardiovasc+Med&#x00026;volume=10&#x00026;pages=1236539" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref47" id="ref47"></a>47. Tadros, R, Zheng, SL, Grace, C, Jord&#x000E0;, P, Francis, C, Jurgens, SJ, et al. Large scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy. <i>med Rxiv</i>. [Preprint] (2023); 2023.01.28.23285147:44) 44. doi: 10.1093/eurheartj/ehad655.3197</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1093/eurheartj/ehad655.3197" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Tadros&#x00026;author=SL+Zheng&#x00026;author=C+Grace&#x00026;author=P+Jord&#x000E0;&#x00026;author=C+Francis&#x00026;author=SJ+Jurgens&#x00026;publication_year=2023&#x00026;title=Large+scale+genome-wide+association+analyses+identify+novel+genetic+loci+and+mechanisms+in+hypertrophic+cardiomyopathy&#x00026;journal=med+Rxiv&#x00026;volume=44&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref48" id="ref48"></a>48. Josephs, KS, Roberts, AM, Theotokis, P, Walsh, R, Ostrowski, PJ, Edwards, M, et al. Beyond gene-disease validity: capturing structured data on inheritance, allelic-requirement, disease-relevant variant classes, and disease mechanism for inherited cardiac conditions. <i>Med Rxiv Prepr Serv Health Sci</i>. (2023) doi: 10.1186/s13073-023-01246-8</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1186/s13073-023-01246-8" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KS+Josephs&#x00026;author=AM+Roberts&#x00026;author=P+Theotokis&#x00026;author=R+Walsh&#x00026;author=PJ+Ostrowski&#x00026;author=M+Edwards&#x00026;publication_year=2023&#x00026;title=Beyond+gene-disease+validity:+capturing+structured+data+on+inheritance+allelic-requirement+disease-relevant+variant+classes+and+disease+mechanism+for+inherited+cardiac+conditions&#x00026;journal=Med+Rxiv+Prepr+Serv+Health+Sci&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref49" id="ref49"></a>49. Zhang, XL, De, S, McIntosh, LP, and Paetzel, M. Structural characterization of the C3 domain of cardiac myosin binding protein C and its hypertrophic cardiomyopathy-related R502W mutant. <i>Biochemistry</i>. (2014) 53:5332&#x2013;42. doi: 10.1021/bi500784g</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1021/bi500784g" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=XL+Zhang&#x00026;author=S+De&#x00026;author=LP+McIntosh&#x00026;author=M+Paetzel&#x00026;publication_year=2014&#x00026;title=Structural+characterization+of+the+C3+domain+of+cardiac+myosin+binding+protein+C+and+its+hypertrophic+cardiomyopathy-related+R502W+mutant&#x00026;journal=Biochemistry&#x00026;volume=53&#x00026;pages=5332-42" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref50" id="ref50"></a>50. Saltzman, AJ, Mancini-DiNardo, D, Li, C, Chung, WK, Ho, CY, Hurst, S, et al. Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy. <i>Circ Res</i>. (2010) 106:1549&#x2013;52. doi: 10.1161/CIRCRESAHA.109.216291 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20378854" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCRESAHA.109.216291" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AJ+Saltzman&#x00026;author=D+Mancini-DiNardo&#x00026;author=C+Li&#x00026;author=WK+Chung&#x00026;author=CY+Ho&#x00026;author=S+Hurst&#x00026;publication_year=2010&#x00026;title=Short+communication:+the+cardiac+myosin+binding+protein+C+Arg502Trp+mutation:+a+common+cause+of+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Res&#x00026;volume=106&#x00026;pages=1549-52" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref51" id="ref51"></a>51. Walsh, R, Thomson, KL, Ware, JS, Funke, BH, Woodley, J, McGuire, KJ, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. <i>Genet Med</i>. (2017) 19:192&#x2013;203. doi: 10.1038/gim.2016.90 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27532257" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/gim.2016.90" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=KL+Thomson&#x00026;author=JS+Ware&#x00026;author=BH+Funke&#x00026;author=J+Woodley&#x00026;author=KJ+McGuire&#x00026;publication_year=2017&#x00026;title=Reassessment+of+Mendelian+gene+pathogenicity+using+7855+cardiomyopathy+cases+and+60706+reference+samples&#x00026;journal=Genet+Med&#x00026;volume=19&#x00026;pages=192-203" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref52" id="ref52"></a>52. Andersen, PS, Havndrup, O, Bundgaard, H, Moolman-Smook, JC, Larsen, LA, Mogensen, J, et al. Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and south African populations. <i>J Med Genet</i>. (2001) 38:43e&#x2013;443e. doi: 10.1136/jmg.38.12.e43 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/11748309" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jmg.38.12.e43" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=PS+Andersen&#x00026;author=O+Havndrup&#x00026;author=H+Bundgaard&#x00026;author=JC+Moolman-Smook&#x00026;author=LA+Larsen&#x00026;author=J+Mogensen&#x00026;publication_year=2001&#x00026;title=Myosin+light+chain+mutations+in+familial+hypertrophic+cardiomyopathy:+phenotypic+presentation+and+frequency+in+Danish+and+south+African+populations&#x00026;journal=J+Med+Genet&#x00026;volume=38&#x00026;pages=43e-443e" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref53" id="ref53"></a>53. Marian, AJ. Molecular genetic basis of hypertrophic cardiomyopathy. <i>Circ Res</i>. (2021) 128:1533. doi: 10.1161/CIRCRESAHA.121.318346 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33983830" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCRESAHA.121.318346" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AJ+Marian&#x00026;publication_year=2021&#x00026;title=Molecular+genetic+basis+of+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Res&#x00026;volume=128&#x00026;pages=1533" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref54" id="ref54"></a>54. Mathew, J, Zahavich, L, Lafreniere-Roula, M, Wilson, J, George, K, Benson, L, et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. <i>Clin Genet</i>. (2018) 93:310&#x2013;9. doi: 10.1111/cge.13157 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29053178" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cge.13157" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Mathew&#x00026;author=L+Zahavich&#x00026;author=M+Lafreniere-Roula&#x00026;author=J+Wilson&#x00026;author=K+George&#x00026;author=L+Benson&#x00026;publication_year=2018&#x00026;title=Utility+of+genetics+for+risk+stratification+in+pediatric+hypertrophic+cardiomyopathy&#x00026;journal=Clin+Genet&#x00026;volume=93&#x00026;pages=310-9" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref55" id="ref55"></a>55. Pham, JH, Giudicessi, JR, Tweet, MS, Boucher, L, Newman, DB, and Geske, JB. Tale of two hearts: a TNNT2 hypertrophic cardiomyopathy case report. <i>Front Cardiovasc Med.</i> (2023) 10:1167256. doi: 10.3389/fcvm.2023.1167256 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/37180798" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fcvm.2023.1167256" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JH+Pham&#x00026;author=JR+Giudicessi&#x00026;author=MS+Tweet&#x00026;author=L+Boucher&#x00026;author=DB+Newman&#x00026;author=JB+Geske&#x00026;publication_year=2023&#x00026;title=Tale+of+two+hearts:+a+TNNT2+hypertrophic+cardiomyopathy+case+report&#x00026;journal=Front+Cardiovasc+Med.&#x00026;volume=10&#x00026;pages=1167256" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref56" id="ref56"></a>56. Allouba, M, Walsh, R, Afify, A, Hosny, M, Halawa, S, Galal, A, et al. Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy. <i>Eur Heart J</i>. (2023) 44:5146&#x2013;58. doi: 10.1093/eurheartj/ehad372</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1093/eurheartj/ehad372" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Allouba&#x00026;author=R+Walsh&#x00026;author=A+Afify&#x00026;author=M+Hosny&#x00026;author=S+Halawa&#x00026;author=A+Galal&#x00026;publication_year=2023&#x00026;title=Ethnicity+consanguinity+and+genetic+architecture+of+hypertrophic+cardiomyopathy&#x00026;journal=Eur+Heart+J&#x00026;volume=44&#x00026;pages=5146-58" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref57" id="ref57"></a>57. Kn&#x000F6;ll, R, Kostin, S, Klede, S, Savvatis, K, Klinge, L, Stehle, I, et al. A common MLP (muscle LIM protein) variant is associated with cardiomyopathy. <i>Circ Res</i>. (2010) 106:695&#x2013;704. doi: 10.1161/CIRCRESAHA.109.206243 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20044516" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCRESAHA.109.206243" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Kn&#x000F6;ll&#x00026;author=S+Kostin&#x00026;author=S+Klede&#x00026;author=K+Savvatis&#x00026;author=L+Klinge&#x00026;author=I+Stehle&#x00026;publication_year=2010&#x00026;title=A+common+MLP+(muscle+LIM+protein)+variant+is+associated+with+cardiomyopathy&#x00026;journal=Circ+Res&#x00026;volume=106&#x00026;pages=695-704" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref58" id="ref58"></a>58. Bagnall, RD, Molloy, LK, Kalman, JM, and Semsarian, C. Exome sequencing identifies a mutation in the ACTN2 gene in a family with idiopathic ventricular fibrillation, left ventricular noncompaction, and sudden death. <i>BMC Med Genet</i>. (2014) 15:99. doi: 10.1186/s12881-014-0099-0 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25224718" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12881-014-0099-0" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RD+Bagnall&#x00026;author=LK+Molloy&#x00026;author=JM+Kalman&#x00026;author=C+Semsarian&#x00026;publication_year=2014&#x00026;title=Exome+sequencing+identifies+a+mutation+in+the+ACTN2+gene+in+a+family+with+idiopathic+ventricular+fibrillation+left+ventricular+noncompaction+and+sudden+death&#x00026;journal=BMC+Med+Genet&#x00026;volume=15&#x00026;pages=99" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref59" id="ref59"></a>59. Fan, L-L, Huang, H, Jin, J-Y, Li, J-J, Chen, Y-Q, and Xiang, R. Whole-exome sequencing identifies a novel mutation (p.L320R) of alpha-Actinin 2 in a Chinese family with dilated cardiomyopathy and ventricular tachycardia. <i>Cytogenet Genome Res</i>. (2019) 157:148&#x2013;52. doi: 10.1159/000496077</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1159/000496077" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L-L+Fan&#x00026;author=H+Huang&#x00026;author=J-Y+Jin&#x00026;author=J-J+Li&#x00026;author=Y-Q+Chen&#x00026;author=R+Xiang&#x00026;publication_year=2019&#x00026;title=Whole-exome+sequencing+identifies+a+novel+mutation+(p.L320R)+of+alpha-Actinin+2+in+a+Chinese+family+with+dilated+cardiomyopathy+and+ventricular+tachycardia&#x00026;journal=Cytogenet+Genome+Res&#x00026;volume=157&#x00026;pages=148-52" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref60" id="ref60"></a>60. Ranta-aho, J, Olive, M, Vandroux, M, Roticiani, G, Dominguez, C, Johari, M, et al. Mutation update for the ACTN2 gene. <i>Hum Mutat</i>. (2022) 43:1745&#x2013;56. doi: 10.1002/humu.24470 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36116040" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.24470" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Ranta-aho&#x00026;author=M+Olive&#x00026;author=M+Vandroux&#x00026;author=G+Roticiani&#x00026;author=C+Dominguez&#x00026;author=M+Johari&#x00026;publication_year=2022&#x00026;title=Mutation+update+for+the+ACTN2+gene&#x00026;journal=Hum+Mutat&#x00026;volume=43&#x00026;pages=1745-56" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref61" id="ref61"></a>61. Kraoua, L, Jaouadi, H, Allouche, M, Achour, A, Kaouther, H, Ahmed, HB, et al. Molecular autopsy and clinical family screening in a case of sudden cardiac death reveals ACTN2 mutation related to hypertrophic/dilated cardiomyopathy and a novel LZTR1 variant associated with Noonan syndrome. <i>Mol Genet Genomic Med</i>. (2022) 10:e1954. doi: 10.1002/mgg3.1954</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1002/mgg3.1954" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Kraoua&#x00026;author=H+Jaouadi&#x00026;author=M+Allouche&#x00026;author=A+Achour&#x00026;author=H+Kaouther&#x00026;author=HB+Ahmed&#x00026;publication_year=2022&#x00026;title=Molecular+autopsy+and+clinical+family+screening+in+a+case+of+sudden+cardiac+death+reveals+ACTN2+mutation+related+to+hypertrophic/dilated+cardiomyopathy+and+a+novel+LZTR1+variant+associated+with+Noonan+syndrome&#x00026;journal=Mol+Genet+Genomic+Med&#x00026;volume=10&#x00026;pages=e1954" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref62" id="ref62"></a>62. Girolami, F, Iascone, M, Tomberli, B, Bardi, S, Benelli, M, Marseglia, G, et al. Novel &#x03B1;-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. <i>Circ Cardiovasc Genet</i>. (2014) 7:741&#x2013;50. doi: 10.1161/CIRCGENETICS.113.000486 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25173926" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCGENETICS.113.000486" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Girolami&#x00026;author=M+Iascone&#x00026;author=B+Tomberli&#x00026;author=S+Bardi&#x00026;author=M+Benelli&#x00026;author=G+Marseglia&#x00026;publication_year=2014&#x00026;title=Novel+&#x03B1;-actinin+2+variant+associated+with+familial+hypertrophic+cardiomyopathy+and+juvenile+atrial+arrhythmias:+a+massively+parallel+sequencing+study&#x00026;journal=Circ+Cardiovasc+Genet&#x00026;volume=7&#x00026;pages=741-50" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref63" id="ref63"></a>63. Arvanitis, M, Tampakakis, E, Zhang, Y, Wang, W, and Auton, A23andMe Research Team, et al. Genome-wide association and multi-omic analyses reveal ACTN2 as a gene linked to heart failure. <i>Nat Commun</i>. (2020) 11:1122. doi: 10.1038/s41467-020-14843-7 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32111823" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41467-020-14843-7" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Arvanitis&#x00026;author=E+Tampakakis&#x00026;author=Y+Zhang&#x00026;author=W+Wang&#x00026;author=A+Auton&#x00026;publication_year=2020&#x00026;title=Genome-wide+association+and+multi-omic+analyses+reveal+ACTN2+as+a+gene+linked+to+heart+failure&#x00026;journal=Nat+Commun&#x00026;volume=11&#x00026;pages=1122" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref64" id="ref64"></a>64. Chiu, C, Bagnall, RD, Ingles, J, Yeates, L, Kennerson, M, Donald, JA, et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. <i>J Am Coll Cardiol</i>. (2010) 55:1127&#x2013;35. doi: 10.1016/j.jacc.2009.11.016 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20022194" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2009.11.016" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Chiu&#x00026;author=RD+Bagnall&#x00026;author=J+Ingles&#x00026;author=L+Yeates&#x00026;author=M+Kennerson&#x00026;author=JA+Donald&#x00026;publication_year=2010&#x00026;title=Mutations+in+alpha-actinin-2+cause+hypertrophic+cardiomyopathy:+a+genome-wide+analysis&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=55&#x00026;pages=1127-35" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref65" id="ref65"></a>65. Agarwal, R, Wakimoto, H, Paulo, JA, Zhang, Q, Reichart, D, Toepfer, C, et al. Pathogenesis of cardiomyopathy caused by variants in ALPK3, an essential Pseudokinase in the cardiomyocyte nucleus and sarcomere. <i>Circulation</i>. (2022) 146:1674&#x2013;93. doi: 10.1161/CIRCULATIONAHA.122.059688 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/36321451" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCULATIONAHA.122.059688" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Agarwal&#x00026;author=H+Wakimoto&#x00026;author=JA+Paulo&#x00026;author=Q+Zhang&#x00026;author=D+Reichart&#x00026;author=C+Toepfer&#x00026;publication_year=2022&#x00026;title=Pathogenesis+of+cardiomyopathy+caused+by+variants+in+ALPK3+an+essential+Pseudokinase+in+the+cardiomyocyte+nucleus+and+sarcomere&#x00026;journal=Circulation&#x00026;volume=146&#x00026;pages=1674-93" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref66" id="ref66"></a>66. &#x000C7;a&#x011F;layan, AO, Sezer, RG, Kaymak&#x000E7;alan, H, Ulgen, E, Yavuz, T, Baranoski, JF, et al. ALPK3 gene mutation in a patient with congenital cardiomyopathy and dysmorphic features. <i>Cold Spring Harb Mol Case Stud</i>. (2017) 3:a001859. doi: 10.1101/mcs.a001859</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1101/mcs.a001859" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AO+&#x000C7;a&#x011F;layan&#x00026;author=RG+Sezer&#x00026;author=H+Kaymak&#x000E7;alan&#x00026;author=E+Ulgen&#x00026;author=T+Yavuz&#x00026;author=JF+Baranoski&#x00026;publication_year=2017&#x00026;title=ALPK3+gene+mutation+in+a+patient+with+congenital+cardiomyopathy+and+dysmorphic+features&#x00026;journal=Cold+Spring+Harb+Mol+Case+Stud&#x00026;volume=3&#x00026;pages=a001859" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref67" id="ref67"></a>67. Jaouadi, H, Kraoua, L, Chaker, L, Atkinson, A, Delague, V, Levy, N, et al. Novel ALPK3 mutation in a Tunisian patient with pediatric cardiomyopathy and facio-thoraco-skeletal features. <i>J Hum Genet</i>. (2018) 63:1077&#x2013;82. doi: 10.1038/s10038-018-0492-1 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30046096" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s10038-018-0492-1" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Jaouadi&#x00026;author=L+Kraoua&#x00026;author=L+Chaker&#x00026;author=A+Atkinson&#x00026;author=V+Delague&#x00026;author=N+Levy&#x00026;publication_year=2018&#x00026;title=Novel+ALPK3+mutation+in+a+Tunisian+patient+with+pediatric+cardiomyopathy+and+facio-thoraco-skeletal+features&#x00026;journal=J+Hum+Genet&#x00026;volume=63&#x00026;pages=1077-82" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref68" id="ref68"></a>68. Lopes, LR, Garcia-Hern&#x000E1;ndez, S, Lorenzini, M, Futema, M, Chumakova, O, Zateyshchikov, D, et al. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. <i>Eur Heart J</i>. (2021) 42:3063&#x2013;73. doi: 10.1093/eurheartj/ehab424 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34263907" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/eurheartj/ehab424" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=LR+Lopes&#x00026;author=S+Garcia-Hern&#x000E1;ndez&#x00026;author=M+Lorenzini&#x00026;author=M+Futema&#x00026;author=O+Chumakova&#x00026;author=D+Zateyshchikov&#x00026;publication_year=2021&#x00026;title=Alpha-protein+kinase+3+(ALPK3)+truncating+variants+are+a+cause+of+autosomal+dominant+hypertrophic+cardiomyopathy&#x00026;journal=Eur+Heart+J&#x00026;volume=42&#x00026;pages=3063-73" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref69" id="ref69"></a>69. Walsh, R, and Bezzina, CR. ALPK3: a full spectrum cardiomyopathy gene? <i>Eur Heart J</i>. (2021) 42:3074&#x2013;7. doi: 10.1093/eurheartj/ehab415 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34263911" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/eurheartj/ehab415" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=CR+Bezzina&#x00026;publication_year=2021&#x00026;title=ALPK3:+a+full+spectrum+cardiomyopathy+gene?&#x00026;journal=Eur+Heart+J&#x00026;volume=42&#x00026;pages=3074-7" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref70" id="ref70"></a>70. Dai, J, Li, K, Huang, M, Sun, Y, Liu, H, Li, Z, et al. The involvement of ALPK3 in hypertrophic cardiomyopathy in East Asia. <i>Front Med</i>. (2022) 9:915649. doi: 10.3389/fmed.2022.915649 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/35783621" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fmed.2022.915649" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Dai&#x00026;author=K+Li&#x00026;author=M+Huang&#x00026;author=Y+Sun&#x00026;author=H+Liu&#x00026;author=Z+Li&#x00026;publication_year=2022&#x00026;title=The+involvement+of+ALPK3+in+hypertrophic+cardiomyopathy+in+East+Asia&#x00026;journal=Front+Med&#x00026;volume=9&#x00026;pages=915649" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref71" id="ref71"></a>71. Su, M, Wang, J, Kang, L, Wang, Y, Zou, Y, Feng, X, et al. Rare variants in genes encoding MuRF1 and MuRF2 are modifiers of hypertrophic cardiomyopathy. <i>Int J Mol Sci</i>. (2014) 15:9302&#x2013;13. doi: 10.3390/ijms15069302 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24865491" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/ijms15069302" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Su&#x00026;author=J+Wang&#x00026;author=L+Kang&#x00026;author=Y+Wang&#x00026;author=Y+Zou&#x00026;author=X+Feng&#x00026;publication_year=2014&#x00026;title=Rare+variants+in+genes+encoding+MuRF1+and+MuRF2+are+modifiers+of+hypertrophic+cardiomyopathy&#x00026;journal=Int+J+Mol+Sci&#x00026;volume=15&#x00026;pages=9302-13" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref72" id="ref72"></a>72. Chen, SN, Czernuszewicz, G, Tan, Y, Lombardi, R, Jin, J, Willerson, JT, et al. Human molecular genetic and functional studies identify TRIM63, encoding muscle RING finger protein 1, as a novel Gene for human hypertrophic cardiomyopathy. <i>Circ Res</i>. (2012) 111:907&#x2013;19. doi: 10.1161/CIRCRESAHA.112.270207 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22821932" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCRESAHA.112.270207" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SN+Chen&#x00026;author=G+Czernuszewicz&#x00026;author=Y+Tan&#x00026;author=R+Lombardi&#x00026;author=J+Jin&#x00026;author=JT+Willerson&#x00026;publication_year=2012&#x00026;title=Human+molecular+genetic+and+functional+studies+identify+TRIM63+encoding+muscle+RING+finger+protein+1+as+a+novel+Gene+for+human+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Res&#x00026;volume=111&#x00026;pages=907-19" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref73" id="ref73"></a>73. Smith, TC, Fridy, PC, Li, Y, Basil, S, Arjun, S, Friesen, RM, et al. Supervillin binding to myosin II and synergism with anillin are required for cytokinesis. <i>Mol Biol Cell</i>. (2013) 24:3603&#x2013;19. doi: 10.1091/mbc.e12-10-0714 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24088567" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1091/mbc.e12-10-0714" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TC+Smith&#x00026;author=PC+Fridy&#x00026;author=Y+Li&#x00026;author=S+Basil&#x00026;author=S+Arjun&#x00026;author=RM+Friesen&#x00026;publication_year=2013&#x00026;title=Supervillin+binding+to+myosin+II+and+synergism+with+anillin+are+required+for+cytokinesis&#x00026;journal=Mol+Biol+Cell&#x00026;volume=24&#x00026;pages=3603-19" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref74" id="ref74"></a>74. Pope, RK, Pestonjamasp, KN, Smith, KP, Wulfkuhle, JD, Strassel, CP, Lawrence, JB, et al. Cloning, characterization, and chromosomal localization of human superillin (SVIL). <i>Genomics</i>. (1998) 52:342&#x2013;51. doi: 10.1006/geno.1998.5466 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/9867483" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1006/geno.1998.5466" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RK+Pope&#x00026;author=KN+Pestonjamasp&#x00026;author=KP+Smith&#x00026;author=JD+Wulfkuhle&#x00026;author=CP+Strassel&#x00026;author=JB+Lawrence&#x00026;publication_year=1998&#x00026;title=Cloning+characterization+and+chromosomal+localization+of+human+superillin+(SVIL)&#x00026;journal=Genomics&#x00026;volume=52&#x00026;pages=342-51" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref75" id="ref75"></a>75. Hedberg-Oldfors, C, Meyer, R, Nolte, K, Abdul Rahim, Y, Lindberg, C, Karason, K, et al. Loss of supervillin causes myopathy with myofibrillar disorganization and autophagic vacuoles. <i>Brain J Neurol</i>. (2020) 143:2406&#x2013;20. doi: 10.1093/brain/awaa206 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32779703" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/brain/awaa206" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Hedberg-Oldfors&#x00026;author=R+Meyer&#x00026;author=K+Nolte&#x00026;author=Y+Abdul+Rahim&#x00026;author=C+Lindberg&#x00026;author=K+Karason&#x00026;publication_year=2020&#x00026;title=Loss+of+supervillin+causes+myopathy+with+myofibrillar+disorganization+and+autophagic+vacuoles&#x00026;journal=Brain+J+Neurol&#x00026;volume=143&#x00026;pages=2406-20" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref76" id="ref76"></a>76. Olivotto, I, Girolami, F, Ackerman, MJ, Nistri, S, Bos, JM, Zachara, E, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. <i>Mayo Clin Proc</i>. (2008) 83:630&#x2013;8. doi: 10.1016/S0025-6196(11)60890-2 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18533079" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/S0025-6196(11)60890-2" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I+Olivotto&#x00026;author=F+Girolami&#x00026;author=MJ+Ackerman&#x00026;author=S+Nistri&#x00026;author=JM+Bos&#x00026;author=E+Zachara&#x00026;publication_year=2008&#x00026;title=Myofilament+protein+gene+mutation+screening+and+outcome+of+patients+with+hypertrophic+cardiomyopathy&#x00026;journal=Mayo+Clin+Proc&#x00026;volume=83&#x00026;pages=630-8" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref77" id="ref77"></a>77. Canepa, M, Fumagalli, C, Tini, G, Vincent-Tompkins, J, Day, SM, Ashley, EA, et al. Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: an analysis of the international Sarcomeric human cardiomyopathy registry. <i>Circ Heart Fail</i>. (2020) 13:e007230. doi: 10.1161/CIRCHEARTFAILURE.120.007230 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32894986" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCHEARTFAILURE.120.007230" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Canepa&#x00026;author=C+Fumagalli&#x00026;author=G+Tini&#x00026;author=J+Vincent-Tompkins&#x00026;author=SM+Day&#x00026;author=EA+Ashley&#x00026;publication_year=2020&#x00026;title=Temporal+trend+of+age+at+diagnosis+in+hypertrophic+cardiomyopathy:+an+analysis+of+the+international+Sarcomeric+human+cardiomyopathy+registry&#x00026;journal=Circ+Heart+Fail&#x00026;volume=13&#x00026;pages=e007230" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref78" id="ref78"></a>78. Marstrand, P, Han, L, Day, SM, Olivotto, I, Ashley, EA, Michels, M, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry. <i>Circulation</i>. (2020) 141:1371&#x2013;83. doi: 10.1161/CIRCULATIONAHA.119.044366 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32228044" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCULATIONAHA.119.044366" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Marstrand&#x00026;author=L+Han&#x00026;author=SM+Day&#x00026;author=I+Olivotto&#x00026;author=EA+Ashley&#x00026;author=M+Michels&#x00026;publication_year=2020&#x00026;title=Hypertrophic+cardiomyopathy+with+left+ventricular+systolic+dysfunction:+insights+from+the+SHaRe+registry&#x00026;journal=Circulation&#x00026;volume=141&#x00026;pages=1371-83" target="_blank">Google Scholar</a></p></div>
</div> <div class="thinLineM20"></div> <div class="AbstractSummary">
<p><span>Keywords:</span> HCM, exome reanalysis, sarcomeric genes, non-sarcomeric genes, novel-associated genes, FHOD3, TRIM63, SVIL</p>
<p><span>Citation:</span> Jaouadi H, Morel V, Martel H, Lindenbaum P, Lamy de la Chapelle L, Herbane M, Lucas C, Magdinier F, Habib G, Schott J-J, Zaffran S and Nguyen K (2024) Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5&#x2009;years after the initial analysis. <i>Front. Med</i>. 11:1480947. doi: 10.3389/fmed.2024.1480947</p>
<p class="timestamps"><span>Received:</span> 14 August 2024; <span>Accepted:</span> 09 October 2024;<br> <span>Published:</span> 31 October 2024.</p> <div>
<p>Edited by:</p> <a href="https://loop.frontiersin.org/people/1570574/overview">Simone Grassi</a>, University of Florence, Italy</div> <div>
<p>Reviewed by:</p> <a href="https://loop.frontiersin.org/people/978038/overview">Lilei Zhang</a>, Baylor College of Medicine, United States<br> <a href="https://loop.frontiersin.org/people/557735/overview">Oscar Campuzano</a>, University of Girona, Spain<br> <a href="https://loop.frontiersin.org/people/2836618/overview">Andrea Costantino</a>, Careggi University Hospital, Italy</div>
<p><span>Copyright</span> &#x000A9; 2024 Jaouadi, Morel, Martel, Lindenbaum, Lamy de la Chapelle, Herbane, Lucas, Magdinier, Habib, Schott, Zaffran and Nguyen. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>&#x0002A;Correspondence:</span> Hager Jaouadi, <a id="encmail">aGFqZXIuamFvdWFkaUB1bml2LWFtdS5mcg==</a>; St&#x000E9;phane Zaffran, <a id="encmail">c3RlcGhhbmUuemFmZnJhbkB1bml2LWFtdS5mcg==</a></p>
<p><span><sup>&#x2020;</sup></span>These authors have contributed equally to this work</p> <div class="clear"></div> </div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fmed.2024.1480947" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">2,887</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">988</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><!----><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/1480947#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fmed.2024.1480947" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fmed.2024.1480947" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/1570574/overview" data-event="editorInfo-a-simoneGrassi" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">S</span><span class="notranslate">G</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Simone  Grassi</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Department of Health Sciences, Section of Forensic Medical Sciences, University of Florence, Italy</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/557735/overview" data-event="editorInfo-a-oscarCampuzano" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">O</span><span class="notranslate">C</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Oscar  Campuzano</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Faculty of Medicine, University of Girona, Spain</div></div></a><a href="https://loop.frontiersin.org/people/978038/overview" data-event="editorInfo-a-lileiZhang" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">L</span><span class="notranslate">Z</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Lilei  Zhang</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Baylor College of Medicine, United States</div></div></a><a href="https://loop.frontiersin.org/people/2836618/overview" data-event="editorInfo-a-andreaCostantino" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">A</span><span class="notranslate">C</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Andrea  Costantino</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Careggi University Hospital, Italy</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"> <li><a href="#h1">Abstract</a></li> <li><a href="#h2">Introduction</a></li> <li><a href="#h3">Methods</a></li> <li><a href="#h4">Results</a></li> <li><a href="#h5">Discussion</a></li> <li><a href="#h6">Data availability statement</a></li> <li><a href="#h7">Ethics statement</a></li> <li><a href="#h8">Author contributions</a></li> <li><a href="#h9">Funding</a></li> <li><a href="#h10">Conflict of interest</a></li> <li><a href="#h11">Publisher&#x2019;s note</a></li> <li><a href="#h12">Supplementary material</a></li> <li><a href="#h13">Footnotes</a></li> <li><a href="#h14">References</a></li> </ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fmed.2024.1480947" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span>Â© 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>Â |Â </span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/medicine/articles/10.3389/fmed.2024.1480947/full",["Reactive",16],{"main":17,"user":514,"article":515,"articleHub":878,"mainHeader":882},{"ibar":18,"footer":268,"newsletterComponent":-1,"snackbarItem":350,"toggleShowSnackbar":351,"contentfulJournal":352,"graphJournal":416,"settingsFeaturesSwitchers":420,"templateToggleBanner":421,"tenantConfig":479},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":199,"aboutJournal":200,"mainLinks":249,"journalLinks":256,"helpCenterLink":265},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIRÂ² Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=39&specialtyid=0&entitytype=2&entityid=602",{"id":115,"name":116,"slug":117,"sections":118},602,"Frontiers in Medicine","medicine",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195],{"id":120,"name":121,"slug":122},797,"Dermatology","dermatology",{"id":124,"name":125,"slug":126},842,"Family Medicine and Primary Care","family-medicine-and-primary-care",{"id":128,"name":129,"slug":130},681,"Gastroenterology","gastroenterology",{"id":132,"name":133,"slug":134},1321,"Gene and Cell Therapy","gene-and-cell-therapy",{"id":136,"name":137,"slug":138},790,"Geriatric Medicine","geriatric-medicine",{"id":140,"name":141,"slug":142},1969,"Healthcare Professions Education","healthcare-professions-education",{"id":144,"name":145,"slug":146},752,"Hematology","hematology",{"id":148,"name":149,"slug":150},3648,"Hepatobiliary Diseases","hepatobiliary-diseases",{"id":152,"name":153,"slug":154},3379,"Infectious Diseases: Pathogenesis and Therapy","infectious-diseases-pathogenesis-and-therapy",{"id":156,"name":157,"slug":158},1139,"Intensive Care Medicine and Anesthesiology","intensive-care-medicine-and-anesthesiology",{"id":160,"name":161,"slug":162},768,"Nephrology","nephrology",{"id":164,"name":165,"slug":166},815,"Nuclear Medicine","nuclear-medicine",{"id":168,"name":169,"slug":170},2526,"Obstetrics and Gynecology","obstetrics-and-gynecology",{"id":172,"name":173,"slug":174},1635,"Ophthalmology","ophthalmology",{"id":176,"name":177,"slug":178},618,"Pathology","pathology",{"id":180,"name":181,"slug":182},1307,"Precision Medicine","precision-medicine",{"id":184,"name":185,"slug":186},678,"Pulmonary Medicine","pulmonary-medicine",{"id":188,"name":189,"slug":190},1306,"Regulatory Science","regulatory-science",{"id":192,"name":193,"slug":194},662,"Rheumatology","rheumatology",{"id":196,"name":197,"slug":198},1318,"Translational Medicine","translational-medicine","Sections",[201,225],{"title":202,"links":203},"Scope",[204,207,210,213,216,219,222],{"text":205,"url":206,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/medicine/about#about-editors",{"text":208,"url":209,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/medicine/about#about-scope",{"text":211,"url":212,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/medicine/about#about-facts",{"text":214,"url":215,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/medicine/about#about-submission",{"text":217,"url":218,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/medicine/about#about-open",{"text":220,"url":221,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/medicine/about#copyright-statement",{"text":223,"url":224,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/medicine/about#about-quality",{"title":226,"links":227},"For authors",[228,231,234,237,240,243,246],{"text":229,"url":230,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/medicine/for-authors/why-submit",{"text":232,"url":233,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/medicine/for-authors/article-types",{"text":235,"url":236,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/medicine/for-authors/author-guidelines",{"text":238,"url":239,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/medicine/for-authors/editor-guidelines",{"text":241,"url":242,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/medicine/for-authors/publishing-fees",{"text":244,"url":245,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/medicine/for-authors/submission-checklist",{"text":247,"url":248,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/medicine/for-authors/contact-editorial-office",[250,253],{"text":251,"url":252,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":254,"url":255,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[257,260,262],{"text":258,"url":259,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":261,"target":27,"ariaLabel":28},"research-topics",{"text":263,"url":264,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":266,"url":267,"target":77,"ariaLabel":266},"Help center","https://helpcenter.frontiersin.org",{"blocks":269,"socialLinks":323,"copyright":347,"termsAndConditionsUrl":348,"privacyPolicyUrl":349},[270,284,294,308],{"title":271,"links":272},"Guidelines",[273,275,278,281,283],{"text":235,"url":274,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":276,"url":277,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":279,"url":280,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":238,"url":282,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":285,"links":286},"Explore",[287,288,291,293],{"text":258,"url":255,"target":27,"ariaLabel":28},{"text":289,"url":290,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":292,"url":252,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":295,"links":296},"Outreach",[297,300,303,307],{"text":298,"url":92,"target":77,"ariaLabel":299},"Frontiers Forum ","Frontiers Forum website",{"text":301,"url":302,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":304,"url":305,"target":77,"ariaLabel":306},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":309,"links":310},"Connect",[311,312,316,319,322],{"text":266,"url":267,"target":77,"ariaLabel":266},{"text":313,"url":314,"target":77,"ariaLabel":315},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":317,"url":111,"target":27,"ariaLabel":318},"Contact us ","Subscribe to newsletter",{"text":320,"url":321,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[324,332,337,342],{"link":325,"type":328,"color":329,"icon":330,"size":331,"hiddenText":13},{"text":326,"url":327,"target":77,"ariaLabel":326},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":333,"type":328,"color":329,"icon":336,"size":331,"hiddenText":13},{"text":334,"url":335,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":338,"type":328,"color":329,"icon":341,"size":331,"hiddenText":13},{"text":339,"url":340,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":343,"type":328,"color":329,"icon":346,"size":331,"hiddenText":13},{"text":344,"url":345,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":353,"identifier":115,"name":116,"slug":117,"banner":354,"description":409,"mission":410,"palette":411,"impactFactor":412,"citeScore":413,"citations":414,"showTagline":28,"twitter":415},"Journal",[355],{"id":356,"src":357,"name":358,"tags":359,"type":367,"width":368,"height":369,"idHash":370,"archive":371,"brandId":372,"limited":371,"fileSize":373,"isPublic":374,"original":375,"copyright":376,"extension":377,"thumbnails":379,"dateCreated":387,"description":388,"orientation":389,"userCreated":390,"watermarked":371,"dateModified":387,"datePublished":391,"ecsArchiveFiles":392,"propertyOptions":393,"property_Channel":398,"property_Sub-Type":400,"property_Asset_Type":402,"activeOriginalFocusPoint":404,"property_Office_Department":407},"3501F557-CAFA-4218-930C20D1D930C78C","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/3501F557-CAFA-4218-930C20D1D930C78C/webimage-5988957C-0534-4338-984381D67214C0AF.png","FMED_Main Visual_Purple_Website",[360,361,362,363,364,365,366],"professional","medical","research","biotechnology","scientific","analy","lab","image",7360,4912,"67388dad93685635",0,"22C10171-81B3-4DA6-99342F272A32E8BB",13595017,1,"https://brand.frontiersin.org/m/67388dad93685635/original/FMED_Main-Visual_Purple_Website.jpg","Copyright (c) 2018 RossHelen/Shutterstock.  No use without permission.",[378],"jpg",{"mini":380,"thul":381,"webimage":357,"Guidelines":382,"WebsiteJpg_XL":383,"WebsiteWebP_L":384,"WebsiteWebP_M":385,"WebsiteWebP_XL":386},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/3501F557-CAFA-4218-930C20D1D930C78C/mini-4EBC2476-6EFB-4A3E-A669185B307FEF72.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/3501F557-CAFA-4218-930C20D1D930C78C/thul-78BD9351-8A86-4C7B-874FC1CC5CAA92CE.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/3501F557-CAFA-4218-930C20D1D930C78C/F6FF788E-26D5-4BC5-8CB92EE85A59CA4A/Guidelines-FMED_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/3501F557-CAFA-4218-930C20D1D930C78C/F6FF788E-26D5-4BC5-8CB92EE85A59CA4A/WebsiteJpg_XL-FMED_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/3501F557-CAFA-4218-930C20D1D930C78C/F6FF788E-26D5-4BC5-8CB92EE85A59CA4A/WebsiteWebP_L-FMED_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/3501F557-CAFA-4218-930C20D1D930C78C/F6FF788E-26D5-4BC5-8CB92EE85A59CA4A/WebsiteWebP_M-FMED_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/3501F557-CAFA-4218-930C20D1D930C78C/F6FF788E-26D5-4BC5-8CB92EE85A59CA4A/WebsiteWebP_XL-FMED_Main Visual_Purple_Website.webp","2022-06-27T10:00:04Z","Laboratory assistant putting test tubes into the holder, Close-up view focused on the tubes","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[394,395,396,397],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[399],"frontiersin_org",[401],"Main_Visual",[403],"Photography",{"x":405,"y":406},3680,2456,[408],"Publishing","A highly cited multidisciplinary journal which advances our medical knowledge. It supports the translation of scientific advances into new therapies and diagnostic tools that will improve patient care.","\u003Cp>Frontiers in Medicine is a broad-scope, multidisciplinary journal covering all established medical disciplines to improve clinical practice and patient care.\u003C/p>\n\n\u003Cp>Led by Field Chief Editor Prof Michel Goldman (UniversitÃ© libre de Bruxelles, Belgium), Frontiers in Medicine is indexed in PubMed Central (PMC), Web of Science (SCIE), and Scopus, among others, and welcomes basic and clinical medical research that facilitate the translation of scientific advances into new therapies or diagnostic tools. Topics include, but are not limited to:\u003C/p>\n\n\u003Cul>\n  \u003Cli>dermatology\u003C/li>\n  \u003Cli>family medicine and primary care\u003C/li>\n  \u003Cli>gastroenterology\u003C/li>\n  \u003Cli>gene and cell therapy\u003C/li>\n  \u003Cli>geriatric medicine\u003C/li>\n  \u003Cli>healthcare professions education\u003C/li>\n  \u003Cli>hematology\u003C/li>\n  \u003Cli>hepatobiliary diseases\u003C/li>\n  \u003Cli>infectious diseases: pathogenesis and therapy\u003C/li>\n  \u003Cli>intensive care medicine and anesthesiology\u003C/li>\n  \u003Cli>nephrology\u003C/li>\n  \u003Cli>nuclear medicine\u003C/li>\n  \u003Cli>obstetrics and gynecology\u003C/li>\n  \u003Cli>ophthalmology\u003C/li>\n  \u003Cli>pathology\u003C/li>\n  \u003Cli>precision medicine\u003C/li>\n  \u003Cli>pulmonary medicine\u003C/li>\n  \u003Cli>regulatory science\u003C/li>\n  \u003Cli>rheumatology\u003C/li>\n  \u003Cli>translational medicine.\u003C/li>\n\u003C/ul>\n\n\u003Cp>In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care.\u003C/p>\n\n\u003Cp>As well as the established medical disciplines, Frontiers in Medicine aims to publish research that will facilitate:\u003C/p>\n\n\u003Cul>\n  \u003Cli>access to medicinal products and medical devices worldwide\u003C/li>\n  \u003Cli>addressing the grand health challenges around the world\u003C/li>\n  \u003Cli>the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines\u003C/li>\n  \u003Cli>the scientific bases for guidelines and decisions from regulatory authorities\u003C/li>\n  \u003Cli>the use of patient-reported outcomes under real world conditions.\u003C/li>\n\u003C/ul>\n\n\u003Cp>All studies must contribute insights into the field of medicine. Papers which do not primarily focus on a medical discipline are not suitable for publication in this journal. Manuscripts that focus solely on the molecular or cellular mechanisms of diseases without a foundation in clinical medicine are not suitable for publication in this journal. Similarly, studies that are purely descriptive or observational, without a clear hypothesis or mechanistic investigation, are not within the scope of this journal. Research that is primarily epidemiological or public health-oriented, without a foundation in the pathophysiology or treatment of disease, is also not appropriate for this journal.\u003C/p>\n\n\u003Cp>Frontiersâ€™ journals require that manuscripts primarily comprising computational studies of public data, must include appropriate validation. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a>, for more information. Manuscripts not adhering to these standards will not be considered.\u003Cp>\n\n\u003Cp>Frontiers in Medicine is committed to advancing developments in the field of medicine by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>\n\n\u003Cp>Ethics Statement:\u003C/p>\n\n\u003Cp>All manuscripts submitted toâ€¯Frontiers in Medicineâ€¯that have been conducted in human subjects must conform with current regulations and the Declaration of Helsinki. Ethics committee approval and informed patient consent are required for studies involving human subjects. Ethics committee approval is also needed for studies involving animals. Phase I - Phase IV clinical trials submitted for publication inâ€¯Frontiers in Medicineâ€¯must have been registered with an appropriate public trials registry at the time or before the first patient enrolment. The information on the clinical trial registration (Unique Identifier and URL) must be included in the abstract. Authors are required to disclose all apparent or potential conflicts of interest according to the ICMJE guidelines and those of Frontiers.\u003C/p>\n\n\u003Cp>Frontiers endeavors to follow the guidelines and best practice recommendations published by the Committee on Publication Ethics (COPE). Authors should refer to theâ€¯author guidelinesâ€¯for full details.\u003C/p>","purple","3.9","3.6","176752","@FrontMedicine",{"id":115,"name":116,"slug":117,"abbreviation":417,"isOnline":13,"isOpenForSubmissions":13,"citeScore":418,"impactFactor":419},"fmed",6,3,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":351},{"isPublic":13,"allowCompanyUsers":351,"whiteListEmails":422,"enableAllJournals":13,"whiteListJournals":444},[423,424,425,426,427,428,429,430,431,428,432,433,434,435,436,437,438,439,440,441,442,443],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[445,446,447,406,448,449,374,450,115,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],2232,1729,2357,2176,2333,1843,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":374,"name":374,"availableJournalPages":480,"announcement":484},[259,264,261,481,482,483],"volumes","about","community-reviewers",{"__typename":485,"sys":486,"preHeader":42,"title":488,"description":489,"image":490,"link":512},"Announcement",{"id":487},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[491],{"archive":371,"brandId":372,"copyright":28,"dateCreated":492,"dateModified":493,"datePublished":494,"description":28,"extension":495,"fileSize":497,"height":498,"id":499,"isPublic":371,"limited":371,"name":500,"orientation":389,"original":28,"thumbnails":501,"type":367,"watermarked":371,"width":508,"videoPreviewURLs":509,"tags":510,"textMetaproperties":511,"src":502},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[496],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":502,"thul":503,"mini":504,"WebsiteWebP_L":505,"WebsiteWebP_M":506,"Guidelines":507},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":513,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":516,"isPreviewPage":351,"hasSupplementalData":351,"showCrossmarkWidget":13,"articleTemplate":718,"currentArticlePageMetaInfo":719,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":517,"doi":518,"title":519,"acceptanceDate":520,"receptionDate":521,"publicationDate":522,"lastModifiedDate":523,"isPublished":13,"abstract":524,"researchTopic":525,"articleType":530,"stage":533,"keywords":535,"authors":544,"editors":629,"reviewers":639,"journal":666,"section":674,"impactMetrics":676,"volume":679,"articleVolume":680,"relatedArticles":681,"isPublishedV2":351,"contents":689,"files":693},1480947,"10.3389/fmed.2024.1480947","Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5â€‰years after the initial analysis",["Date","2024-10-09T14:58:54.000Z"],["Date","2024-08-14T19:34:27.000Z"],["Date","2024-10-31T00:00:00.000Z"],["Date","2025-11-25T02:36:39.227Z"],"Background: Approximately half of hypertrophic cardiomyopathy (HCM) patients lack a precise genetic diagnosis. The likelihood of identifying clinically relevant variants increased over time.Methods: Herein, we conducted a gene-centric reanalysis of exome data of 200 HCM cases 5 years after the initial analysis. In this reanalysis, priority was given to genes with a matched HCM entry in OMIM database and recently emerging HCM-associated genes gathered using text mining-based literature review. Further classification of the identified genes and variants was performed using ClinGen resource and ACMG guidelines to assess the robustness of gene-disease association and the clinical actionability of the prioritized variants.Results: As expected, the majority of patients carried variants in MYBPC3 and MYH7 genes 26% (n=51) and 8% (n=16) respectively, in accordance with the initial analysis. The vast majority of pathogenic and likely pathogenic variants were found in MYBPC3 (22 out of 40 variants) and MYH7 (8 out of 16 variants) genes. Three genes, not included in the initial analysis, were identified: SVIL, FHOD3, and TRIM63. Considering only patients with unique variants in the last three genes, there was a 9% enhancement in variant identification.Importantly, SVIL variants carriers presented apical and septal HCM, aortopathies, and severe scoliosis for one patient. Ten patients (5%) carried variants in FHOD3 gene, six of them in hotspot regions (Exons 12 and 15). We identified seven variants within the TRIM63 gene in 12 patients (6%). Homozygous variants were detected in 2.5% of the cohort in MYBPC3 (n=1), MYL3 (n=1), and TRIM63 (n=3) genes.No variants were found in the ACTC1, TPM1, and TNNI3 genes in the HYPERGEN cohort. Thus, variants were identified in five out of the eight HCM core genes with high prevalence in young patients. We identified variants in three recent HCMassociated genes (SVIL, FHOD3, and TRIM63) in 35 patients, with 18 patients carrying unique variants (9%). Our results further emphasize the usefulness of exome data reanalysis particularly in genotype-negative patients.",{"id":526,"title":527,"articlesCount":418,"isMagazinePage":13,"slug":528,"isOpenForSubmission":351,"views":529},48823,"Precision Medicine: Biomarker Testing for Diagnosis and Treatment of Cardiovascular Disease","precision-medicine-biomarker-testing-for-diagnosis-and-treatment-of-cardiovascular-disease",13818,{"id":531,"name":532},24,"Original Research",{"id":534,"name":19},18,[536,537,538,539,540,541,542,543],"HCM","Exome reanalysis","Sarcomeric Genes","non-sarcomeric genes","novelassociated genes","FHOD3","trim63","SVIL",[545,554,562,569,577,583,589,595,602,609,615,622],{"id":546,"firstName":547,"middleName":19,"lastName":548,"givenNames":549,"isCorresponding":351,"isProfilePublic":13,"userId":546,"email":-1,"affiliations":550},2817503,"Hager","Jaouadi","Hager ",[551],{"organizationName":552,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},"Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251","France",{"id":555,"firstName":556,"middleName":19,"lastName":557,"givenNames":558,"isCorresponding":351,"isProfilePublic":13,"userId":555,"email":-1,"affiliations":559},2355955,"Victor","Morel","Victor ",[560],{"organizationName":561,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},"Department of Medical Genetics, La Timone Hospital, AP-HM, La Timone Childrenâ€™s Hospital",{"id":371,"firstName":563,"middleName":19,"lastName":564,"givenNames":565,"isCorresponding":351,"isProfilePublic":351,"userId":371,"email":-1,"affiliations":566},"Helene","Martel","Helene ",[567],{"organizationName":568,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},"Department of Cardiology, La Timone Hospital, AP-HM",{"id":570,"firstName":571,"middleName":19,"lastName":572,"givenNames":573,"isCorresponding":351,"isProfilePublic":13,"userId":570,"email":-1,"affiliations":574},2817593,"Pierre","Lindenbaum","Pierre ",[575],{"organizationName":576,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},"Nantes UniversitÃ©, CHU Nantes, CNRS, INSERM, lâ€™institut du Thorax",{"id":371,"firstName":578,"middleName":19,"lastName":579,"givenNames":580,"isCorresponding":351,"isProfilePublic":351,"userId":371,"email":-1,"affiliations":581},"Lorcan","Lamy de la Chapelle","Lorcan ",[582],{"organizationName":552,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":584,"middleName":19,"lastName":585,"givenNames":586,"isCorresponding":351,"isProfilePublic":351,"userId":371,"email":-1,"affiliations":587},"Marine","Herbane","Marine ",[588],{"organizationName":552,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":590,"middleName":19,"lastName":591,"givenNames":592,"isCorresponding":351,"isProfilePublic":351,"userId":371,"email":-1,"affiliations":593},"Claire","Lucas","Claire ",[594],{"organizationName":568,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},{"id":596,"firstName":597,"middleName":19,"lastName":598,"givenNames":599,"isCorresponding":351,"isProfilePublic":13,"userId":596,"email":-1,"affiliations":600},351861,"FrÃ©dÃ©rique","Magdinier","FrÃ©dÃ©rique ",[601],{"organizationName":552,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},{"id":603,"firstName":604,"middleName":19,"lastName":605,"givenNames":606,"isCorresponding":351,"isProfilePublic":13,"userId":603,"email":-1,"affiliations":607},1073045,"Gilbert","Habib","Gilbert ",[608],{"organizationName":568,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":610,"middleName":19,"lastName":611,"givenNames":612,"isCorresponding":351,"isProfilePublic":351,"userId":371,"email":-1,"affiliations":613},"Jean-Jacques","Schott","Jean-Jacques ",[614],{"organizationName":576,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},{"id":616,"firstName":617,"middleName":19,"lastName":618,"givenNames":619,"isCorresponding":351,"isProfilePublic":13,"userId":616,"email":-1,"affiliations":620},1012177,"StÃ©phane","Zaffran","StÃ©phane ",[621],{"organizationName":552,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":623,"middleName":19,"lastName":624,"givenNames":625,"isCorresponding":351,"isProfilePublic":351,"userId":371,"email":-1,"affiliations":626},"Karine","Nguyen","Karine ",[627,628],{"organizationName":552,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":561,"countryName":553,"cityName":19,"stateName":19,"zipCode":19},[630],{"id":631,"firstName":632,"middleName":19,"lastName":633,"givenNames":634,"isCorresponding":351,"isProfilePublic":13,"userId":631,"email":-1,"affiliations":635},1570574,"Simone","Grassi","Simone ",[636],{"organizationName":637,"countryName":638,"cityName":19,"stateName":19,"zipCode":19},"Department of Health Sciences, Section of Forensic Medical Sciences, University of Florence","Italy",[640,649,658],{"id":641,"firstName":642,"middleName":19,"lastName":643,"givenNames":644,"isCorresponding":351,"isProfilePublic":13,"userId":641,"email":-1,"affiliations":645},557735,"Oscar","Campuzano","Oscar ",[646],{"organizationName":647,"countryName":648,"cityName":19,"stateName":19,"zipCode":19},"Faculty of Medicine, University of Girona","Spain",{"id":650,"firstName":651,"middleName":19,"lastName":652,"givenNames":653,"isCorresponding":351,"isProfilePublic":13,"userId":650,"email":-1,"affiliations":654},978038,"Lilei","Zhang","Lilei ",[655],{"organizationName":656,"countryName":657,"cityName":19,"stateName":19,"zipCode":19},"Baylor College of Medicine","United States",{"id":659,"firstName":660,"middleName":19,"lastName":661,"givenNames":662,"isCorresponding":351,"isProfilePublic":13,"userId":659,"email":-1,"affiliations":663},2836618,"Andrea","Costantino","Andrea ",[664],{"organizationName":665,"countryName":638,"cityName":19,"stateName":19,"zipCode":19},"Careggi University Hospital",{"id":115,"slug":117,"name":116,"shortName":667,"electronicISSN":668,"field":669,"specialtyId":28,"journalSectionPaths":672},"Front. Med.","2296-858X",{"id":670,"domainId":671},39,2,[673],{"section":674},{"id":180,"name":181,"slug":182,"specialtyId":675},1754,{"views":677,"downloads":678,"citations":371},2887,988,11,"Volume 11 - 2024",[682],{"id":683,"typeId":684,"typeName":685,"title":686,"url":687,"isOriginalArticle":351,"recentDate":688},1595049,128,"Correction","Corrigendum: Exome Sequencing Data Reanalysis of 200 Hypertrophic Cardiomyopathy patients: The HYPERGEN French Cohort 5 years after the initial analysis","/articles/10.3389/fmed.2025.1595049",["Date","2025-05-06T00:00:00.000Z"],{"titleHtml":690,"fullTextHtml":691,"menuHtml":692},"Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5&#x2009;years after the initial analysis","\u003Cdiv class=\"JournalAbstract\"> \u003Ca id=\"h1\" name=\"h1\">\u003C/a>\n \u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2817503\" class=\"user-id-2817503\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2817503/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Hager Jaouadi&#xA;\">Hager Jaouadi\u003C/a>\u003Csup>1\u003C/sup>\u003Csup>&#x0002A;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2355955\" class=\"user-id-2355955\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2355955/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Victor Morel\">Victor Morel\u003C/a>\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Helene Martel\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Helene Martel\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2817593\" class=\"user-id-2817593\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2817593/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Pierre Lindenbaum\">Pierre Lindenbaum\u003C/a>\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Lorcan Lamy de la Chapelle\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Lorcan Lamy de la Chapelle\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Marine Herbane\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Marine Herbane\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Claire Lucas\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Claire Lucas\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/351861\" class=\"user-id-351861\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/351861/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Fr&#xE;d&#xE;rique Magdinier\">Fr&#x000E9;d&#x000E9;rique Magdinier\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1073045\" class=\"user-id-1073045\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1073045/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Gilbert Habib\">Gilbert Habib\u003C/a>\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jean-Jacques Schott\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jean-Jacques Schott\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1012177\" class=\"user-id-1012177\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1012177/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"St&#xE;phane Zaffran&#xA;&#x;\">St&#x000E9;phane Zaffran\u003C/a>\u003Csup>1\u003C/sup>\u003Csup>&#x0002A;\u003C/sup>\u003Csup>&#x2020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Karine Nguyen,&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Karine Nguyen\u003Csup>1,2\u003C/sup>\u003Csup>&#x2020;\u003C/sup>\u003C/span>\u003C/div> \u003Cul class=\"notes\"> \u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Aix Marseille Universit&#x00E9;, INSERM, Marseille Medical Genetics (MMG), U1251, Marseille, France\u003C/li> \u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Department of Medical Genetics, La Timone Hospital, AP-HM, La Timone Children&#x2019;s Hospital, Marseille, France\u003C/li> \u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Department of Cardiology, La Timone Hospital, AP-HM, Marseille, France\u003C/li> \u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Nantes Universit&#x000E9;, CHU Nantes, CNRS, INSERM, l&#x2019;institut du Thorax, Nantes, France\u003C/li> \u003C/ul>\n\u003Cp class=\"mb15\">\u003Cb>Background:\u003C/b> Approximately half of hypertrophic cardiomyopathy (HCM) patients lack a precise genetic diagnosis. The likelihood of identifying clinically relevant variants increased over time.\u003C/p>\n\u003Cp class=\"mb15\">\u003Cb>Methods:\u003C/b> In this study, we conducted a gene-centric reanalysis of exome data of 200 HCM cases 5&#x2009;years after the initial analysis. This reanalysis prioritized genes with a matched HCM entry in the OMIM database and recently emerging HCM-associated genes gathered using a text mining-based literature review. Further classification of the identified genes and variants was performed using the Clinical Genome Resource (ClinGen) resource and American College of Medical Genetics and Genomics (ACMG) guidelines to assess the robustness of gene&#x2013;disease association and the clinical actionability of the prioritized variants.\u003C/p>\n\u003Cp class=\"mb15\">\u003Cb>Results:\u003C/b> As expected, the majority of patients carried variants in \u003Ci>MYBPC3\u003C/i> and M\u003Ci>YH7\u003C/i> genes, 26% (\u003Ci>n\u003C/i>&#x2009;=&#x2009;51) and 8% (\u003Ci>n\u003C/i>&#x2009;=&#x2009;16), respectively, in accordance with the initial analysis. The vast majority of pathogenic (P) and likely pathogenic (LP) variants were found in \u003Ci>MYBPC3\u003C/i> (22 out of 40 variants) and \u003Ci>MYH7\u003C/i> (8 out of 16 variants) genes. Three genes&#x2014;not included in the initial analysis&#x2014;were identified: \u003Ci>SVIL\u003C/i>, \u003Ci>FHOD3\u003C/i>, and \u003Ci>TRIM63\u003C/i>. Considering only patients with unique variants in the last three genes, there was a 9% enhancement in variant identification. Importantly, \u003Ci>SVIL\u003C/i> variant carriers presented apical and septal HCM, aortopathies, and severe scoliosis for one patient. Ten patients (5%) carried variants in the \u003Ci>FHOD3\u003C/i> gene, six in hotspot regions (exons 12 and 15). We identified seven variants within the \u003Ci>TRIM63\u003C/i> gene in 12 patients (6%). Homozygous variants were detected in 2.5% of the cohort in \u003Ci>MYBPC3\u003C/i> (\u003Ci>n\u003C/i>&#x2009;=&#x2009;1), \u003Ci>MYL3\u003C/i> (\u003Ci>n\u003C/i>&#x2009;=&#x2009;1), and \u003Ci>TRIM63\u003C/i> (\u003Ci>n\u003C/i>&#x2009;=&#x2009;3) genes.\u003C/p>\n\u003Cp class=\"mb0\">\u003Cb>Conclusion:\u003C/b> Our study revealed that no variants were found in the \u003Ci>ACTC1\u003C/i>, \u003Ci>TPM1\u003C/i>, and \u003Ci>TNNI3\u003C/i> genes in the HYPERGEN cohort. However, we identified variants in five out of the eight HCM core genes, with a high prevalence in young patients. We identified variants in three recent HCM-associated genes (\u003Ci>SVIL\u003C/i>, \u003Ci>FHOD3\u003C/i>, and \u003Ci>TRIM63\u003C/i>) in 35 patients, with 18 patients carrying unique variants (9%). Our results further emphasize the usefulness of exome data reanalysis, particularly in genotype-negative patients.\u003C/p> \u003Cdiv class=\"clear\">\u003C/div> \u003C/div> \u003Cdiv class=\"JournalFullText\"> \u003Ca id=\"h2\" name=\"h2\">\u003C/a>\n\u003Ch2>Introduction\u003C/h2>\n\u003Cp class=\"mb15\">Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease, defined by left ventricular (LV) wall thickness greater than 15&#x2009;mm, in the absence of other loading conditions that could explain the hypertrophy (\u003Ca href=\"#ref1\">1\u003C/a>). The degree, localization, and distribution of the hypertrophy are variable (\u003Ca href=\"#ref2\">2\u003C/a>). The LV systolic function can be preserved, increased, or reduced (\u003Ca href=\"#ref2\">2\u003C/a>). Consequently, HCM is characterized by a phenotypic heterogeneity that could be partly explained by the heterogeneity of the genetic underlying etiology.\u003C/p>\n\u003Cp class=\"mb15\">The estimated prevalence of HCM is 1:500 in the general population based on the recognition of the disease phenotype (\u003Ca href=\"#ref3\">3\u003C/a>&#x2013;\u003Ca href=\"#ref5\">5\u003C/a>). However, considering familial transmission, genotype-positive cases for sarcomeric genes, and subclinical cases, a higher prevalence (1:200) is reported (\u003Ca href=\"#ref6\">6\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The clinical manifestations of HCM typically occur between the ages of 20 and 40, although they can develop at any age (\u003Ca href=\"#ref7\">7\u003C/a>). It is noteworthy that 50&#x2013;60% of cases are diagnosed after the age of 30, reflecting the variable penetrance and expressivity of the disease (\u003Ca href=\"#ref3\">3\u003C/a>). The average life expectancy for HCM patients is typically favorable, approaching 70&#x2009;years in effectively managed cases (\u003Ca href=\"#ref6\">6\u003C/a>), although outcomes are greatly dependent on the presence of risk factors for complications such as early onset of the disease, arrhythmias, and heart failure. The annual risk of sudden cardiac death (SCD) in high-risk patients is estimated to range from 0.5 to 1%, with the highest risk observed in young cases under 30&#x2009;years of age (\u003Ca href=\"#ref8\">8\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">HCM is widely recognized as a sarcomeric disease since the vast majority of patients carry variants within the eight core genes encoding sarcomeric proteins (\u003Ca href=\"#ref9\">9\u003C/a>). Indeed, the myosin-binding protein C (\u003Ci>MYBPC3\u003C/i>) and the \u003Ci>&#x03B2;\u003C/i>-myosin heavy chain (\u003Ci>MYH7\u003C/i>) genes account for 50&#x2013;70% of HCM cases that undergo genetic testing (\u003Ca href=\"#ref1\">1\u003C/a>&#x2013;\u003Ca href=\"#ref3\">3\u003C/a>, \u003Ca href=\"#ref10\">10\u003C/a>, \u003Ca href=\"#ref11\">11\u003C/a>). The remaining patients harbor variants in other sarcomeric genes, such as myosin light chain (MLC) genes (\u003Ci>MYL2\u003C/i> and \u003Ci>MYL3\u003C/i>), troponin encoding genes (\u003Ci>TNNT2\u003C/i> and \u003Ci>TNNI3\u003C/i>), tropomyosin 1 (\u003Ci>TPM1\u003C/i>), and actin \u003Ci>&#x03B1;\u003C/i>-cardiac muscle 1 (\u003Ci>ACTC1\u003C/i>) (\u003Ca href=\"#ref4\">4\u003C/a>, \u003Ca href=\"#ref11\">11\u003C/a>, \u003Ca href=\"#ref12\">12\u003C/a>). Collectively, actionable variants in sarcomeric-positive (sarc+) patients account for &#x0003E;90% of the totality of pathogenic (P) variants in HCM patients (\u003Ca href=\"#ref12\">12\u003C/a>). Of note, these percentages vary widely depending on the studied populations, the clinical profiling, the sequencing method used (panel, whole-exome sequencing [WES], etc.), and variant prioritization criteria.\u003C/p>\n\u003Cp class=\"mb15\">Several additional genes have been linked to HCM encoding non-sarcomeric proteins, including, but not restricted to, proteins of the Z-disk (\u003Ci>ACTN2\u003C/i>, \u003Ci>TCAP\u003C/i>, and \u003Ci>VCL\u003C/i>), calcium handling genes (\u003Ci>TNNC1\u003C/i>, \u003Ci>RYR2\u003C/i>, \u003Ci>JPH2\u003C/i>, \u003Ci>PLN\u003C/i>), and the proteasome (\u003Ci>TRIM63\u003C/i>) (\u003Ca href=\"#ref4\">4\u003C/a>). Similarly to the sarcomeric genes, both inheritance models are reported in these genes with a predominance of the autosomal dominant pattern (\u003Ca href=\"#ref12\">12\u003C/a>, \u003Ca href=\"#ref13\">13\u003C/a>). However, the contribution of these genes is minor, ranging from 0.06 to 8.7% based on combined published data involving genes with strong, moderate, and weak evidence of causality and HCM-associated genes supported only by functional data (\u003Ca href=\"#ref13\">13\u003C/a>). These findings reinforce the fact that sarcomeric genes predominantly cause HCM and emphasize the significant proportion of the missing heritability in HCM (\u003Ca href=\"#ref13\">13\u003C/a>). Therefore, up to 50% of HCM patients do not have an identifiable pathogenic disease-causing variant (\u003Ca href=\"#ref14\">14\u003C/a>, \u003Ca href=\"#ref15\">15\u003C/a>). So far, this missing heritability is increasingly explained by the fact that sarcomeric-negative (Sarc-) and genotype-negative patients have a non-Mendelian or near-Mendelian disease caused by a joint effect of genetic and non-genetic factors (\u003Ca href=\"#ref13\">13\u003C/a>, \u003Ca href=\"#ref16\">16\u003C/a>). Thus, the additive effect of allelic heterogeneity and additional genetic variants, along with variants in cis causing allelic imbalance, could also partially explain the missing heritability, the phenotypic variability, and the incomplete penetrance. In this line, many studies have suggested the oligogenic inheritance model in HCM patients lacking an identifiable highly penetrant variant (\u003Ca href=\"#ref16\">16\u003C/a>&#x2013;\u003Ca href=\"#ref20\">20\u003C/a>). Furthermore, rare variants are broadly acknowledged among the plausible sources of missing heritability and the likely contributors to the oligogenic inheritance rather than common variants. Indeed, variants with strong effects are expected to be kept under selective pressure and remain at low to extremely low frequencies in the population (\u003Ca href=\"#ref21\">21\u003C/a>, \u003Ca href=\"#ref22\">22\u003C/a>). Altogether, incomplete penetrance, variable expressivity, and missing heritability in HCM make the genetic diagnosis and clinical prognosis challenging.\u003C/p>\n\u003Cp class=\"mb15\">The efficiency of WES reanalysis has been demonstrated to improve genetic testing yield, especially by adding the newly associated genes previously unrecognized as clinically relevant. It is estimated that the genetic diagnostic yield could be enhanced by approximately 15% when including new disease-gene associations, up-to-date software, variant frequency databases, and text mining for genetic and clinical re-evaluation (\u003Ca href=\"#ref23\">23\u003C/a>). Moreover, it is recommended that the dataset initially analyzed over 2&#x2009;years ago should be prioritized for reanalysis (\u003Ca href=\"#ref24\">24\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">In this study, we sought to refine the initial Hypertension Genetic Epidemiology Network (HYPERGEN) analysis by focusing on HCM-causing genes (that are known and recently associated). Additionally, we assessed the usefulness of our reanalysis regarding the clinical actionability of the identified variants by applying the American College of Medical Genetics and Genomics/Association of Molecular Pathologists (ACMG/AMP) criteria.\u003C/p> \u003Ca id=\"h3\" name=\"h3\">\u003C/a>\n\u003Ch2>Methods\u003C/h2>\n\u003Cp class=\"mb0\">This study was approved by an institutional review committee. All subjects gave informed consent for genetic studies. WES was performed on the NGS Illumina HiSeq2500 platform using Agilent SureSelect V6 technology (Genwiz, United States) (\u003Ca href=\"#ref25\">25\u003C/a>).\u003C/p>\n\u003Ch3>The HYPERGEN cohort\u003C/h3>\n\u003Cp class=\"mb15\">The HYPERGEN cohort included 132 men and 68 women (mean age, 55&#x2009;years; range, 19&#x2013;91&#x2009;years; 86.5% above 40; 34% familial cases). The patients were enrolled in five French centers: Marseille, Bordeaux, Paris, Dijon, and Rennes.\u003C/p>\n\u003Cp class=\"mb15\">A definite echocardiographic evidence of HCM was considered based on the measurements of maximal wall thickness&#x2009;&#x02265;&#x2009;15&#x2009;mm in sporadic and&#x2009;&#x0003E;&#x2009;13&#x2009;mm in familial cases without dilatation or any cardiovascular comorbidities or systemic disease.\u003C/p>\n\u003Cp class=\"mb0\">None of the patients was reported by the clinicians as syndromic or likely syndromic. However, the first HYPERGEN study identified one novel variant in the \u003Ci>GLA\u003C/i> gene (p.Leu311Profs&#x0002A;4), and the clinical re-evaluation of the patient confirmed a Fabry disease diagnosis. A second case with the disease-causing variant \u003Ci>TTR\u003C/i>: p.Val50Met has been reported with transthyretin cardiac amyloidosis (\u003Ca href=\"#ref25\">25\u003C/a>). Of note, this study&#x2019;s variant prioritization strategy is different from the first HYPERGEN analysis. Thus, an important caveat to our reanalysis is that an accurate comparison of the genetic diagnosis yield cannot be assessed as the initial analysis pipeline differs from this reanalysis. Additionally, since we do not have access to the variant coordinates identified in the first analysis, it is impossible to determine whether any variants have been downgraded or upgraded. The significant differences are detailed in the following.\u003C/p>\n\u003Ch3>Initial HYPERGEN analysis vs. the 5&#x2009;years interval analysis\u003C/h3>\n\u003Cp class=\"mb15\">In the initial HYPERGEN study, bioinformatic analyses were performed by retaining exonic and intronic variants with a minor allele frequency (MAF) lower than 1% and predicted as P or likely pathogenic LP mainly according to the Universal Mutation Database (UMD) predictor. The first step of WES data analysis consisted of searching for variants in a virtual panel of 167 genes involved in cardiomyopathies and other various cardiac hereditary diseases (\u003Ca href=\"#ref25\">25\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">In contrast, in this reanalysis, priority was given to genes with a matched HCM entry in Mendelian disease in the Online Mendelian Inheritance in Man (OMIM) database and the ClinGen\u003Csup id=\"footnotesuper1\">\u003Ca id=\"xfn0001\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#fn0001\">1\u003C/a>\u003C/sup> as well as recently emerging HCM-associated genes gathered using text mining-based literature review from 2016 to 2023 (\u003Ca href=\"#fig1\">Figure 1\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Figure 1\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg\" name=\"figure1\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg\" alt=\"www.frontiersin.org\" id=\"fig1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Figure 1\u003C/b>. Venn diagram visualization of genes across initial and 5-year analyses. The &#x201C;previously analyzed genes&#x201D; section includes genes from the 167-gene panel used in the original HYPERGEN study; the &#x201C;overlapping genes&#x201D; section contains genes identified in both the initial and current analyses; the &#x201C;newly identified genes&#x201D; section consists of genes associated with HCM between 2019 and 2024.\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb15\">More importantly, variant pathogenicity was assessed according to ACMG/AMP guidelines, and the consistency of a predicted deleterious effect by at least 3 prediction tools and a high combined annotation-dependent depletion (CADD) score.\u003C/p>\n\u003Cp class=\"mb15\">As aforementioned, the initial HYPERGEN analysis showed two HCM phenocopies. In this study, a preanalysis included the significant syndromic genes and genes yielding known HCM phenocopies. None of the variants identified within these genes were classified as P or LP according to ACMG or reported in ClinVar database (data not shown). Moreover, all these variants were found along with other HCM-relevant variants. Thus, in this reanalysis, variants in genes causing syndromic HCM and phenocopies are not included. The \u003Ci>TTN\u003C/i> gene is not included as well.\u003C/p>\n\u003Cp class=\"mb0\">The Venn diagram shown in \u003Ca href=\"#fig1\">Figure 1\u003C/a> illustrates the relationship between the genes previously prioritized in the first analysis and those reanalyzed in this study. The overlapping section represents genes shared between both analyses.\u003C/p>\n\u003Ch3>Variant filtering, prioritization, and sanger validation\u003C/h3>\n\u003Cp class=\"mb15\">The first criterion of this reanalysis is variant rarity. Thus, a filtering allele frequency of &#x0003C;1% in gnomAD database was applied. Subsequently, intergenic, intronic, and synonymous variants were removed. The remaining variants were prioritized based on their \u003Ci>in silico\u003C/i> predicted impact on protein function. This analysis&#x2019;s primary scoring tool is the CADD (\u003Ca href=\"#ref26\">26\u003C/a>). Indeed, variants predicted as damaging or probably damaging, deleterious, disease-causing by PolyPhen-2 and SIFT, and/or MutationTaster while also having a CADD score&#x2009;&#x0003E;&#x2009;15 were considered as variants of high confidence of pathogenicity (\u003Ca href=\"#ref27\">27\u003C/a>&#x2013;\u003Ca href=\"#ref29\">29\u003C/a>). Of note, up to two-thirds of the variants of uncertain significance (VUS) in confirmed sarcomeric genes are considered causal of HCM (\u003Ca href=\"#ref30\">30\u003C/a>). Thus, suspicious VUS with some evidence of causality (a rarity, VUS within well-established HCM genes, mutational hotspots&#x2026;) is reported in this reanalysis.\u003C/p>\n\u003Cp class=\"mb15\">Finally, to gauge the clinical actionability of the detected variants, a subsequent classification according to ACMG criteria was performed (\u003Ca href=\"#ref31\">31\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">All the prioritized variants within the core and minor HCM genes were validated by Sanger sequencing when DNA samples were available (\u003Ca href=\"#SM1\">Supplementary File 1\u003C/a>).\u003C/p>\n\u003Ch3>Biological pathway and gene ontology analyses\u003C/h3>\n\u003Cp class=\"mb0\">Given a large number of variants, even after the filtering steps, variants within HCM-minor genes could be missed. To facilitate and ensure the identification of these variants, a biological pathway analysis including Reactome and KEGG databases as well as gene (GO) and human phenotype (HPO) ontologies terms was carried out using VarAFT software (\u003Ca href=\"#ref32\">32\u003C/a>&#x2013;\u003Ca href=\"#ref36\">36\u003C/a>). For example, querying the HPO and GO databases with the keywords &#x201C;cardiomyopathy phenotype&#x201D; and &#x201C;cardiac hypertrophy&#x201D; results in 3 HPO term identifiers (HP:0001639, HP:0005157, HP:0031992), 27 disease terms (matching all the OMIM phenotypes) and 83 additional genes. VarAFT software allowed us to query each variant call format (VCF) file for all the possible combinations.\u003C/p>\n\u003Ch3>French control cohort\u003C/h3>\n\u003Cp class=\"mb0\">French healthy controls (\u003Ci>n\u003C/i>&#x2009;=&#x2009;960) were queried to compare variants allele frequencies. Exons coordinate on GRCh37 were extracted for the genes of interest and extended by 50 bases. Those regions were called using GATK (4.3.0.0) with a set of Binary Alignment Map (BAM) files using a nextflow-based pipeline for joint-genotyping.\u003Csup id=\"footnotesuper2\">\u003Ca id=\"xfn0002\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#fn0002\">2\u003C/a>\u003C/sup> Resulting VCF was annotated with snpEff (\u003Ca href=\"#ref37\">37\u003C/a>) and jvarkit/GnomAD.\u003Csup id=\"footnotesuper3\">\u003Ca id=\"xfn0003\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#fn0003\">3\u003C/a>\u003C/sup> Variants known to be filtered in gnomAD or having an allele frequency greater than 1% in the non-finish population were excluded. Protein truncating and splice site variants were kept using jvarkit/vcffilterso.\u003C/p> \u003Ca id=\"h4\" name=\"h4\">\u003C/a>\n\u003Ch2>Results\u003C/h2>\n\u003Ch3>Variant identification among the definitive HCM genes\u003C/h3>\n\u003Ch4>\u003Ci>MYBPC3\u003C/i> and \u003Ci>MYH7\u003C/i> genes: the permanently significant HCM genes\u003C/h4>\n\u003Cp class=\"mb15\">Definitive HCM genes with a well-established disease association are mainly the eight sarcomeric genes with strong evidence of causality (\u003Ci>MYBPC3\u003C/i>, \u003Ci>MYH7\u003C/i>, \u003Ci>TNNT2\u003C/i>, \u003Ci>TNNI3\u003C/i>, \u003Ci>TPM1\u003C/i>, \u003Ci>ACTC1\u003C/i>, \u003Ci>MYL3\u003C/i>, and \u003Ci>MYL2\u003C/i>) (\u003Ca href=\"#ref38\">38\u003C/a>, \u003Ca href=\"#ref39\">39\u003C/a>). In our analysis, variants were found in five out of these eight well-established genes.\u003C/p>\n\u003Cp class=\"mb0\">Not surprisingly, the most prevalent genes in our case cohort are \u003Ci>MYBPC3\u003C/i> and \u003Ci>MYH7\u003C/i> genes, which is in accordance with the initial HYPERGEN study (\u003Ca href=\"#fig2\">Figure 2\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Figure 2\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg\" name=\"figure2\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g002.jpg\" alt=\"www.frontiersin.org\" id=\"fig2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Figure 2\u003C/b>. Variant distribution within HCM well-established genes. The number of patients harboring variants in each HCM core gene is dark purple. The number of variants within each gene is indicated in light purple.\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0\">Variants coordinates are detailed in \u003Ca href=\"#tab1\">Tables 1\u003C/a>&#x2013;\u003Ca href=\"#tab4\">4\u003C/a>.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Table 1\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg\" name=\"table1\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t001.jpg\" alt=\"www.frontiersin.org\" id=\"tab1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 1\u003C/b>. Variants identified in the \u003Ci>MYBPC3\u003C/i> gene (transcript NM_000256, MANE select).\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Table 2\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg\" name=\"table2\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t002.jpg\" alt=\"www.frontiersin.org\" id=\"tab2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 2\u003C/b>. Variants identified in the \u003Ci>MYH7\u003C/i> gene (transcript NM_000257, MANE select).\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Table 3\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg\" name=\"table3\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t003.jpg\" alt=\"www.frontiersin.org\" id=\"tab3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 3\u003C/b>. Variants identified in the \u003Ci>TNNT2\u003C/i> gene (transcript NM_001276345, MANE select).\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Table 4\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg\" name=\"table4\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t004.jpg\" alt=\"www.frontiersin.org\" id=\"tab4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 4\u003C/b>. Variants identified in myosin light chain (MLC) genes.\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0\">We identified 24 missense variants and 16 protein-truncating variants (PTV) in \u003Ci>MYBPC3\u003C/i> gene (\u003Ca href=\"#fig2\">Figure 2\u003C/a>). The vast majority of the identified \u003Ci>MYBPC3\u003C/i> variants are unique (42 out of 51 patients; 82%), 3 patients are double heterozygous (HCM-5, HCM-6, and HCM-14) harboring each a missense variant classified as a VUS and a second PTV or splice-site variant reported in ClinVar database and classified as P according to ACMG. Six patients with variants in the \u003Ci>MYBPC3\u003C/i> carrying one or more additional variants in minor HCM genes (\u003Ci>ACTN2\u003C/i> and \u003Ci>MYH6\u003C/i>) and in recent HCM-associated genes (\u003Ci>FHOD3\u003C/i>, \u003Ci>TRIM63\u003C/i>, and \u003Ci>SVIL\u003C/i>) (\u003Ca href=\"#tab1\">Table 1\u003C/a>; see \u003Ca href=\"#fig3\">Figure 3\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Figure 3\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg\" name=\"figure3\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g003.jpg\" alt=\"www.frontiersin.org\" id=\"fig3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Figure 3\u003C/b>. Variant type distribution of \u003Ci>MYBPC3\u003C/i> gene.\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0\">We identified 16 distinct variants in the \u003Ci>MYH7\u003C/i> gene, suggesting that these variants are more likely private. Importantly, in our case cohort, no PTV \u003Ci>MYH7\u003C/i> variant has been identified, and 8 out of the 16 missense variants are classified P and reported P or LP according to ACMG rules and ClinVar Database, respectively (\u003Ca href=\"#tab2\">Table 2\u003C/a>). It should be noted that \u003Ci>MYBPC3\u003C/i> and \u003Ci>MYH7\u003C/i> are not only the most prevalent genes but also the most genes with P/LP classified variants following ACMG/AMP criteria (\u003Ca href=\"#fig4\">Figure 4\u003C/a>). The remaining variants in this study are predicted to be deleterious through several tools. Each variant&#x2019;s detailed \u003Ci>in silico\u003C/i> prediction is available in \u003Ca href=\"#SM1\">Supplementary File 2\u003C/a>.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Figure 4\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg\" name=\"figure4\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g004.jpg\" alt=\"www.frontiersin.org\" id=\"fig4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Figure 4\u003C/b>. Proportion of \u003Ci>MYBPC3\u003C/i> and \u003Ci>MYH7\u003C/i> variants with P/LP ACMG classification. B, Benign; P, Pathogenic; LP, Likely Pathogenic; VUS, Variant of Uncertain Significance.\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Ch4>Troponin T2 and MLC genes: the minor sarcomeric genes\u003C/h4>\n\u003Cp class=\"mb15\">We identified a small proportion of patients carrying variants in \u003Ci>TNNT2\u003C/i>, \u003Ci>MYL2\u003C/i>, and \u003Ci>MYL3\u003C/i> genes (\u003Ci>n\u003C/i>&#x2009;=&#x2009;6; 3%) (\u003Ca href=\"#tab3\">Table 3\u003C/a>). Two patients carried missense variants in \u003Ci>TNNT2\u003C/i> (p.Val95Met and p.Lys283Glu), reported in ClinVar as LP and P, respectively. Furthermore, we identified four variants in \u003Ci>MYL2\u003C/i> (\u003Ci>n\u003C/i>&#x2009;=&#x2009;1) and \u003Ci>MYL3\u003C/i> (\u003Ci>n\u003C/i>&#x2009;=&#x2009;3) genes, one of which is at a homozygous state (\u003Ci>MYL3\u003C/i> p.Ala57Asp) with the conflicting interpretation of pathogenicity in ClinVar (\u003Ca href=\"#tab4\">Table 4\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">All the variants in troponin T2 and MLC genes are unique.\u003C/p>\n\u003Ch3>Variant identification among minor HCM genes\u003C/h3>\n\u003Cp class=\"mb0\">Several additional genes are consistently reported as HCM-causing genes encoding sarcomeric and non-sarcomeric proteins and contributing to a small proportion of HCM genetic etiology (\u003Ca href=\"#ref13\">13\u003C/a>). In our reanalysis, we identified variants in 12 HCM minor genes. Rare and deleterious variants in \u003Ci>FLNC\u003C/i>, \u003Ci>MYH6\u003C/i>, \u003Ci>MYPN\u003C/i>, and \u003Ci>ACTN2\u003C/i> genes accounted for the majority of the prioritized variants among these genes (\u003Ca href=\"#tab5\">Table 5\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Table 5\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg\" name=\"table5\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t005.jpg\" alt=\"www.frontiersin.org\" id=\"tab5\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 5\u003C/b>. Variants identified in minor HCM genes.\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb15\">Ten patients were found to carry unique variants in the \u003Ci>FLNC\u003C/i> gene, and three were digenic (HCM-67, HCM-66, and HCM-100) harboring an additional variant in the \u003Ci>MYH6\u003C/i>, \u003Ci>MYH7\u003C/i>, and \u003Ci>MYPN\u003C/i> genes, respectively. Unique variants in the \u003Ci>MYH6\u003C/i> gene were identified in five patients. Three out of six patients with \u003Ci>MYPN\u003C/i> variants carried the same p.Pro1112Leu variant.\u003C/p>\n\u003Cp class=\"mb0\">Less unique variants were detected in the remaining minor genes \u003Ci>ALPK3\u003C/i>, \u003Ci>CSRP3\u003C/i>, \u003Ci>MYLK2\u003C/i>, \u003Ci>CAV3\u003C/i>, \u003Ci>VCL\u003C/i>, and \u003Ci>JPH2\u003C/i> genes. Of note, variants in \u003Ci>NEXN\u003C/i> (p.Glu332Ala) and \u003Ci>TCAP\u003C/i> (p.Met71Thr) are unique.\u003C/p>\n\u003Ch4>Emerging HCM genes: \u003Ci>TRIM63\u003C/i>, \u003Ci>FHOD3\u003C/i>, and \u003Ci>SVIL\u003C/i>\u003C/h4>\n\u003Cp class=\"mb0\">The main goal of this reanalysis was to identify variants within the recently associated genes not included in the initial HYPERGEN analysis. Three genes were identified toward this goal\u003Ci>TRIM63\u003C/i>, \u003Ci>FHOD3\u003C/i>, and \u003Ci>SVIL\u003C/i>.\u003C/p>\n\u003Ch5>\u003Ci>TRIM63\u003C/i> gene\u003C/h5>\n\u003Cp class=\"mb0\">The \u003Ci>TRIM63\u003C/i> gene was associated with an autosomal recessive form of HCM (\u003Ca href=\"#ref40\">40\u003C/a>, \u003Ca href=\"#ref41\">41\u003C/a>). In this study, we identified variants within the \u003Ci>TRIM63\u003C/i> gene in 12 patients. Three patients presented homozygous variants for \u003Ci>TRIM63\u003C/i> gene, and 6 variants were unique (\u003Ca href=\"#tab6\">Table 6\u003C/a>). Indeed, the missense variants (p.Cys23Tyr and p.Cys75Tyr) were identified in patients at the heterozygous and homozygous states. Similarly, the stop variant (p.Gln247&#x0002A;) was found at the homozygous state in one patient and heterozygous for two other patients. According to ACMG/AMP classification, the missense variants Cys23Tyr and Cys75Tyr are LP. The \u003Ci>TRIM63\u003C/i> p.Gln247&#x0002A; stop variant is reported in ClinVar with conflicting interpretations of pathogenicity. A second stopgain variant (p.Glu261&#x0002A;) was found in a single patient (\u003Ca href=\"#fig5\">Figure 5\u003C/a>). Of note, PTVs were identified only in \u003Ci>MYBPC3\u003C/i> and \u003Ci>TRIM63\u003C/i> genes.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Table 6\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg\" name=\"table6\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t006.jpg\" alt=\"www.frontiersin.org\" id=\"tab6\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 6\u003C/b>. Variants identified in the \u003Ci>TRIM63\u003C/i> gene (transcript NM_032588, MANE select).\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Figure 5\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg\" name=\"figure5\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g005.jpg\" alt=\"www.frontiersin.org\" id=\"fig5\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Figure 5\u003C/b>. Schematic representation of the \u003Ci>TRIM63\u003C/i> gene. Upside: Rare variants identified in HYPERGEN cohort: Green: B/LB; Yellow: VUS; Red: LP/P; Downside: Variants reported in Clinvar database (clinical significance at last reviewed): Grey: VUS and conflicting interpretations of pathogenicity; Black: LP/P; Protein domains: Red = RING-finger domain (Zn-finger of 40 to 60 residue); Blue = B-Box-type zinc finger; Green = Zn2+ binding site; Yellow&#x2009;= Inter-Src homology 2 (iSH2) helical domain of Class IA Phosphoinositide 3-kinase Regulatory subunits. Figure created with ProteinPaint (\u003Ca href=\"https://proteinpaint.stjude.org/\">https://proteinpaint.stjude.org/\u003C/a>).\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0\">Clinical data were gathered for some patients with \u003Ci>TRIM63\u003C/i> variants. Two patients have septal hypertrophy and normal left ventricular ejection fraction (LVEF) (HCM-44 and HCM-113). Two patients with homozygous \u003Ci>TRIM63\u003C/i> variants (HCM-112 and HCM-114) have apical hypertrophy. The patient (HCM-117) with the stop variant p.Glu261&#x0002A; has a severe biventricular HCM with LVEF&#x2009;=&#x2009;49% and mild aortic regurgitation.\u003C/p>\n\u003Ch5>\u003Ci>FHOD3\u003C/i> gene\u003C/h5>\n\u003Cp class=\"mb0\">The \u003Ci>FHOD3\u003C/i> locus is one of the most vital signals for HCM in genome-wide association study (GWAS) studies (\u003Ca href=\"#ref42\">42\u003C/a>). Pathogenic variants are mainly located in two regions in the FHOD3 diaphanous inhibitory domain (exon 12) and the coiled&#x2013;coil domain (exons 15 and 16). Moreover, it has been demonstrated that exons 11 and 12 are crucial for MybpC-mediated localization of the FHOD3 protein to the sarcomeric C-zone (\u003Ca href=\"#ref12\">12\u003C/a>, \u003Ca href=\"#ref43\">43\u003C/a>&#x2013;\u003Ca href=\"#ref45\">45\u003C/a>). Our reanalysis further strengthens these associations by the identification of 3 missense variants in exon 12 and 15 in 6 patients of the HYPERGEN cohort. In total, 7 rare variants were prioritized in the \u003Ci>FHOD3\u003C/i> gene in 10 patients (\u003Ca href=\"#fig6\">Figure 6\u003C/a>). The majority of variants are unique except for two patients (HCM-48 and HCM-27) with the recurrent \u003Ci>FHOD3\u003C/i> p.Arg637Gln variant. Both patients carried \u003Ci>MYBPC3\u003C/i> variants, p.(Cys1202Leufs&#x0002A;35) and p.(Arg597Gln), respectively (\u003Ca href=\"#tab7\">Table 7\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Figure 6\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg\" name=\"figure6\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g006.jpg\" alt=\"www.frontiersin.org\" id=\"fig6\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Figure 6\u003C/b>. Schematic representation of the \u003Ci>FHOD3\u003C/i> gene. Upside: Rare variants identified in HYPERGEN cohort: Green&#x2009;=&#x2009;B/LB; Yellow&#x2009;=&#x2009;VUS; Red&#x2009;=&#x2009;LP/P; Downside: Variants reported in ClinVar database (clinical significance at last reviewed): Gray&#x2009;=&#x2009;VUS and conflicting interpretations of pathogenicity; Black&#x2009;=&#x2009;LP/P; protein domain: Green&#x2009;=&#x2009;Formin Homology 2 Domain. Figure was created with ProteinPaint (\u003Ca href=\"https://proteinpaint.stjude.org/\">https://proteinpaint.stjude.org/\u003C/a>).\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Table 7\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg\" name=\"table7\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t007.jpg\" alt=\"www.frontiersin.org\" id=\"tab7\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 7\u003C/b>. Variants identified in the \u003Ci>FHOD3\u003C/i> gene (transcript NM_001281740, MANE select).\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0\">We had access to the clinical description of one patient (HCM-104) with \u003Ci>FHOD3\u003C/i> variant (p.Leu177Phe). A definite HCM diagnosis was made at the age of 13&#x2009;years. The patient had a concentric HCM with biventricular dilation. At the age of 31&#x2009;years, his LVEF&#x2009;=&#x2009;71% and RVEF&#x2009;=&#x2009;53%.\u003C/p>\n\u003Ch5>\u003Ci>SVIL\u003C/i> gene\u003C/h5>\n\u003Cp class=\"mb0\">Recently, the \u003Ci>SVIL\u003C/i> gene was associated with HCM (\u003Ca href=\"#ref46\">46\u003C/a>, \u003Ca href=\"#ref47\">47\u003C/a>). Thus, we performed a gene-targeted analysis for the \u003Ci>SVIL\u003C/i> gene. No PTV or homozygous variants were found in patients of the HYPERGEN cohort. Nevertheless, we identified 10 missense \u003Ci>SVIL\u003C/i> variants in 13 patients (\u003Ca href=\"#tab8\">Table 8\u003C/a>; \u003Ca href=\"#fig7\">Figure 7\u003C/a>). The prioritized variants are absent in 1920 control alleles. Five variants are unique. To better characterize the clinical presentation of \u003Ci>SVIL\u003C/i> variant carriers, cardiac and extracardiac features were gathered for 7 patients, two women and 5 men (\u003Ca href=\"#tab9\">Table 9\u003C/a>). The age at onset of women patients was 29 and 27&#x2009;years, one of them in the postpartum period. Moreover, the patient with \u003Ci>SVIL\u003C/i>: p.(Arg215Trp) had severe scoliosis with permanent bracing and muscle fasciculations. Three patients had aortopathies including a bicuspid aortic valve with severe regurgitation, isolated ectasia of the Valsalva sinus, and degenerative aortic insufficiency. A consistent pattern of fibrosis localization was noted in these patients in the septum and LV apex. Magnetic resonance imaging (MRI) findings showed significant myocardial fibrosis for the majority of patients with intramyocardial delayed contrast in the inferior and lateral walls (\u003Ca href=\"#tab9\">Table 9\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Table 8\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg\" name=\"table8\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t008.jpg\" alt=\"www.frontiersin.org\" id=\"tab8\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 8\u003C/b>. Variants identified in the \u003Ci>SVIL\u003C/i> gene (transcript NM_021738, MANE select).\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Figure 7\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg\" name=\"figure7\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g007.jpg\" alt=\"www.frontiersin.org\" id=\"fig7\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Figure 7\u003C/b>. Schematic representation of the \u003Ci>SVIL\u003C/i> gene. Upside: Rare variants identified in HYPERGEN cohort: Green&#x2009;=&#x2009;B/LB; Yellow&#x2009;=&#x2009;VUS; Downside: Variants reported in ClinVar database (clinical significance at last reviewed): Gray&#x2009;=&#x2009;VUS and conflicting interpretations of pathogenicity; Black&#x2009;=&#x2009;LP/P; Protein domains: Green, blue, yellow, gray, and brown&#x2009;=&#x2009;gelsolin-like domains. Figure was created with ProteinPaint (\u003Ca href=\"https://proteinpaint.stjude.org/\">https://proteinpaint.stjude.org/\u003C/a>).\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Table 9\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg\" name=\"table9\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t009.jpg\" alt=\"www.frontiersin.org\" id=\"tab9\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 9\u003C/b>. Clinical findings of \u003Ci>SVIL\u003C/i> variant carriers.\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0\">Only seven variants of the HYPERGEN cohort were present in the control cohort with low allele frequencies (\u003Ca href=\"#tab10\">Table 10\u003C/a>). Moreover, four out of these seven variants were found to have the highest allele frequencies in the European non-Finnish population in gnomAD.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Table 10\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg\" name=\"table10\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t010.jpg\" alt=\"www.frontiersin.org\" id=\"tab10\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 10\u003C/b>. HYPERGEN variants found in the control cohort.\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Ch4>The genetic landscape of young HYPERGEN patients\u003C/h4>\n\u003Cp class=\"mb0\">The HYPERGEN cohort included 27 patients with HCM occurring at a very young age or in early adulthood (13.5%). The HCM clinical diagnosis of the patients was definite before the age of 40&#x2009;years. We sought to determine the genetic architecture of this young proportion. Indeed, sarcomeric genes were the most involved genes, as 50% of the identified variants are within the \u003Ci>MYBPC3\u003C/i> gene. Interestingly, variants in \u003Ci>SVIL\u003C/i> and \u003Ci>FHOD3\u003C/i> genes accounted for 10 and 7% of young HYPERGEN patients, respectively (\u003Ca href=\"#fig8\">Figure 8\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Figure 8\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg\" name=\"figure8\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g008.jpg\" alt=\"www.frontiersin.org\" id=\"fig8\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Figure 8\u003C/b>. Percentages of gene variants distribution among young patients.\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0\">In summary, a total of 20 genes have been identified in the HYPERGEN cohort, with a significant implication of the \u003Ci>MYBPC3\u003C/i> gene, followed by \u003Ci>MYH7\u003C/i> and \u003Ci>SVIL\u003C/i> genes (\u003Ca href=\"#fig9\">Figure 9\u003C/a>). According to ClinGen, 8 out of the 20 identified genes are classified with a robust association with HCM, 7 with disputed/limited evidence, and the \u003Ci>JPH2\u003C/i> gene with a moderate gene&#x2013;disease validity. The \u003Ci>FLNC\u003C/i>, \u003Ci>CAV\u003C/i>, and \u003Ci>SVIL\u003C/i> are not curated for HCM, and the \u003Ci>FHOD3\u003C/i> gene is under curation (\u003Ca href=\"#tab11\">Table 11\u003C/a>). However, those genes are reported in the literature and in the OMIM database in association with HCM.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div> \u003Cdiv class=\"Imageheaders\">Figure 9\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg\" name=\"figure9\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g009.jpg\" alt=\"www.frontiersin.org\" id=\"fig9\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Figure 9\u003C/b>. Genes implicated in the HYPERGEN cohort. The number of variants is indicated in dark purple, and the number of patients is indicated in light purple.\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">Table 11\u003C/div> \u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg\" name=\"table11\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-t011.jpg\" alt=\"www.frontiersin.org\" id=\"tab11\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cb>Table 11\u003C/b>. List of the identified genes in the HYPERGEN cohort and their matched ClinGen classification.\n\u003C/p>\u003C/div> \u003Cdiv class=\"clear\">\u003C/div> \u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb15\">Our reanalysis yielded 16 novel variants, including four in the \u003Ci>MYBPC3\u003C/i> gene, three in \u003Ci>MYH7\u003C/i>, two variants were found in each of \u003Ci>MYH6\u003C/i> and \u003Ci>FLNC\u003C/i> genes, and one novel variant in \u003Ci>TNNT2\u003C/i>, \u003Ci>MYL2\u003C/i>, \u003Ci>MYPN\u003C/i>, \u003Ci>ALPK3\u003C/i>, and \u003Ci>CSRP3\u003C/i>, respectively.\u003C/p>\n\u003Cp class=\"mb15\">Of note, considering only patients with unique variants in \u003Ci>TRIM63\u003C/i>, \u003Ci>FHOD3\u003C/i>, and \u003Ci>SVIL\u003C/i> genes, there was a 9% enhancement in variant identification following this reanalysis.\u003C/p>\n\u003Cp class=\"mb0\">All the identified genes and their matched phenotypes in the OMIM database are summarized in \u003Ca href=\"#SM1\">Supplementary File 3\u003C/a>.\u003C/p> \u003Ca id=\"h5\" name=\"h5\">\u003C/a>\n\u003Ch2>Discussion\u003C/h2>\n\u003Cp class=\"mb15\">Despite the advent of next-generation sequencing, approximately 50% of cases remain genotype-elusive. In this study, a reanalysis of exome data from 200 HCM patients was carried out 5&#x2009;years after the initial analysis with the goal of refining the initial analysis, reporting all the relevant, prioritized variants, and particularly identifying rare variants within the novel HCM-associated genes.\u003C/p>\n\u003Cp class=\"mb15\">In the present reanalysis, nearly 34% of patients were found to carry variants in \u003Ci>MYBPC3\u003C/i> and \u003Ci>MYH7\u003C/i> genes. This yield of sarc+ patients reached 37% when including patients with \u003Ci>TNNT2\u003C/i>, \u003Ci>MYL2\u003C/i>, and \u003Ci>MYL3\u003C/i> variants.\u003C/p>\n\u003Cp class=\"mb15\">Haploinsufficiency is the primary mechanism driving HCM linked to \u003Ci>MYBPC3\u003C/i> (myosin binding protein C3) gene (\u003Ca href=\"#ref38\">38\u003C/a>, \u003Ca href=\"#ref48\">48\u003C/a>). Thus, non-truncating variants (missense, in-frame indels, PTV predicted to escape non-sense mediated decay [NMD], and stop-loss) are prioritized whether they are predicted as pathogenic with high or low confidence. Our reanalysis yielded a total of 40 \u003Ci>MYBPC3\u003C/i> variants, including 24 missense, 4 splice-site, 6 stopgain, and 6 frameshift variants. The most recurrent and common HCM causal variant \u003Ci>MYBPC3\u003C/i>, p.Arg502Trp, was identified in only three patients (1.5%). This variant was found in 2.4% of the European-descent patients (\u003Ca href=\"#ref15\">15\u003C/a>, \u003Ca href=\"#ref49\">49\u003C/a>&#x2013;\u003Ca href=\"#ref51\">51\u003C/a>). However, the pathogenic \u003Ci>MYBPC3\u003C/i>: c1928-2A&#x2009;&#x0003E;&#x2009;G variant was the most commonly identified variant in the HYPERGEN cohort (\u003Ci>n\u003C/i>&#x2009;=&#x2009;7; 3.5%). Notably, these variants are unique except for one patient (HCM-5) harboring a second \u003Ci>MYBPC3\u003C/i> variant (p.Leu183Ile) (\u003Ca href=\"#tab1\">Table 1\u003C/a>). Contrary to the \u003Ci>MYBPC3\u003C/i> gene, mostly known with haploinsufficiency and allelic imbalance as the underlying mechanism of the disease, the pathophysiology mechanism of \u003Ci>MYH7\u003C/i> (myosin heavy chain 7) missense variants is the dominant negative effect, which implies that the \u003Ci>MYH7\u003C/i> gene is tolerant to loss of function (LoF) variants (\u003Ca href=\"#ref10\">10\u003C/a>, \u003Ca href=\"#ref38\">38\u003C/a>, \u003Ca href=\"#ref39\">39\u003C/a>, \u003Ca href=\"#ref52\">52\u003C/a>, \u003Ca href=\"#ref53\">53\u003C/a>). Thus, prioritizing the \u003Ci>MYH7\u003C/i> missense variant with a predicted deleterious impact according to different \u003Ci>in silico\u003C/i> algorithms may increase the identification rate of actionable variants. Moreover, gene regions in which rare and likely causal variants are significantly clustered; therefore, a new etiological fraction-based ACMG rule on rare missense \u003Ci>MYH7\u003C/i> variants was proposed to improve genetic testing yield in HCM (\u003Ca href=\"#ref30\">30\u003C/a>). All the identified \u003Ci>MYH7\u003C/i> variants in this study are missense (\u003Ci>n\u003C/i>&#x2009;=&#x2009;16) with 8 P/LP variants. Of note, variants in the \u003Ci>MYH7\u003C/i> gene were associated with significant LV hypertrophy, which is the hallmark of HCM and an unfavorable prognosis compared to patients carrying variants in the other HCM genes (\u003Ca href=\"#ref54\">54\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">We identified a small proportion of patients (3%) carrying variants in \u003Ci>TNNT2\u003C/i>, \u003Ci>MYL2\u003C/i>, and \u003Ci>MYL3\u003C/i> genes. Only two variants in the \u003Ci>TNNT2\u003C/i> gene were identified. The \u003Ci>TNNT2\u003C/i> gene encodes the cardiac troponin T2 which is a regulatory protein of the thin filament troponin complex in the sarcomere playing a crucial role in contractility function (\u003Ca href=\"#ref39\">39\u003C/a>, \u003Ca href=\"#ref55\">55\u003C/a>). More than 30 \u003Ci>TNNT2\u003C/i> P/LP variants have been linked to HCM, with individual variants being unique and private to distinct families (\u003Ca href=\"#ref55\">55\u003C/a>). Moreover, phenotypic variability was reported among patients carrying the same \u003Ci>TNNT2\u003C/i> variant (\u003Ca href=\"#ref55\">55\u003C/a>). The MLCs are composed of a regulatory light chain (\u003Ci>MYL2\u003C/i>) and an essential light chain (\u003Ci>MYL3\u003C/i>). These genes contribute to the stability of myosin head and the regulation of cardiac contraction by phosphorylation and Ca\u003Csup>2+\u003C/sup> binding (\u003Ca href=\"#ref52\">52\u003C/a>). Despite these genes being considered well-established HCM genes, their contribution to HCM etiology is limited. A study by Borrelli et al. estimated that the contribution of genes encoding sarcomere thin filaments does not exceed 5% (\u003Ca href=\"#ref11\">11\u003C/a>). In our cohort, no high or moderate confidence variants were found in \u003Ci>ACTC1\u003C/i>, \u003Ci>TPM1\u003C/i>, \u003Ci>TNNC1\u003C/i>, or \u003Ci>TNNI3\u003C/i> genes. A recent study by Allouba et al. (\u003Ca href=\"#ref56\">56\u003C/a>) showed that homozygous variants are more prevalent within \u003Ci>MYL2\u003C/i> and \u003Ci>MYL3\u003C/i> genes than within major sarcomeric HCM genes. In the HYPERGEN cohort, only one homozygous variant was identified (\u003Ci>MYL3\u003C/i>: p.Ala57Asp) in a patient with a family history of HCM.\u003C/p>\n\u003Cp class=\"mb15\">Although HCM has been recognized as a monogenic disease for a long time, the wide utilization of high-throughput sequencing has demonstrated that it may be caused by the occurrence of more than one variant, particularly for sarc&#x02212;patients. In this reanalysis, considering sarc+patients, we identified three patients with two variants within the \u003Ci>MYBPC3\u003C/i> gene, seven cases carrying digenic variants, and five patients carrying more than two variants (\u003Ca href=\"#tab1\">Tables 1\u003C/a>, \u003Ca href=\"#tab2\">2\u003C/a>). In some sarc&#x02212;cases, unique variants were found in genes encoding proteins located in the Z-disc, namely, \u003Ci>FLNC\u003C/i>, \u003Ci>ACTN2\u003C/i>, \u003Ci>CSRP3\u003C/i>, \u003Ci>TRIM63\u003C/i>, and \u003Ci>SVIL\u003C/i> (\u003Ca href=\"#tab5\">Tables 5\u003C/a>&#x2013;\u003Ca href=\"#tab8\">8\u003C/a>). Of note, variants within \u003Ci>CAV3\u003C/i>, \u003Ci>VCL\u003C/i>, and \u003Ci>JPH2\u003C/i> genes were found along with additional sarcomeric and non-sarcomeric variants.\u003C/p>\n\u003Cp class=\"mb15\">We identified three \u003Ci>CSRP3\u003C/i> variants, including the known p.Trp4Arg variant. The \u003Ci>CSRP3\u003C/i> gene, encoding cysteine and glycine-rich protein 3, is one of the non-sarcomeric HCM-associated genes with strong evidence for a primary pathogenic role in HCM (\u003Ca href=\"#ref13\">13\u003C/a>). It plays different roles in mechanosensory functions and actin cytoskeleton assembly (\u003Ca href=\"#ref12\">12\u003C/a>, \u003Ca href=\"#ref57\">57\u003C/a>). Functional analysis of \u003Ci>Csrp3\u003C/i> knock-in animals (\u003Ci>Csrp3\u003Csup>Trp4Arg/+\u003C/sup>\u003C/i>) and (\u003Ci>Csrp3\u003Csup>Trp4Arg/Trp4Arg\u003C/sup>\u003C/i>) showed an age-and gene dosage-dependent HCM and heart failure, characterized by a nearly complete loss of contractile function under catecholamine-induced stress. Moreover, \u003Ci>Cspr3\u003C/i> mRNA and protein levels were significantly decreased in the hearts of heterozygous and homozygous \u003Ci>Cspr3\u003Csup>Trp4Arg\u003C/sup>\u003C/i> knock-in animals (\u003Ca href=\"#ref57\">57\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">We identified five variants in the \u003Ci>ACTN2\u003C/i> gene, three of which were unique, and two patients were digenic and were carrying additional variants in \u003Ci>MYBPC3\u003C/i> and \u003Ci>TRIM63\u003C/i> genes. The \u003Ci>ACTN2\u003C/i> gene (major Z-disc cross-linking protein) is of particular interest as variants within this gene have been linked to diverse cardiac phenotypes such as HCM, dilated cardiomyopathy (DCM), LV non-compaction (LVNC), and SCD (\u003Ca href=\"#SM1\">Supplementary File 3\u003C/a>) (\u003Ca href=\"#ref58\">58\u003C/a>&#x2013;\u003Ca href=\"#ref61\">61\u003C/a>). Patients with \u003Ci>ACTN2\u003C/i> pathogenic variants showed no specific hypertrophy pattern, as septal, apical, concentric, and biventricular hypertrophy were reported. More importantly, patients with mild hypertrophy had severe complications such as resuscitated cardiac arrest and heart failure (\u003Ca href=\"#ref12\">12\u003C/a>, \u003Ca href=\"#ref61\">61\u003C/a>&#x2013;\u003Ca href=\"#ref64\">64\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">A small number of variants was identified within the \u003Ci>ALPK3\u003C/i> gene (\u003Ci>n\u003C/i>&#x2009;=&#x2009;4), 3 out of the 4 variants were unique. Of note, the \u003Ci>ALPK3\u003C/i> gene (\u003Ci>&#x03B1;\u003C/i>-protein kinase 3) was initially linked to an autosomal recessive form of severe pediatric mixed cardiomyopathy (HCM/DCM phenotype) (\u003Ca href=\"#ref65\">65\u003C/a>&#x2013;\u003Ca href=\"#ref67\">67\u003C/a>). In 2020, the \u003Ci>ALPK3\u003C/i> gene reached a definitive classification of strong evidence for an autosomal recessive form of HCM with an infant onset (\u003Ca href=\"#ref46\">46\u003C/a>). However, cases harboring heterozygous LoF variants were reported with mild-to-moderate phenotypes, and an autosomal dominant pattern of inheritance was subsequently associated with an adult-onset HCM (\u003Ca href=\"#ref12\">12\u003C/a>, \u003Ca href=\"#ref46\">46\u003C/a>, \u003Ca href=\"#ref68\">68\u003C/a>, \u003Ca href=\"#ref69\">69\u003C/a>). Recently, rare missense \u003Ci>ALPK3\u003C/i> variants have been identified in Asian HCM patients (\u003Ca href=\"#ref46\">46\u003C/a>, \u003Ca href=\"#ref70\">70\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Three genes were recently associated with HCM and identified in this reanalysis: \u003Ci>TRIM63\u003C/i>, \u003Ci>FHOD3\u003C/i>, and \u003Ci>SVIL\u003C/i>. \u003Ci>TRIM63\u003C/i> is one of the rare genes recently described as a cause of HCM with autosomal-recessive inheritance. \u003Ci>TRIM63\u003C/i> encodes muscle-specific RING-finger protein 1 (MuRF1), a member of the ubiquitin ligases subfamily, such as MuRF-2 and MuRF-3 (\u003Ca href=\"#ref71\">71\u003C/a>, \u003Ca href=\"#ref72\">72\u003C/a>). It is an E3 ubiquitin&#x02212;protein that regulates the degradation of sarcomeric proteins such as Mybpc3 and Myh6 through ubiquitylation (\u003Ca href=\"#ref12\">12\u003C/a>, \u003Ca href=\"#ref72\">72\u003C/a>). Homozygous and compound heterozygous rare variants in the \u003Ci>TRIM63\u003C/i> gene were linked to HCM. \u003Ci>TRIM63\u003C/i> variant carriers showed concentric LV hypertrophy, significant cardiac fibrosis, LV systolic dysfunction, and arrhythmias (\u003Ca href=\"#ref12\">12\u003C/a>, \u003Ca href=\"#ref40\">40\u003C/a>, \u003Ca href=\"#ref41\">41\u003C/a>). Furthermore, systolic dysfunction and late gadolinium enhancement have been reported as characteristic features of \u003Ci>TRIM63\u003C/i>-associated cardiomyopathies (\u003Ca href=\"#ref41\">41\u003C/a>). Rare missense variants in \u003Ci>TRIM63\u003C/i> at the heterozygous state were reported as genetic modifiers of HCM. Although the \u003Ci>TRIM63\u003C/i> missense variants had limited evidence of disease causality, \u003Ci>TRIM63\u003C/i> knockouts are likely to be associated with HCM, given their enrichment in HCM patients and their absence in gnomAD (\u003Ca href=\"#ref12\">12\u003C/a>, \u003Ca href=\"#ref41\">41\u003C/a>). In our reanalysis, the two LP missense variants (p.Cys23Tyr and p.Cys75Tyr) were identified in 5 patients of the HYPERGEN cohort. The \u003Ci>TRIM63\u003C/i>: (p.Gln247&#x0002A;) stop variant was identified in three patients, one at the homozygous state and two patients were heterozygous. The p.Gln247&#x0002A; variant is reported in the ClinVar database with a conflicting interpretation of pathogenicity. Nevertheless, \u003Ci>in vitro\u003C/i> and \u003Ci>in vivo\u003C/i> functional studies showed near complete loss of auto-ubiquitination in cells transduced with the TRIM63Q247&#x0002A; lentiviral construct (\u003Ca href=\"#ref12\">12\u003C/a>, \u003Ca href=\"#ref41\">41\u003C/a>). Several other \u003Ci>TRIM63\u003C/i> variants impair the ubiquitination of Trim63 substrates in adult cardiomyocytes. These findings implicate the impaired protein degradation as a pathophysiology mechanism of HCM (\u003Ca href=\"#ref40\">40\u003C/a>, \u003Ca href=\"#ref41\">41\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Of note, in the HYPERGEN cohort, five patients (2.5%) carried homozygous variants in \u003Ci>MYBPC3\u003C/i> (\u003Ci>n\u003C/i> =&#x2009;1), \u003Ci>MYL3\u003C/i> (\u003Ci>n\u003C/i> =&#x2009;1), and \u003Ci>TRIM63\u003C/i> (\u003Ci>n\u003C/i> =&#x2009;3) genes.\u003C/p>\n\u003Cp class=\"mb15\">The second recent gene identified in this reanalysis is the \u003Ci>FHOD3\u003C/i> gene. \u003Ci>FHOD3\u003C/i> encodes the cardiac formin homology 2 domain containing three proteins that localize in the thin filament of the sarcomere and promote actin filament polymerization in cardiomyocytes (\u003Ca href=\"#ref44\">44\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Rare pathogenic \u003Ci>FHOD3\u003C/i> variants were linked to HCM etiology through association analysis of 3,189 HCM patients and familial segregation studies (\u003Ca href=\"#ref43\">43\u003C/a>). \u003Ci>FHOD3\u003C/i> variants associated with HCM are mostly non-truncating and disturb the diaphanous inhibitory domain of the protein. Patients carrying likely causative \u003Ci>FHOD3\u003C/i> variants showed mild-to-moderate LV hypertrophy and a 1% annual incidence of cardiovascular mortality (\u003Ca href=\"#ref43\">43\u003C/a>). Additionally, \u003Ci>FHOD3\u003C/i>-HCM patients were diagnosed in adulthood (mean age 46.1&#x2009;years), and two-thirds (66%) were men. The majority of patients (82%) had asymmetric septal hypertrophy (mean 18.8&#x2009;&#x000B1;&#x2009;5&#x2009;mm). LV ejection fraction &#x0003C;50% was present in 14% of the cohort and hypertrabeculation in 16% (\u003Ca href=\"#ref43\">43\u003C/a>). Moreover, the cardiomyopathic phenotype of \u003Ci>cMyBP-C\u003C/i> null mice was aggravated by Fhod3 overexpression with a sarcomere integrity disruption. This phenotype was partially improved by a reduction in the Fhod3 protein levels, suggesting that Fhod3 has a damaging impact on cardiac function under \u003Ci>cMyBP-C\u003C/i> null conditions where Fhod3 is mis-localized (\u003Ca href=\"#ref44\">44\u003C/a>). These findings suggest the likely contribution of Fhod3 to the pathogenesis of cMyBP-C-related cardiomyopathy and that Fhod3 is implicated in cardiac cMyBP-C-mediated regulation via direct interaction (\u003Ca href=\"#ref44\">44\u003C/a>). In this study, rare missense \u003Ci>FHOD3\u003C/i> variants were identified in the hotspot exons (12 and 15), and two patients with the recurrent \u003Ci>FHOD3\u003C/i> p.Arg637Gln variant were digenic, carrying additional variants in the \u003Ci>MYBPC3\u003C/i> gene (p.Cys1202Leufs&#x0002A;35 and p.Arg597Gln).\u003C/p>\n\u003Cp class=\"mb15\">More recently, the \u003Ci>SVIL\u003C/i> gene was associated with HCM (\u003Ca href=\"#ref46\">46\u003C/a>, \u003Ca href=\"#ref47\">47\u003C/a>). The \u003Ci>SVIL\u003C/i> (Supervillin) encodes a multidomain actin and myosin-binding protein in the Z-disc (\u003Ca href=\"#ref73\">73\u003C/a>, \u003Ca href=\"#ref74\">74\u003C/a>). Biallelic LoF \u003Ci>SVIL\u003C/i> variants were identified in patients with skeletal myopathy, mild LV hypertrophy, and smaller descending aortic diameter (\u003Ca href=\"#ref75\">75\u003C/a>). Indeed, a 10.5-fold excess burden of \u003Ci>SVIL\u003C/i> rare PTV variants in HCM cases has been demonstrated in a recent GWAS (\u003Ca href=\"#ref47\">47\u003C/a>). Patients harboring rare truncating \u003Ci>SVIL\u003C/i> variants were found to have an increased LV contractility in both obstructive and non-obstructive forms of HCM, as demonstrated by Mendelian randomization analyses (\u003Ca href=\"#ref47\">47\u003C/a>). In one family, the \u003Ci>SVIL\u003C/i>: p.(Gln255&#x0002A;) variant was found in two affected cousins, providing some evidence of familial segregation (\u003Ca href=\"#ref47\">47\u003C/a>). In this reanalysis, clinical data were gathered for 7 out of the 13 patients with \u003Ci>SVIL\u003C/i> variants (\u003Ca href=\"#tab9\">Table 9\u003C/a>). Three patients harboring the \u003Ci>SVIL\u003C/i>: p.(Ser1414Thr), p.(Glu1286Lys), and p.(Lys1960Arg) variants presented an aortic phenotype including bicuspid aortic valve disease, isolated ectasia of Valsalva sinus, and mild aortic insufficiency. Overall, the majority of \u003Ci>SVIL\u003C/i> patients showed severe intramyocardial late gadolinium enhancement. One patient (HCM-108) experienced SCD, and another patient (HCM-139) had a history of syncopes during physical effort. Of note, the patient (HCM-108) carried an additional variant in the \u003Ci>FHOD3\u003C/i> gene (p.Arg638Trp). A severe scoliosis was diagnosed in one patient (HCM-129).\u003C/p>\n\u003Cp class=\"mb15\">Interestingly, variants in \u003Ci>SVIL\u003C/i> and \u003Ci>FHOD3\u003C/i> genes accounted for 10 and 7%, respectively, of patients with early HCM onset. Patients with sarcomere mutations have been reported to show earlier adverse complications and a worse prognosis (\u003Ca href=\"#ref76\">76\u003C/a>). Several published HCM cohorts, studies, and data provided by the Sarcomeric Human Cardiomyopathy Registry (SHaRe) have shown that cases with sarcomeric variants had an early onset of the disease and a more severe phenotype with malignant complications. Thus, patients diagnosed in early adulthood (&#x0003C;40&#x2009;years) had more severe outcomes with many adverse complications compared to patients with late-onset HCM. Moreover, HCM young patients (20&#x2013;29&#x2009;years) had a 4-fold increase in the risk of death compared to the general population (\u003Ca href=\"#ref76\">76\u003C/a>&#x2013;\u003Ca href=\"#ref78\">78\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">All the identified variants in this reanalysis were searched in a French control cohort, gathering 960 healthy individuals. Only seven variants were present (\u003Ca href=\"#tab10\">Table 10\u003C/a>). Of note, \u003Ci>TCAP\u003C/i>: p.(Met71Thr), \u003Ci>ALPK3\u003C/i>: p.(Arg1483Trp), \u003Ci>FLNC\u003C/i>: p.(Arg1860Cys) and \u003Ci>MYPN\u003C/i>: p.(Pro1112Leu) variants were unique in HYPERGEN carriers. The \u003Ci>VCL\u003C/i>: p.(His636Arg) and \u003Ci>MYPN\u003C/i>: p.P (ro1112Leu) variants were found in Finnish and Ashkenazi Jewish populations, respectively, suggesting that these variants could be more prevalent in these bottleneck populations.\u003C/p>\n\u003Cp class=\"mb15\">Although the identification of variants in genes lacking strong evidence for disease causality and/or VUS in minor HCM genes does not increase the clinically actionable genes/variants discovery, it sheds light on the possibility of a combinatorial joint effect where VUS variants may act as a small risk increasing genetic factor.\u003C/p>\n\u003Cp class=\"mb15\">Gathering strong proof of disease causality remains challenging for many reasons, such as the unavailability of family members to undergo co-segregation and funding constraints for functional studies. Indeed, genes such as \u003Ci>ALPK3\u003C/i> and \u003Ci>FHOD3\u003C/i> have been considered disease-causing by large gene-centric case&#x2013;control studies. This strategy is an effective approach to reaching the needed statistical power supporting gene&#x2013;disease association (\u003Ca href=\"#ref46\">46\u003C/a>). Furthermore, the publication of cases with variants of low to moderate evidence was recommended, as the identical variants may be detected in extended families with similar phenotypes by researchers interested in functional validation (\u003Ca href=\"#ref46\">46\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Presently, we aimed to reanalyze a cohort of 200 HCM patients by focusing on genes strongly associated with HCM while also investigating newly linked genes with limited or insufficient evidence of causality to determine their potential involvement in our cohort. Overall, our results strengthen the implication of \u003Ci>FHOD3\u003C/i>, \u003Ci>TRIM63\u003C/i>, and \u003Ci>SVIL\u003C/i> genes in HCM as minor genes. Variants in the \u003Ci>SVIL\u003C/i> gene, recently linked to HCM, were found in 13 HYPERGEN patients. More importantly, patients harboring \u003Ci>SVIL\u003C/i> variants presented a similar hypertrophic pattern (significant myocardial fibrosis for six out of the seven patients/apical for three patients), and aortopathy was reported for three patients. The findings from our study extend the clinical and genetic spectrum of \u003Ci>SVIL\u003C/i> gene carriers. While Tadros et al. (\u003Ca href=\"#ref47\">47\u003C/a>) identified \u003Ci>SVIL\u003C/i> variants in HCM patients, our study reveals additional cases, underscoring the need for expanded genetic screening. This broader understanding can facilitate future investigations into the pathophysiological mechanisms associated with \u003Ci>SVIL\u003C/i> variants, potentially leading to improved risk stratification and management strategies for patients.\u003C/p>\n\u003Cp class=\"mb15\">The assessing and reporting of the identified variants&#x2014;particularly within the novel associated genes&#x2014;may provide additional strength to the previously reported variants and identify novel variants that help an accurate classification and interpretation. This study contributes to defining the genetic landscape of French HCM patients, which facilitates cascade genetic testing in familial cases and ultimately could guide personalized treatment.\u003C/p>\n\u003Cp class=\"mb0\">The main goal of this study was to assess and report actionable and high-confidence variants in known and emerging HCM genes. However, there are several limitations in our study, making an accurate estimation of the increased diagnostic yield challenging. This is mainly due to the absence of detailed genetic results from the initial analysis. In addition, detailed patient phenotyping and clinical data are lacking. Thus, genotype&#x2013;phenotype correlations and risk stratification were difficult to achieve.\u003C/p> \u003Ca id=\"h6\" name=\"h6\">\u003C/a>\n\u003Ch2>Data availability statement\u003C/h2>\n\u003Cp class=\"mb0\">The data presented in the study are deposited in the ClinVar database under the following link: \u003Ca href=\"https://www.ncbi.nlm.nih.gov/clinvar/submitters/508840/\">https://www.ncbi.nlm.nih.gov/clinvar/submitters/508840/\u003C/a>.\u003C/p> \u003Ca id=\"h7\" name=\"h7\">\u003C/a>\n\u003Ch2>Ethics statement\u003C/h2>\n\u003Cp class=\"mb0\">The studies involving humans were approved by Comit&#x000E9; d&#x2019;&#x000E9;thique de la Recherche d&#x2019;Aix-Marseille Universit&#x000E9;. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.\u003C/p> \u003Ca id=\"h8\" name=\"h8\">\u003C/a>\n\u003Ch2>Author contributions\u003C/h2>\n\u003Cp class=\"mb0\">HJ: Conceptualization, Data curation, Formal analysis, Investigation, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. VM: Data curation, Formal analysis, Writing &#x2013; review &#x0026; editing. HM: Data curation, Investigation, Writing &#x2013; review &#x0026; editing. PL: Data curation, Formal analysis, Methodology, Writing &#x2013; review &#x0026; editing. LL: Formal analysis, Investigation, Writing &#x2013; review &#x0026; editing. MH: Formal analysis, Investigation, Writing &#x2013; review &#x0026; editing. CL: Data curation, Writing &#x2013; review &#x0026; editing. FM: Resources, Supervision, Validation, Writing &#x2013; review &#x0026; editing. GH: Data curation, Investigation, Resources, Supervision, Validation, Writing &#x2013; review &#x0026; editing. J-JS: Data curation, Resources, Validation, Writing &#x2013; review &#x0026; editing. SZ: Conceptualization, Data curation, Investigation, Resources, Supervision, Validation, Writing &#x2013; review &#x0026; editing. KN: Data curation, Formal analysis, Investigation, Resources, Validation, Writing &#x2013; review &#x0026; editing.\u003C/p> \u003Ca id=\"h9\" name=\"h9\">\u003C/a>\n\u003Ch2>Funding\u003C/h2>\n\u003Cp class=\"mb0\">The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by SANOFI GENZYME SA (contract number C01550), the \"Association Fran&#x000E7;aise contre les Myopathies\" (NMH-Decrypt Project), and the \"Institut National de la Sant&#x000E9; et de la Recherche M&#x000E9;dicale\" to SZ. HJ received a postdoctoral fellowship from the \"Fondation Lefoulon Delalande\".\u003C/p> \u003Ca id=\"h10\" name=\"h10\">\u003C/a>\n\u003Ch2>Conflict of interest\u003C/h2>\n\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p> \u003Ca id=\"h11\" name=\"h11\">\u003C/a>\n\u003Ch2>Publisher&#x2019;s note\u003C/h2>\n\u003Cp class=\"mb0\">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C/p> \u003Ca id=\"h12\" name=\"h12\">\u003C/a>\n\u003Ch2>Supplementary material\u003C/h2>\n\u003Cp class=\"mb0\" id=\"SM1\">The Supplementary material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fmed.2024.1480947/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fmed.2024.1480947/full#supplementary-material\u003C/a>\u003C/p> \u003Ca id=\"h13\" name=\"h13\">\u003C/a>\n\u003Ch2>Footnotes\u003C/h2> \u003Cdiv id=\"footnotetext\" class=\"fulltextdescription\">\n\u003Cp style=\"margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;\" id=\"fn0001\">1. \u003Ca class=\"footnotetextanchor\" href=\"#xfn0001\" title=\"\">^\u003C/a>\u003Ca href=\"https://www.clinicalgenome.org/\">https://www.clinicalgenome.org/\u003C/a>\u003C/p>\n\u003Cp style=\"margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;\" id=\"fn0002\">2. \u003Ca class=\"footnotetextanchor\" href=\"#xfn0002\" title=\"\">^\u003C/a>\u003Ca href=\"https://github.com/lindenb/gazoduc-nf/tree/aab8c83f47267e64a24a37bed686ec4f041003e6/workflows/gatk/gatk4gvcfs\">https://github.com/lindenb/gazoduc-nf/tree/aab8c83f47267e64a24a37bed686ec4f041003e6/workflows/gatk/gatk4gvcfs\u003C/a>\u003C/p>\n\u003Cp style=\"margin-top:0em;margin-bottom:0em;margin-left:1em;text-indent:-1em;\" id=\"fn0003\">3. \u003Ca class=\"footnotetextanchor\" href=\"#xfn0003\" title=\"\">^\u003C/a>\u003Ca href=\"https://doi.org/10.6084/m9.figshare.1425030.v1\">https://doi.org/10.6084/m9.figshare.1425030.v1\u003C/a>\u003C/p>\n\u003C/div> \u003Ca id=\"h14\" name=\"h14\">\u003C/a>\n\u003Ch2>References\u003C/h2>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref1\" id=\"ref1\">\u003C/a>1. Richard, P, Charron, P, Carrier, L, Ledeuil, C, Cheav, T, Pichereau, C, et al. Hypertrophic cardiomyopathy: distribution of disease genes, Spectrum of mutations, and implications for a molecular diagnosis strategy. \u003Ci>Circulation\u003C/i>. (2003) 107:2227&#x2013;32. doi: 10.1161/01.CIR.0000066323.15244.54\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1161/01.CIR.0000066323.15244.54\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Richard&#x00026;author=P+Charron&#x00026;author=L+Carrier&#x00026;author=C+Ledeuil&#x00026;author=T+Cheav&#x00026;author=C+Pichereau&#x00026;publication_year=2003&#x00026;title=Hypertrophic+cardiomyopathy:+distribution+of+disease+genes+Spectrum+of+mutations+and+implications+for+a+molecular+diagnosis+strategy&#x00026;journal=Circulation&#x00026;volume=107&#x00026;pages=2227-32\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref2\" id=\"ref2\">\u003C/a>2. Muresan, ID, and Agoston-Coldea, L. Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging. \u003Ci>Heart Fail Rev\u003C/i>. (2021) 26:1023&#x2013;36. doi: 10.1007/s10741-020-09931-1 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32040801\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10741-020-09931-1\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=ID+Muresan&#x00026;author=L+Agoston-Coldea&#x00026;publication_year=2021&#x00026;title=Phenotypes+of+hypertrophic+cardiomyopathy:+genetics+clinics+and+modular+imaging&#x00026;journal=Heart+Fail+Rev&#x00026;volume=26&#x00026;pages=1023-36\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref3\" id=\"ref3\">\u003C/a>3. Maron, BJ, Desai, MY, Nishimura, RA, Spirito, P, Rakowski, H, Towbin, JA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. \u003Ci>J Am Coll Cardiol\u003C/i>. (2022) 79:372&#x2013;89. doi: 10.1016/j.jacc.2021.12.002\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1016/j.jacc.2021.12.002\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BJ+Maron&#x00026;author=MY+Desai&#x00026;author=RA+Nishimura&#x00026;author=P+Spirito&#x00026;author=H+Rakowski&#x00026;author=JA+Towbin&#x00026;publication_year=2022&#x00026;title=Diagnosis+and+evaluation+of+hypertrophic+cardiomyopathy:+JACC+state-of-the-art+review&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=79&#x00026;pages=372-89\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref4\" id=\"ref4\">\u003C/a>4. Litt, MJ, Ali, A, and Reza, N. Familial hypertrophic cardiomyopathy: diagnosis and management. \u003Ci>Vasc Health Risk Manag\u003C/i>. (2023) 19:211&#x2013;21. doi: 10.2147/VHRM.S365001 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/37050929\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.2147/VHRM.S365001\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MJ+Litt&#x00026;author=A+Ali&#x00026;author=N+Reza&#x00026;publication_year=2023&#x00026;title=Familial+hypertrophic+cardiomyopathy:+diagnosis+and+management&#x00026;journal=Vasc+Health+Risk+Manag&#x00026;volume=19&#x00026;pages=211-21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref5\" id=\"ref5\">\u003C/a>5. Bourfiss, M, van Vugt, M, Alasiri, AI, Ruijsink, B, van Setten, J, Schmidt, AF, et al. Prevalence and disease expression of pathogenic and likely pathogenic variants associated with inherited cardiomyopathies in the general population. \u003Ci>Circ Genomic Precis Med\u003C/i>. (2022) 15:e003704. doi: 10.1161/CIRCGEN.122.003704\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1161/CIRCGEN.122.003704\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Bourfiss&#x00026;author=M+van+Vugt&#x00026;author=AI+Alasiri&#x00026;author=B+Ruijsink&#x00026;author=J+van+Setten&#x00026;author=AF+Schmidt&#x00026;publication_year=2022&#x00026;title=Prevalence+and+disease+expression+of+pathogenic+and+likely+pathogenic+variants+associated+with+inherited+cardiomyopathies+in+the+general+population&#x00026;journal=Circ+Genomic+Precis+Med&#x00026;volume=15&#x00026;pages=e003704\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref6\" id=\"ref6\">\u003C/a>6. Maron, BJ, Desai, MY, Nishimura, RA, Spirito, P, Rakowski, H, Towbin, JA, et al. Management of Hypertrophic Cardiomyopathy: JACC state-of-the-art review. \u003Ci>J Am Coll Cardiol\u003C/i>. (2022) 79:390&#x2013;414. doi: 10.1016/j.jacc.2021.11.021\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1016/j.jacc.2021.11.021\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BJ+Maron&#x00026;author=MY+Desai&#x00026;author=RA+Nishimura&#x00026;author=P+Spirito&#x00026;author=H+Rakowski&#x00026;author=JA+Towbin&#x00026;publication_year=2022&#x00026;title=Management+of+Hypertrophic+Cardiomyopathy:+JACC+state-of-the-art+review&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=79&#x00026;pages=390-414\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref7\" id=\"ref7\">\u003C/a>7. Semsarian, C, Ingles, J, Maron, MS, and Maron, BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. \u003Ci>J Am Coll Cardiol\u003C/i>. (2015) 65:1249&#x2013;54. doi: 10.1016/j.jacc.2015.01.019 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25814232\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2015.01.019\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Semsarian&#x00026;author=J+Ingles&#x00026;author=MS+Maron&#x00026;author=BJ+Maron&#x00026;publication_year=2015&#x00026;title=New+perspectives+on+the+prevalence+of+hypertrophic+cardiomyopathy&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=65&#x00026;pages=1249-54\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref8\" id=\"ref8\">\u003C/a>8. Members, WC, Ommen, SR, Mital, S, Burke, MA, Day, SM, Deswal, A, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. \u003Ci>Circulation\u003C/i>. (2020) 142:e533&#x2013;57. doi: 10.1161/CIR.0000000000000938\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1161/CIR.0000000000000938\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WC+Members&#x00026;author=SR+Ommen&#x00026;author=S+Mital&#x00026;author=MA+Burke&#x00026;author=SM+Day&#x00026;author=A+Deswal&#x00026;publication_year=2020&#x00026;title=2020+AHA/ACC+guideline+for+the+diagnosis+and+treatment+of+patients+with+hypertrophic+cardiomyopathy:+Executive+summary:+A+report+of+the+American+College+of+Cardiology/American+Heart+Association+joint+committee+on+clinical+practice+guidelines&#x00026;journal=Circulation&#x00026;volume=142&#x00026;pages=e533-57\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref9\" id=\"ref9\">\u003C/a>9. Morimoto, S. Sarcomeric proteins and inherited cardiomyopathies. \u003Ci>Cardiovasc Res\u003C/i>. (2008) 77:659&#x2013;66. doi: 10.1093/cvr/cvm084 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18056765\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/cvr/cvm084\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Morimoto&#x00026;publication_year=2008&#x00026;title=Sarcomeric+proteins+and+inherited+cardiomyopathies&#x00026;journal=Cardiovasc+Res&#x00026;volume=77&#x00026;pages=659-66\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref10\" id=\"ref10\">\u003C/a>10. Sabater-Molina, M, P&#x000E9;rez-S&#x000E1;nchez, I, JPH, R, and Gimeno, JR. Genetics of hypertrophic cardiomyopathy: a review of current state. \u003Ci>Clin Genet\u003C/i>. (2018) 93:3&#x2013;14. doi: 10.1111/cge.13027\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1111/cge.13027\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Sabater-Molina&#x00026;author=I+P&#x000E9;rez-S&#x000E1;nchez&#x00026;author=R+JPH&#x00026;author=JR+Gimeno&#x00026;publication_year=2018&#x00026;title=Genetics+of+hypertrophic+cardiomyopathy:+a+review+of+current+state&#x00026;journal=Clin+Genet&#x00026;volume=93&#x00026;pages=3-14\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref11\" id=\"ref11\">\u003C/a>11. Borrelli, F, Losi, MA, Canciello, G, Todde, G, Perillo, EF, Ordine, L, et al. Sarcomeric versus non-Sarcomeric HCM. \u003Ci>Cardiogenetics\u003C/i>. (2023) 13:92&#x2013;105. doi: 10.3390/cardiogenetics13020009\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.3390/cardiogenetics13020009\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F+Borrelli&#x00026;author=MA+Losi&#x00026;author=G+Canciello&#x00026;author=G+Todde&#x00026;author=EF+Perillo&#x00026;author=L+Ordine&#x00026;publication_year=2023&#x00026;title=Sarcomeric+versus+non-Sarcomeric+HCM&#x00026;journal=Cardiogenetics&#x00026;volume=13&#x00026;pages=92-105\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref12\" id=\"ref12\">\u003C/a>12. Walsh, R, Offerhaus, JA, Tadros, R, and Bezzina, CR. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. \u003Ci>Nat Rev Cardiol\u003C/i>. (2022) 19:151&#x2013;67. doi: 10.1038/s41569-021-00608-2 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34526680\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41569-021-00608-2\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=JA+Offerhaus&#x00026;author=R+Tadros&#x00026;author=CR+Bezzina&#x00026;publication_year=2022&#x00026;title=Minor+hypertrophic+cardiomyopathy+genes+major+insights+into+the+genetics+of+cardiomyopathies&#x00026;journal=Nat+Rev+Cardiol&#x00026;volume=19&#x00026;pages=151-67\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref13\" id=\"ref13\">\u003C/a>13. Walsh, R, Buchan, R, Wilk, A, John, S, Felkin, LE, Thomson, KL, et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. \u003Ci>Eur Heart J\u003C/i>. (2017) 38:3461&#x2013;8. doi: 10.1093/eurheartj/ehw603 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28082330\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/eurheartj/ehw603\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=R+Buchan&#x00026;author=A+Wilk&#x00026;author=S+John&#x00026;author=LE+Felkin&#x00026;author=KL+Thomson&#x00026;publication_year=2017&#x00026;title=Defining+the+genetic+architecture+of+hypertrophic+cardiomyopathy:+re-evaluating+the+role+of+non-sarcomeric+genes&#x00026;journal=Eur+Heart+J&#x00026;volume=38&#x00026;pages=3461-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref14\" id=\"ref14\">\u003C/a>14. Lopes, LR, Syrris, P, Guttmann, OP, O&#x2019;Mahony, C, Tang, HC, Dalageorgou, C, et al. Novel genotype&#x2013;phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. \u003Ci>Heart\u003C/i>. (2015) 101:294&#x2013;301. doi: 10.1136/heartjnl-2014-306387 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25351510\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/heartjnl-2014-306387\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=LR+Lopes&#x00026;author=P+Syrris&#x00026;author=OP+Guttmann&#x00026;author=C+O&#x2019;Mahony&#x00026;author=HC+Tang&#x00026;author=C+Dalageorgou&#x00026;publication_year=2015&#x00026;title=Novel+genotype&#x2013;phenotype+associations+demonstrated+by+high-throughput+sequencing+in+patients+with+hypertrophic+cardiomyopathy&#x00026;journal=Heart&#x00026;volume=101&#x00026;pages=294-301\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref15\" id=\"ref15\">\u003C/a>15. Lopes, LR, Zekavati, A, Syrris, P, Hubank, M, Giambartolomei, C, Dalageorgou, C, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. \u003Ci>J Med Genet\u003C/i>. (2013) 50:228&#x2013;39. doi: 10.1136/jmedgenet-2012-101270 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23396983\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jmedgenet-2012-101270\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=LR+Lopes&#x00026;author=A+Zekavati&#x00026;author=P+Syrris&#x00026;author=M+Hubank&#x00026;author=C+Giambartolomei&#x00026;author=C+Dalageorgou&#x00026;publication_year=2013&#x00026;title=Genetic+complexity+in+hypertrophic+cardiomyopathy+revealed+by+high-throughput+sequencing&#x00026;journal=J+Med+Genet&#x00026;volume=50&#x00026;pages=228-39\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref16\" id=\"ref16\">\u003C/a>16. Maron, BJ, Maron, MS, Maron, BA, and Loscalzo, J. Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy. \u003Ci>J Am Coll Cardiol\u003C/i>. (2019) 73:1978&#x2013;86. doi: 10.1016/j.jacc.2019.01.061 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31000001\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2019.01.061\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BJ+Maron&#x00026;author=MS+Maron&#x00026;author=BA+Maron&#x00026;author=J+Loscalzo&#x00026;publication_year=2019&#x00026;title=Moving+beyond+the+sarcomere+to+explain+heterogeneity+in+hypertrophic+cardiomyopathy&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=73&#x00026;pages=1978-86\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref17\" id=\"ref17\">\u003C/a>17. Marian, AJ. Oligogenic cardiomyopathy. J Cardiovasc. \u003Ci>Aging\u003C/i>. (2022) 2:3. doi: 10.20517/jca.2021.27\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.20517/jca.2021.27\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AJ+Marian&#x00026;publication_year=2022&#x00026;title=Oligogenic+cardiomyopathy.+J+Cardiovasc&#x00026;journal=Aging&#x00026;volume=2&#x00026;pages=3\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref18\" id=\"ref18\">\u003C/a>18. Baulina, NM, Kiselev, IS, Chumakova, OS, and Favorova, OO. Hypertrophic cardiomyopathy as an Oligogenic disease: transcriptomic arguments. \u003Ci>Mol Biol\u003C/i>. (2020) 54:840&#x2013;50. doi: 10.1134/S0026893320060023\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1134/S0026893320060023\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=NM+Baulina&#x00026;author=IS+Kiselev&#x00026;author=OS+Chumakova&#x00026;author=OO+Favorova&#x00026;publication_year=2020&#x00026;title=Hypertrophic+cardiomyopathy+as+an+Oligogenic+disease:+transcriptomic+arguments&#x00026;journal=Mol+Biol&#x00026;volume=54&#x00026;pages=840-50\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref19\" id=\"ref19\">\u003C/a>19. Helms, AS, and Day, SM. Other side of the coin: the missing heritability in hypertrophic cardiomyopathy. \u003Ci>Eur Heart J\u003C/i>. (2017) 38:3469&#x2013;71. doi: 10.1093/eurheartj/ehx024 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28201496\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/eurheartj/ehx024\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AS+Helms&#x00026;author=SM+Day&#x00026;publication_year=2017&#x00026;title=Other+side+of+the+coin:+the+missing+heritability+in+hypertrophic+cardiomyopathy&#x00026;journal=Eur+Heart+J&#x00026;volume=38&#x00026;pages=3469-71\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref20\" id=\"ref20\">\u003C/a>20. Li, L, Bainbridge, MN, Tan, Y, Willerson, JT, and Marian, AJ. A potential Oligogenic etiology of hypertrophic cardiomyopathy novelty and significance: a classic single-gene disorder. \u003Ci>Circ Res\u003C/i>. (2017) 120:1084&#x2013;90. doi: 10.1161/CIRCRESAHA.116.310559 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28223422\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCRESAHA.116.310559\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Li&#x00026;author=MN+Bainbridge&#x00026;author=Y+Tan&#x00026;author=JT+Willerson&#x00026;author=AJ+Marian&#x00026;publication_year=2017&#x00026;title=A+potential+Oligogenic+etiology+of+hypertrophic+cardiomyopathy+novelty+and+significance:+a+classic+single-gene+disorder&#x00026;journal=Circ+Res&#x00026;volume=120&#x00026;pages=1084-90\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref21\" id=\"ref21\">\u003C/a>21. Gorlov, I, Gorlova, O, Frazier, M, Spitz, M, and Amos, C. Evolutionary evidence of the effect of rare variants on disease etiology. \u003Ci>Clin Genet\u003C/i>. (2011) 79:199&#x2013;206. doi: 10.1111/j.1399-0004.2010.01535.x \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20831747\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/j.1399-0004.2010.01535.x\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I+Gorlov&#x00026;author=O+Gorlova&#x00026;author=M+Frazier&#x00026;author=M+Spitz&#x00026;author=C+Amos&#x00026;publication_year=2011&#x00026;title=Evolutionary+evidence+of+the+effect+of+rare+variants+on+disease+etiology&#x00026;journal=Clin+Genet&#x00026;volume=79&#x00026;pages=199-206\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref22\" id=\"ref22\">\u003C/a>22. Zuk, O, Schaffner, SF, Samocha, K, Do, R, Hechter, E, Kathiresan, S, et al. Searching for missing heritability: designing rare variant association studies. \u003Ci>Proc Natl Acad Sci\u003C/i>. (2014) 111:E455&#x2013;64. doi: 10.1073/pnas.1322563111\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1073/pnas.1322563111\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=O+Zuk&#x00026;author=SF+Schaffner&#x00026;author=K+Samocha&#x00026;author=R+Do&#x00026;author=E+Hechter&#x00026;author=S+Kathiresan&#x00026;publication_year=2014&#x00026;title=Searching+for+missing+heritability:+designing+rare+variant+association+studies&#x00026;journal=Proc+Natl+Acad+Sci&#x00026;volume=111&#x00026;pages=E455-64\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref23\" id=\"ref23\">\u003C/a>23. Schobers, G, Schieving, JH, Yntema, HG, Pennings, M, Pfundt, R, Derks, R, et al. Reanalysis of exome negative patients with rare disease: a pragmatic workflow for diagnostic applications. \u003Ci>Genome Med\u003C/i>. (2022) 14:66. doi: 10.1186/s13073-022-01069-z \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35710456\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13073-022-01069-z\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Schobers&#x00026;author=JH+Schieving&#x00026;author=HG+Yntema&#x00026;author=M+Pennings&#x00026;author=R+Pfundt&#x00026;author=R+Derks&#x00026;publication_year=2022&#x00026;title=Reanalysis+of+exome+negative+patients+with+rare+disease:+a+pragmatic+workflow+for+diagnostic+applications&#x00026;journal=Genome+Med&#x00026;volume=14&#x00026;pages=66\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref24\" id=\"ref24\">\u003C/a>24. Hiatt, SM, Amaral, MD, Bowling, KM, Finnila, CR, Thompson, ML, Gray, DE, et al. Systematic reanalysis of genomic data improves quality of variant interpretation. \u003Ci>Clin Genet\u003C/i>. (2018) 94:174&#x2013;8. doi: 10.1111/cge.13259 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29652076\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cge.13259\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SM+Hiatt&#x00026;author=MD+Amaral&#x00026;author=KM+Bowling&#x00026;author=CR+Finnila&#x00026;author=ML+Thompson&#x00026;author=DE+Gray&#x00026;publication_year=2018&#x00026;title=Systematic+reanalysis+of+genomic+data+improves+quality+of+variant+interpretation&#x00026;journal=Clin+Genet&#x00026;volume=94&#x00026;pages=174-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref25\" id=\"ref25\">\u003C/a>25. Nguyen, K, Roche, S, Donal, E, Odent, S, Eicher, J-C, Faivre, L, et al. Whole exome sequencing reveals a large genetic heterogeneity and revisits the causes of hypertrophic cardiomyopathy. \u003Ci>Circ Genomic Precis Med\u003C/i>. (2019) 12:e002500. doi: 10.1161/CIRCGEN.119.002500 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31112424\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCGEN.119.002500\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Nguyen&#x00026;author=S+Roche&#x00026;author=E+Donal&#x00026;author=S+Odent&#x00026;author=J-C+Eicher&#x00026;author=L+Faivre&#x00026;publication_year=2019&#x00026;title=Whole+exome+sequencing+reveals+a+large+genetic+heterogeneity+and+revisits+the+causes+of+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Genomic+Precis+Med&#x00026;volume=12&#x00026;pages=e002500\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref26\" id=\"ref26\">\u003C/a>26. Rentzsch, P, Witten, D, Cooper, GM, Shendure, J, and Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. \u003Ci>Nucleic Acids Res\u003C/i>. (2019) 47:D886&#x2013;94. doi: 10.1093/nar/gky1016\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1093/nar/gky1016\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Rentzsch&#x00026;author=D+Witten&#x00026;author=GM+Cooper&#x00026;author=J+Shendure&#x00026;author=M+Kircher&#x00026;publication_year=2019&#x00026;title=CADD:+predicting+the+deleteriousness+of+variants+throughout+the+human+genome&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=47&#x00026;pages=D886-94\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref27\" id=\"ref27\">\u003C/a>27. Adzhubei, I, Jordan, DM, and Sunyaev, SR. Predicting functional effect of human missense mutations using poly Phen-2. \u003Ci>Curr Protoc Hum Genet\u003C/i>. (2013) Chapter 7: Unit 7.20 doi: 10.1002/0471142905.hg0720s76\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1002/0471142905.hg0720s76\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I+Adzhubei&#x00026;author=DM+Jordan&#x00026;author=SR+Sunyaev&#x00026;publication_year=2013&#x00026;title=Predicting+functional+effect+of+human+missense+mutations+using+poly+Phen-2&#x00026;journal=Curr+Protoc+Hum+Genet&#x00026;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref28\" id=\"ref28\">\u003C/a>28. Ng, PC, and Henikoff, S. SIFT: predicting amino acid changes that affect protein function. \u003Ci>Nucleic Acids Res\u003C/i>. (2003) 31:3812&#x2013;4. doi: 10.1093/nar/gkg509 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12824425\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkg509\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=PC+Ng&#x00026;author=S+Henikoff&#x00026;publication_year=2003&#x00026;title=SIFT:+predicting+amino+acid+changes+that+affect+protein+function&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=31&#x00026;pages=3812-4\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref29\" id=\"ref29\">\u003C/a>29. Schwarz, JM, Cooper, DN, Schuelke, M, and Seelow, D. Mutation taster 2: mutation prediction for the deep-sequencing age. \u003Ci>Nat Methods\u003C/i>. (2014) 11:361&#x2013;2. doi: 10.1038/nmeth.2890 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24681721\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nmeth.2890\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JM+Schwarz&#x00026;author=DN+Cooper&#x00026;author=M+Schuelke&#x00026;author=D+Seelow&#x00026;publication_year=2014&#x00026;title=Mutation+taster+2:+mutation+prediction+for+the+deep-sequencing+age&#x00026;journal=Nat+Methods&#x00026;volume=11&#x00026;pages=361-2\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref30\" id=\"ref30\">\u003C/a>30. Walsh, R, Mazzarotto, F, Whiffin, N, Buchan, R, Midwinter, W, Wilk, A, et al. Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. \u003Ci>Genome Med\u003C/i>. (2019) 11:5. doi: 10.1186/s13073-019-0616-z \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30696458\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13073-019-0616-z\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=F+Mazzarotto&#x00026;author=N+Whiffin&#x00026;author=R+Buchan&#x00026;author=W+Midwinter&#x00026;author=A+Wilk&#x00026;publication_year=2019&#x00026;title=Quantitative+approaches+to+variant+classification+increase+the+yield+and+precision+of+genetic+testing+in+Mendelian+diseases:+the+case+of+hypertrophic+cardiomyopathy&#x00026;journal=Genome+Med&#x00026;volume=11&#x00026;pages=5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref31\" id=\"ref31\">\u003C/a>31. Richards, S, Aziz, N, Bale, S, Bick, D, Das, S, Gastier-Foster, J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. \u003Ci>Genet Med Off J Am Coll Med Genet\u003C/i>. (2015) 17:405&#x2013;24. doi: 10.1038/gim.2015.30\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1038/gim.2015.30\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Richards&#x00026;author=N+Aziz&#x00026;author=S+Bale&#x00026;author=D+Bick&#x00026;author=S+Das&#x00026;author=J+Gastier-Foster&#x00026;publication_year=2015&#x00026;title=Standards+and+guidelines+for+the+interpretation+of+sequence+variants:+a+joint+consensus+recommendation+of+the+American+College+of+Medical+Genetics+and+Genomics+and+the+Association+for+Molecular+Pathology&#x00026;journal=Genet+Med+Off+J+Am+Coll+Med+Genet&#x00026;volume=17&#x00026;pages=405-24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref32\" id=\"ref32\">\u003C/a>32. Kanehisa, M, Sato, Y, Kawashima, M, Furumichi, M, and Tanabe, M. KEGG as a reference resource for gene and protein annotation. \u003Ci>Nucleic Acids Res\u003C/i>. (2016) 44:D457&#x2013;62. doi: 10.1093/nar/gkv1070\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1093/nar/gkv1070\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Kanehisa&#x00026;author=Y+Sato&#x00026;author=M+Kawashima&#x00026;author=M+Furumichi&#x00026;author=M+Tanabe&#x00026;publication_year=2016&#x00026;title=KEGG+as+a+reference+resource+for+gene+and+protein+annotation&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=44&#x00026;pages=D457-62\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref33\" id=\"ref33\">\u003C/a>33. Jassal, B, Matthews, L, Viteri, G, Gong, C, Lorente, P, Fabregat, A, et al. The reactome pathway knowledgebase. \u003Ci>Nucleic Acids Res\u003C/i>. (2020) 48:D498&#x2013;503. doi: 10.1093/nar/gkz1031 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31691815\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkz1031\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=B+Jassal&#x00026;author=L+Matthews&#x00026;author=G+Viteri&#x00026;author=C+Gong&#x00026;author=P+Lorente&#x00026;author=A+Fabregat&#x00026;publication_year=2020&#x00026;title=The+reactome+pathway+knowledgebase&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=48&#x00026;pages=D498-503\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref34\" id=\"ref34\">\u003C/a>34. K&#x000F6;hler, S, Gargano, M, Matentzoglu, N, Carmody, LC, Lewis-Smith, D, Vasilevsky, NA, et al. The human phenotype ontology in 2021. \u003Ci>Nucleic Acids Res\u003C/i>. (2021) 49:D1207&#x2013;17. doi: 10.1093/nar/gkaa1043 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33264411\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkaa1043\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+K&#x000F6;hler&#x00026;author=M+Gargano&#x00026;author=N+Matentzoglu&#x00026;author=LC+Carmody&#x00026;author=D+Lewis-Smith&#x00026;author=NA+Vasilevsky&#x00026;publication_year=2021&#x00026;title=The+human+phenotype+ontology+in+2021&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=49&#x00026;pages=D1207-17\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref35\" id=\"ref35\">\u003C/a>35. Gene Ontology Consortium. Gene ontology consortium: going forward. \u003Ci>Nucleic Acids Res\u003C/i>. (2015) 43:D1049&#x2013;56. doi: 10.1093/nar/gku1179 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25428369\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gku1179\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?publication_year=2015&#x00026;title=Gene+ontology+consortium:+going+forward&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=43&#x00026;pages=D1049-56\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref36\" id=\"ref36\">\u003C/a>36. Desvignes, J-P, Bartoli, M, Delague, V, Krahn, M, Miltgen, M, B&#x000E9;roud, C, et al. Var AFT: a variant annotation and filtration system for human next generation sequencing data. \u003Ci>Nucleic Acids Res\u003C/i>. (2018) 46:W545&#x2013;53. doi: 10.1093/nar/gky471 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29860484\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gky471\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J-P+Desvignes&#x00026;author=M+Bartoli&#x00026;author=V+Delague&#x00026;author=M+Krahn&#x00026;author=M+Miltgen&#x00026;author=C+B&#x000E9;roud&#x00026;publication_year=2018&#x00026;title=Var+AFT:+a+variant+annotation+and+filtration+system+for+human+next+generation+sequencing+data&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=46&#x00026;pages=W545-53\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref37\" id=\"ref37\">\u003C/a>37. Cingolani, P, Platts, A, Wang, LL, Coon, M, Nguyen, T, Wang, L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of \u003Ci>Drosophila melanogaster\u003C/i> strain w1118; iso-2; iso-3. \u003Ci>Fly (Austin)\u003C/i>. (2012) 6:80&#x2013;92. doi: 10.4161/fly.19695 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22728672\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4161/fly.19695\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Cingolani&#x00026;author=A+Platts&#x00026;author=LL+Wang&#x00026;author=M+Coon&#x00026;author=T+Nguyen&#x00026;author=L+Wang&#x00026;publication_year=2012&#x00026;title=A+program+for+annotating+and+predicting+the+effects+of+single+nucleotide+polymorphisms+SnpEff:+SNPs+in+the+genome+of+Drosophila+melanogaster+strain+w1118;+iso-2;+iso-3&#x00026;journal=Fly+(Austin)&#x00026;volume=6&#x00026;pages=80-92\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref38\" id=\"ref38\">\u003C/a>38. Park, J, Packard, EA, Levin, MG, Judy, RL, Damrauer, SM, Day, SM, et al. A genome-first approach to rare variants in hypertrophic cardiomyopathy genes MYBPC3 and MYH7 in a medical biobank. \u003Ci>Hum Mol Genet\u003C/i>. (2021) 31:827&#x2013;37. doi: 10.1093/hmg/ddab249\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1093/hmg/ddab249\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Park&#x00026;author=EA+Packard&#x00026;author=MG+Levin&#x00026;author=RL+Judy&#x00026;author=SM+Damrauer&#x00026;author=SM+Day&#x00026;publication_year=2021&#x00026;title=A+genome-first+approach+to+rare+variants+in+hypertrophic+cardiomyopathy+genes+MYBPC3+and+MYH7+in+a+medical+biobank&#x00026;journal=Hum+Mol+Genet&#x00026;volume=31&#x00026;pages=827-37\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref39\" id=\"ref39\">\u003C/a>39. Ingles, J, Goldstein, J, Thaxton, C, Caleshu, C, Corty, EW, Crowley, SB, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. \u003Ci>Circ Genomic Precis Med\u003C/i>. (2019) 12:e002460. doi: 10.1161/CIRCGEN.119.002460 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30681346\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCGEN.119.002460\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Ingles&#x00026;author=J+Goldstein&#x00026;author=C+Thaxton&#x00026;author=C+Caleshu&#x00026;author=EW+Corty&#x00026;author=SB+Crowley&#x00026;publication_year=2019&#x00026;title=Evaluating+the+clinical+validity+of+hypertrophic+cardiomyopathy+genes&#x00026;journal=Circ+Genomic+Precis+Med&#x00026;volume=12&#x00026;pages=e002460\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref40\" id=\"ref40\">\u003C/a>40. Andreeva, S, Chumakova, O, Karelkina, E, Lebedeva, V, Lubimtseva, T, Semenov, A, et al. Case report: two new cases of autosomal-recessive hypertrophic cardiomyopathy associated with TRIM63-compound heterozygous variant. \u003Ci>Front Genet\u003C/i>. (2022) 13:743472. doi: 10.3389/fgene.2022.743472 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35273634\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fgene.2022.743472\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Andreeva&#x00026;author=O+Chumakova&#x00026;author=E+Karelkina&#x00026;author=V+Lebedeva&#x00026;author=T+Lubimtseva&#x00026;author=A+Semenov&#x00026;publication_year=2022&#x00026;title=Case+report:+two+new+cases+of+autosomal-recessive+hypertrophic+cardiomyopathy+associated+with+TRIM63-compound+heterozygous+variant&#x00026;journal=Front+Genet&#x00026;volume=13&#x00026;pages=743472\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref41\" id=\"ref41\">\u003C/a>41. Salazar-Mendiguch&#x000ED;a, J, Ochoa, JP, Palomino-Doza, J, Dom&#x000ED;nguez, F, D&#x000ED;ez-L&#x000F3;pez, C, Akhtar, M, et al. Mutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy. \u003Ci>Heart\u003C/i>. (2020) 106:1342&#x2013;8. doi: 10.1136/heartjnl-2020-316913 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32451364\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/heartjnl-2020-316913\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Salazar-Mendiguch&#x000ED;a&#x00026;author=JP+Ochoa&#x00026;author=J+Palomino-Doza&#x00026;author=F+Dom&#x000ED;nguez&#x00026;author=C+D&#x000ED;ez-L&#x000F3;pez&#x00026;author=M+Akhtar&#x00026;publication_year=2020&#x00026;title=Mutations+in+TRIM63+cause+an+autosomal-recessive+form+of+hypertrophic+cardiomyopathy&#x00026;journal=Heart&#x00026;volume=106&#x00026;pages=1342-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref42\" id=\"ref42\">\u003C/a>42. Harper, AR, Goel, A, Grace, C, Thomson, KL, Petersen, SE, Xu, X, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. \u003Ci>Nat Genet\u003C/i>. (2021) 53:135&#x2013;42. doi: 10.1038/s41588-020-00764-0 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33495597\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41588-020-00764-0\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AR+Harper&#x00026;author=A+Goel&#x00026;author=C+Grace&#x00026;author=KL+Thomson&#x00026;author=SE+Petersen&#x00026;author=X+Xu&#x00026;publication_year=2021&#x00026;title=Common+genetic+variants+and+modifiable+risk+factors+underpin+hypertrophic+cardiomyopathy+susceptibility+and+expressivity&#x00026;journal=Nat+Genet&#x00026;volume=53&#x00026;pages=135-42\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref43\" id=\"ref43\">\u003C/a>43. Ochoa, JP, Sabater-Molina, M, Garc&#x000ED;a-Pinilla, JM, Mogensen, J, Restrepo-C&#x000F3;rdoba, A, Palomino-Doza, J, et al. Formin homology 2 domain containing 3 (FHOD3) is a genetic basis for hypertrophic cardiomyopathy. \u003Ci>J Am Coll Cardiol\u003C/i>. (2018) 72:2457&#x2013;67. doi: 10.1016/j.jacc.2018.10.001 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30442288\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2018.10.001\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JP+Ochoa&#x00026;author=M+Sabater-Molina&#x00026;author=JM+Garc&#x000ED;a-Pinilla&#x00026;author=J+Mogensen&#x00026;author=A+Restrepo-C&#x000F3;rdoba&#x00026;author=J+Palomino-Doza&#x00026;publication_year=2018&#x00026;title=Formin+homology+2+domain+containing+3+(FHOD3)+is+a+genetic+basis+for+hypertrophic+cardiomyopathy&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=72&#x00026;pages=2457-67\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref44\" id=\"ref44\">\u003C/a>44. Matsuyama, S, Kage, Y, Fujimoto, N, Ushijima, T, Tsuruda, T, Kitamura, K, et al. Interaction between cardiac myosin-binding protein C and formin Fhod 3. \u003Ci>Proc Natl Acad Sci USA\u003C/i>. (2018) 115:E4386&#x2013;95. doi: 10.1073/pnas.1716498115 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29686099\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1073/pnas.1716498115\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Matsuyama&#x00026;author=Y+Kage&#x00026;author=N+Fujimoto&#x00026;author=T+Ushijima&#x00026;author=T+Tsuruda&#x00026;author=K+Kitamura&#x00026;publication_year=2018&#x00026;title=Interaction+between+cardiac+myosin-binding+protein+C+and+formin+Fhod+3&#x00026;journal=Proc+Natl+Acad+Sci+USA&#x00026;volume=115&#x00026;pages=E4386-95\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref45\" id=\"ref45\">\u003C/a>45. Wooten, EC, Hebl, VB, Wolf, MJ, Greytak, SR, Orr, NM, Draper, I, et al. Formin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy. \u003Ci>Circ Cardiovasc Genet\u003C/i>. (2013) 6:10&#x2013;8. doi: 10.1161/CIRCGENETICS.112.965277 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23255317\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCGENETICS.112.965277\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=EC+Wooten&#x00026;author=VB+Hebl&#x00026;author=MJ+Wolf&#x00026;author=SR+Greytak&#x00026;author=NM+Orr&#x00026;author=I+Draper&#x00026;publication_year=2013&#x00026;title=Formin+homology+2+domain+containing+3+variants+associated+with+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Cardiovasc+Genet&#x00026;volume=6&#x00026;pages=10-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref46\" id=\"ref46\">\u003C/a>46. Chumakova, OS, and Baulina, NM. Advanced searching for hypertrophic cardiomyopathy heritability in real practice tomorrow. \u003Ci>Front Cardiovasc Med\u003C/i>. (2023) 10:1236539. doi: 10.3389/fcvm.2023.1236539 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/37583586\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fcvm.2023.1236539\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=OS+Chumakova&#x00026;author=NM+Baulina&#x00026;publication_year=2023&#x00026;title=Advanced+searching+for+hypertrophic+cardiomyopathy+heritability+in+real+practice+tomorrow&#x00026;journal=Front+Cardiovasc+Med&#x00026;volume=10&#x00026;pages=1236539\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref47\" id=\"ref47\">\u003C/a>47. Tadros, R, Zheng, SL, Grace, C, Jord&#x000E0;, P, Francis, C, Jurgens, SJ, et al. Large scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy. \u003Ci>med Rxiv\u003C/i>. [Preprint] (2023); 2023.01.28.23285147:44) 44. doi: 10.1093/eurheartj/ehad655.3197\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1093/eurheartj/ehad655.3197\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Tadros&#x00026;author=SL+Zheng&#x00026;author=C+Grace&#x00026;author=P+Jord&#x000E0;&#x00026;author=C+Francis&#x00026;author=SJ+Jurgens&#x00026;publication_year=2023&#x00026;title=Large+scale+genome-wide+association+analyses+identify+novel+genetic+loci+and+mechanisms+in+hypertrophic+cardiomyopathy&#x00026;journal=med+Rxiv&#x00026;volume=44&#x00026;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref48\" id=\"ref48\">\u003C/a>48. Josephs, KS, Roberts, AM, Theotokis, P, Walsh, R, Ostrowski, PJ, Edwards, M, et al. Beyond gene-disease validity: capturing structured data on inheritance, allelic-requirement, disease-relevant variant classes, and disease mechanism for inherited cardiac conditions. \u003Ci>Med Rxiv Prepr Serv Health Sci\u003C/i>. (2023) doi: 10.1186/s13073-023-01246-8\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1186/s13073-023-01246-8\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KS+Josephs&#x00026;author=AM+Roberts&#x00026;author=P+Theotokis&#x00026;author=R+Walsh&#x00026;author=PJ+Ostrowski&#x00026;author=M+Edwards&#x00026;publication_year=2023&#x00026;title=Beyond+gene-disease+validity:+capturing+structured+data+on+inheritance+allelic-requirement+disease-relevant+variant+classes+and+disease+mechanism+for+inherited+cardiac+conditions&#x00026;journal=Med+Rxiv+Prepr+Serv+Health+Sci&#x00026;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref49\" id=\"ref49\">\u003C/a>49. Zhang, XL, De, S, McIntosh, LP, and Paetzel, M. Structural characterization of the C3 domain of cardiac myosin binding protein C and its hypertrophic cardiomyopathy-related R502W mutant. \u003Ci>Biochemistry\u003C/i>. (2014) 53:5332&#x2013;42. doi: 10.1021/bi500784g\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1021/bi500784g\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=XL+Zhang&#x00026;author=S+De&#x00026;author=LP+McIntosh&#x00026;author=M+Paetzel&#x00026;publication_year=2014&#x00026;title=Structural+characterization+of+the+C3+domain+of+cardiac+myosin+binding+protein+C+and+its+hypertrophic+cardiomyopathy-related+R502W+mutant&#x00026;journal=Biochemistry&#x00026;volume=53&#x00026;pages=5332-42\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref50\" id=\"ref50\">\u003C/a>50. Saltzman, AJ, Mancini-DiNardo, D, Li, C, Chung, WK, Ho, CY, Hurst, S, et al. Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy. \u003Ci>Circ Res\u003C/i>. (2010) 106:1549&#x2013;52. doi: 10.1161/CIRCRESAHA.109.216291 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20378854\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCRESAHA.109.216291\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AJ+Saltzman&#x00026;author=D+Mancini-DiNardo&#x00026;author=C+Li&#x00026;author=WK+Chung&#x00026;author=CY+Ho&#x00026;author=S+Hurst&#x00026;publication_year=2010&#x00026;title=Short+communication:+the+cardiac+myosin+binding+protein+C+Arg502Trp+mutation:+a+common+cause+of+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Res&#x00026;volume=106&#x00026;pages=1549-52\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref51\" id=\"ref51\">\u003C/a>51. Walsh, R, Thomson, KL, Ware, JS, Funke, BH, Woodley, J, McGuire, KJ, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. \u003Ci>Genet Med\u003C/i>. (2017) 19:192&#x2013;203. doi: 10.1038/gim.2016.90 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27532257\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/gim.2016.90\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=KL+Thomson&#x00026;author=JS+Ware&#x00026;author=BH+Funke&#x00026;author=J+Woodley&#x00026;author=KJ+McGuire&#x00026;publication_year=2017&#x00026;title=Reassessment+of+Mendelian+gene+pathogenicity+using+7855+cardiomyopathy+cases+and+60706+reference+samples&#x00026;journal=Genet+Med&#x00026;volume=19&#x00026;pages=192-203\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref52\" id=\"ref52\">\u003C/a>52. Andersen, PS, Havndrup, O, Bundgaard, H, Moolman-Smook, JC, Larsen, LA, Mogensen, J, et al. Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and south African populations. \u003Ci>J Med Genet\u003C/i>. (2001) 38:43e&#x2013;443e. doi: 10.1136/jmg.38.12.e43 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11748309\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jmg.38.12.e43\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=PS+Andersen&#x00026;author=O+Havndrup&#x00026;author=H+Bundgaard&#x00026;author=JC+Moolman-Smook&#x00026;author=LA+Larsen&#x00026;author=J+Mogensen&#x00026;publication_year=2001&#x00026;title=Myosin+light+chain+mutations+in+familial+hypertrophic+cardiomyopathy:+phenotypic+presentation+and+frequency+in+Danish+and+south+African+populations&#x00026;journal=J+Med+Genet&#x00026;volume=38&#x00026;pages=43e-443e\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref53\" id=\"ref53\">\u003C/a>53. Marian, AJ. Molecular genetic basis of hypertrophic cardiomyopathy. \u003Ci>Circ Res\u003C/i>. (2021) 128:1533. doi: 10.1161/CIRCRESAHA.121.318346 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33983830\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCRESAHA.121.318346\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AJ+Marian&#x00026;publication_year=2021&#x00026;title=Molecular+genetic+basis+of+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Res&#x00026;volume=128&#x00026;pages=1533\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref54\" id=\"ref54\">\u003C/a>54. Mathew, J, Zahavich, L, Lafreniere-Roula, M, Wilson, J, George, K, Benson, L, et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. \u003Ci>Clin Genet\u003C/i>. (2018) 93:310&#x2013;9. doi: 10.1111/cge.13157 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29053178\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cge.13157\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Mathew&#x00026;author=L+Zahavich&#x00026;author=M+Lafreniere-Roula&#x00026;author=J+Wilson&#x00026;author=K+George&#x00026;author=L+Benson&#x00026;publication_year=2018&#x00026;title=Utility+of+genetics+for+risk+stratification+in+pediatric+hypertrophic+cardiomyopathy&#x00026;journal=Clin+Genet&#x00026;volume=93&#x00026;pages=310-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref55\" id=\"ref55\">\u003C/a>55. Pham, JH, Giudicessi, JR, Tweet, MS, Boucher, L, Newman, DB, and Geske, JB. Tale of two hearts: a TNNT2 hypertrophic cardiomyopathy case report. \u003Ci>Front Cardiovasc Med.\u003C/i> (2023) 10:1167256. doi: 10.3389/fcvm.2023.1167256 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/37180798\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fcvm.2023.1167256\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JH+Pham&#x00026;author=JR+Giudicessi&#x00026;author=MS+Tweet&#x00026;author=L+Boucher&#x00026;author=DB+Newman&#x00026;author=JB+Geske&#x00026;publication_year=2023&#x00026;title=Tale+of+two+hearts:+a+TNNT2+hypertrophic+cardiomyopathy+case+report&#x00026;journal=Front+Cardiovasc+Med.&#x00026;volume=10&#x00026;pages=1167256\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref56\" id=\"ref56\">\u003C/a>56. Allouba, M, Walsh, R, Afify, A, Hosny, M, Halawa, S, Galal, A, et al. Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy. \u003Ci>Eur Heart J\u003C/i>. (2023) 44:5146&#x2013;58. doi: 10.1093/eurheartj/ehad372\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1093/eurheartj/ehad372\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Allouba&#x00026;author=R+Walsh&#x00026;author=A+Afify&#x00026;author=M+Hosny&#x00026;author=S+Halawa&#x00026;author=A+Galal&#x00026;publication_year=2023&#x00026;title=Ethnicity+consanguinity+and+genetic+architecture+of+hypertrophic+cardiomyopathy&#x00026;journal=Eur+Heart+J&#x00026;volume=44&#x00026;pages=5146-58\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref57\" id=\"ref57\">\u003C/a>57. Kn&#x000F6;ll, R, Kostin, S, Klede, S, Savvatis, K, Klinge, L, Stehle, I, et al. A common MLP (muscle LIM protein) variant is associated with cardiomyopathy. \u003Ci>Circ Res\u003C/i>. (2010) 106:695&#x2013;704. doi: 10.1161/CIRCRESAHA.109.206243 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20044516\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCRESAHA.109.206243\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Kn&#x000F6;ll&#x00026;author=S+Kostin&#x00026;author=S+Klede&#x00026;author=K+Savvatis&#x00026;author=L+Klinge&#x00026;author=I+Stehle&#x00026;publication_year=2010&#x00026;title=A+common+MLP+(muscle+LIM+protein)+variant+is+associated+with+cardiomyopathy&#x00026;journal=Circ+Res&#x00026;volume=106&#x00026;pages=695-704\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref58\" id=\"ref58\">\u003C/a>58. Bagnall, RD, Molloy, LK, Kalman, JM, and Semsarian, C. Exome sequencing identifies a mutation in the ACTN2 gene in a family with idiopathic ventricular fibrillation, left ventricular noncompaction, and sudden death. \u003Ci>BMC Med Genet\u003C/i>. (2014) 15:99. doi: 10.1186/s12881-014-0099-0 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25224718\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s12881-014-0099-0\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RD+Bagnall&#x00026;author=LK+Molloy&#x00026;author=JM+Kalman&#x00026;author=C+Semsarian&#x00026;publication_year=2014&#x00026;title=Exome+sequencing+identifies+a+mutation+in+the+ACTN2+gene+in+a+family+with+idiopathic+ventricular+fibrillation+left+ventricular+noncompaction+and+sudden+death&#x00026;journal=BMC+Med+Genet&#x00026;volume=15&#x00026;pages=99\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref59\" id=\"ref59\">\u003C/a>59. Fan, L-L, Huang, H, Jin, J-Y, Li, J-J, Chen, Y-Q, and Xiang, R. Whole-exome sequencing identifies a novel mutation (p.L320R) of alpha-Actinin 2 in a Chinese family with dilated cardiomyopathy and ventricular tachycardia. \u003Ci>Cytogenet Genome Res\u003C/i>. (2019) 157:148&#x2013;52. doi: 10.1159/000496077\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1159/000496077\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L-L+Fan&#x00026;author=H+Huang&#x00026;author=J-Y+Jin&#x00026;author=J-J+Li&#x00026;author=Y-Q+Chen&#x00026;author=R+Xiang&#x00026;publication_year=2019&#x00026;title=Whole-exome+sequencing+identifies+a+novel+mutation+(p.L320R)+of+alpha-Actinin+2+in+a+Chinese+family+with+dilated+cardiomyopathy+and+ventricular+tachycardia&#x00026;journal=Cytogenet+Genome+Res&#x00026;volume=157&#x00026;pages=148-52\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref60\" id=\"ref60\">\u003C/a>60. Ranta-aho, J, Olive, M, Vandroux, M, Roticiani, G, Dominguez, C, Johari, M, et al. Mutation update for the ACTN2 gene. \u003Ci>Hum Mutat\u003C/i>. (2022) 43:1745&#x2013;56. doi: 10.1002/humu.24470 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/36116040\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.24470\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Ranta-aho&#x00026;author=M+Olive&#x00026;author=M+Vandroux&#x00026;author=G+Roticiani&#x00026;author=C+Dominguez&#x00026;author=M+Johari&#x00026;publication_year=2022&#x00026;title=Mutation+update+for+the+ACTN2+gene&#x00026;journal=Hum+Mutat&#x00026;volume=43&#x00026;pages=1745-56\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref61\" id=\"ref61\">\u003C/a>61. Kraoua, L, Jaouadi, H, Allouche, M, Achour, A, Kaouther, H, Ahmed, HB, et al. Molecular autopsy and clinical family screening in a case of sudden cardiac death reveals ACTN2 mutation related to hypertrophic/dilated cardiomyopathy and a novel LZTR1 variant associated with Noonan syndrome. \u003Ci>Mol Genet Genomic Med\u003C/i>. (2022) 10:e1954. doi: 10.1002/mgg3.1954\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1002/mgg3.1954\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Kraoua&#x00026;author=H+Jaouadi&#x00026;author=M+Allouche&#x00026;author=A+Achour&#x00026;author=H+Kaouther&#x00026;author=HB+Ahmed&#x00026;publication_year=2022&#x00026;title=Molecular+autopsy+and+clinical+family+screening+in+a+case+of+sudden+cardiac+death+reveals+ACTN2+mutation+related+to+hypertrophic/dilated+cardiomyopathy+and+a+novel+LZTR1+variant+associated+with+Noonan+syndrome&#x00026;journal=Mol+Genet+Genomic+Med&#x00026;volume=10&#x00026;pages=e1954\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref62\" id=\"ref62\">\u003C/a>62. Girolami, F, Iascone, M, Tomberli, B, Bardi, S, Benelli, M, Marseglia, G, et al. Novel &#x03B1;-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. \u003Ci>Circ Cardiovasc Genet\u003C/i>. (2014) 7:741&#x2013;50. doi: 10.1161/CIRCGENETICS.113.000486 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25173926\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCGENETICS.113.000486\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F+Girolami&#x00026;author=M+Iascone&#x00026;author=B+Tomberli&#x00026;author=S+Bardi&#x00026;author=M+Benelli&#x00026;author=G+Marseglia&#x00026;publication_year=2014&#x00026;title=Novel+&#x03B1;-actinin+2+variant+associated+with+familial+hypertrophic+cardiomyopathy+and+juvenile+atrial+arrhythmias:+a+massively+parallel+sequencing+study&#x00026;journal=Circ+Cardiovasc+Genet&#x00026;volume=7&#x00026;pages=741-50\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref63\" id=\"ref63\">\u003C/a>63. Arvanitis, M, Tampakakis, E, Zhang, Y, Wang, W, and Auton, A23andMe Research Team, et al. Genome-wide association and multi-omic analyses reveal ACTN2 as a gene linked to heart failure. \u003Ci>Nat Commun\u003C/i>. (2020) 11:1122. doi: 10.1038/s41467-020-14843-7 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32111823\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41467-020-14843-7\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Arvanitis&#x00026;author=E+Tampakakis&#x00026;author=Y+Zhang&#x00026;author=W+Wang&#x00026;author=A+Auton&#x00026;publication_year=2020&#x00026;title=Genome-wide+association+and+multi-omic+analyses+reveal+ACTN2+as+a+gene+linked+to+heart+failure&#x00026;journal=Nat+Commun&#x00026;volume=11&#x00026;pages=1122\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref64\" id=\"ref64\">\u003C/a>64. Chiu, C, Bagnall, RD, Ingles, J, Yeates, L, Kennerson, M, Donald, JA, et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. \u003Ci>J Am Coll Cardiol\u003C/i>. (2010) 55:1127&#x2013;35. doi: 10.1016/j.jacc.2009.11.016 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20022194\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2009.11.016\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Chiu&#x00026;author=RD+Bagnall&#x00026;author=J+Ingles&#x00026;author=L+Yeates&#x00026;author=M+Kennerson&#x00026;author=JA+Donald&#x00026;publication_year=2010&#x00026;title=Mutations+in+alpha-actinin-2+cause+hypertrophic+cardiomyopathy:+a+genome-wide+analysis&#x00026;journal=J+Am+Coll+Cardiol&#x00026;volume=55&#x00026;pages=1127-35\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref65\" id=\"ref65\">\u003C/a>65. Agarwal, R, Wakimoto, H, Paulo, JA, Zhang, Q, Reichart, D, Toepfer, C, et al. Pathogenesis of cardiomyopathy caused by variants in ALPK3, an essential Pseudokinase in the cardiomyocyte nucleus and sarcomere. \u003Ci>Circulation\u003C/i>. (2022) 146:1674&#x2013;93. doi: 10.1161/CIRCULATIONAHA.122.059688 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/36321451\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCULATIONAHA.122.059688\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Agarwal&#x00026;author=H+Wakimoto&#x00026;author=JA+Paulo&#x00026;author=Q+Zhang&#x00026;author=D+Reichart&#x00026;author=C+Toepfer&#x00026;publication_year=2022&#x00026;title=Pathogenesis+of+cardiomyopathy+caused+by+variants+in+ALPK3+an+essential+Pseudokinase+in+the+cardiomyocyte+nucleus+and+sarcomere&#x00026;journal=Circulation&#x00026;volume=146&#x00026;pages=1674-93\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref66\" id=\"ref66\">\u003C/a>66. &#x000C7;a&#x011F;layan, AO, Sezer, RG, Kaymak&#x000E7;alan, H, Ulgen, E, Yavuz, T, Baranoski, JF, et al. ALPK3 gene mutation in a patient with congenital cardiomyopathy and dysmorphic features. \u003Ci>Cold Spring Harb Mol Case Stud\u003C/i>. (2017) 3:a001859. doi: 10.1101/mcs.a001859\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1101/mcs.a001859\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AO+&#x000C7;a&#x011F;layan&#x00026;author=RG+Sezer&#x00026;author=H+Kaymak&#x000E7;alan&#x00026;author=E+Ulgen&#x00026;author=T+Yavuz&#x00026;author=JF+Baranoski&#x00026;publication_year=2017&#x00026;title=ALPK3+gene+mutation+in+a+patient+with+congenital+cardiomyopathy+and+dysmorphic+features&#x00026;journal=Cold+Spring+Harb+Mol+Case+Stud&#x00026;volume=3&#x00026;pages=a001859\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref67\" id=\"ref67\">\u003C/a>67. Jaouadi, H, Kraoua, L, Chaker, L, Atkinson, A, Delague, V, Levy, N, et al. Novel ALPK3 mutation in a Tunisian patient with pediatric cardiomyopathy and facio-thoraco-skeletal features. \u003Ci>J Hum Genet\u003C/i>. (2018) 63:1077&#x2013;82. doi: 10.1038/s10038-018-0492-1 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30046096\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s10038-018-0492-1\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Jaouadi&#x00026;author=L+Kraoua&#x00026;author=L+Chaker&#x00026;author=A+Atkinson&#x00026;author=V+Delague&#x00026;author=N+Levy&#x00026;publication_year=2018&#x00026;title=Novel+ALPK3+mutation+in+a+Tunisian+patient+with+pediatric+cardiomyopathy+and+facio-thoraco-skeletal+features&#x00026;journal=J+Hum+Genet&#x00026;volume=63&#x00026;pages=1077-82\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref68\" id=\"ref68\">\u003C/a>68. Lopes, LR, Garcia-Hern&#x000E1;ndez, S, Lorenzini, M, Futema, M, Chumakova, O, Zateyshchikov, D, et al. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. \u003Ci>Eur Heart J\u003C/i>. (2021) 42:3063&#x2013;73. doi: 10.1093/eurheartj/ehab424 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34263907\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/eurheartj/ehab424\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=LR+Lopes&#x00026;author=S+Garcia-Hern&#x000E1;ndez&#x00026;author=M+Lorenzini&#x00026;author=M+Futema&#x00026;author=O+Chumakova&#x00026;author=D+Zateyshchikov&#x00026;publication_year=2021&#x00026;title=Alpha-protein+kinase+3+(ALPK3)+truncating+variants+are+a+cause+of+autosomal+dominant+hypertrophic+cardiomyopathy&#x00026;journal=Eur+Heart+J&#x00026;volume=42&#x00026;pages=3063-73\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref69\" id=\"ref69\">\u003C/a>69. Walsh, R, and Bezzina, CR. ALPK3: a full spectrum cardiomyopathy gene? \u003Ci>Eur Heart J\u003C/i>. (2021) 42:3074&#x2013;7. doi: 10.1093/eurheartj/ehab415 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34263911\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/eurheartj/ehab415\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Walsh&#x00026;author=CR+Bezzina&#x00026;publication_year=2021&#x00026;title=ALPK3:+a+full+spectrum+cardiomyopathy+gene?&#x00026;journal=Eur+Heart+J&#x00026;volume=42&#x00026;pages=3074-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref70\" id=\"ref70\">\u003C/a>70. Dai, J, Li, K, Huang, M, Sun, Y, Liu, H, Li, Z, et al. The involvement of ALPK3 in hypertrophic cardiomyopathy in East Asia. \u003Ci>Front Med\u003C/i>. (2022) 9:915649. doi: 10.3389/fmed.2022.915649 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35783621\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fmed.2022.915649\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Dai&#x00026;author=K+Li&#x00026;author=M+Huang&#x00026;author=Y+Sun&#x00026;author=H+Liu&#x00026;author=Z+Li&#x00026;publication_year=2022&#x00026;title=The+involvement+of+ALPK3+in+hypertrophic+cardiomyopathy+in+East+Asia&#x00026;journal=Front+Med&#x00026;volume=9&#x00026;pages=915649\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref71\" id=\"ref71\">\u003C/a>71. Su, M, Wang, J, Kang, L, Wang, Y, Zou, Y, Feng, X, et al. Rare variants in genes encoding MuRF1 and MuRF2 are modifiers of hypertrophic cardiomyopathy. \u003Ci>Int J Mol Sci\u003C/i>. (2014) 15:9302&#x2013;13. doi: 10.3390/ijms15069302 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24865491\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/ijms15069302\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Su&#x00026;author=J+Wang&#x00026;author=L+Kang&#x00026;author=Y+Wang&#x00026;author=Y+Zou&#x00026;author=X+Feng&#x00026;publication_year=2014&#x00026;title=Rare+variants+in+genes+encoding+MuRF1+and+MuRF2+are+modifiers+of+hypertrophic+cardiomyopathy&#x00026;journal=Int+J+Mol+Sci&#x00026;volume=15&#x00026;pages=9302-13\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref72\" id=\"ref72\">\u003C/a>72. Chen, SN, Czernuszewicz, G, Tan, Y, Lombardi, R, Jin, J, Willerson, JT, et al. Human molecular genetic and functional studies identify TRIM63, encoding muscle RING finger protein 1, as a novel Gene for human hypertrophic cardiomyopathy. \u003Ci>Circ Res\u003C/i>. (2012) 111:907&#x2013;19. doi: 10.1161/CIRCRESAHA.112.270207 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22821932\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCRESAHA.112.270207\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SN+Chen&#x00026;author=G+Czernuszewicz&#x00026;author=Y+Tan&#x00026;author=R+Lombardi&#x00026;author=J+Jin&#x00026;author=JT+Willerson&#x00026;publication_year=2012&#x00026;title=Human+molecular+genetic+and+functional+studies+identify+TRIM63+encoding+muscle+RING+finger+protein+1+as+a+novel+Gene+for+human+hypertrophic+cardiomyopathy&#x00026;journal=Circ+Res&#x00026;volume=111&#x00026;pages=907-19\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref73\" id=\"ref73\">\u003C/a>73. Smith, TC, Fridy, PC, Li, Y, Basil, S, Arjun, S, Friesen, RM, et al. Supervillin binding to myosin II and synergism with anillin are required for cytokinesis. \u003Ci>Mol Biol Cell\u003C/i>. (2013) 24:3603&#x2013;19. doi: 10.1091/mbc.e12-10-0714 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24088567\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1091/mbc.e12-10-0714\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TC+Smith&#x00026;author=PC+Fridy&#x00026;author=Y+Li&#x00026;author=S+Basil&#x00026;author=S+Arjun&#x00026;author=RM+Friesen&#x00026;publication_year=2013&#x00026;title=Supervillin+binding+to+myosin+II+and+synergism+with+anillin+are+required+for+cytokinesis&#x00026;journal=Mol+Biol+Cell&#x00026;volume=24&#x00026;pages=3603-19\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref74\" id=\"ref74\">\u003C/a>74. Pope, RK, Pestonjamasp, KN, Smith, KP, Wulfkuhle, JD, Strassel, CP, Lawrence, JB, et al. Cloning, characterization, and chromosomal localization of human superillin (SVIL). \u003Ci>Genomics\u003C/i>. (1998) 52:342&#x2013;51. doi: 10.1006/geno.1998.5466 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/9867483\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1006/geno.1998.5466\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RK+Pope&#x00026;author=KN+Pestonjamasp&#x00026;author=KP+Smith&#x00026;author=JD+Wulfkuhle&#x00026;author=CP+Strassel&#x00026;author=JB+Lawrence&#x00026;publication_year=1998&#x00026;title=Cloning+characterization+and+chromosomal+localization+of+human+superillin+(SVIL)&#x00026;journal=Genomics&#x00026;volume=52&#x00026;pages=342-51\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref75\" id=\"ref75\">\u003C/a>75. Hedberg-Oldfors, C, Meyer, R, Nolte, K, Abdul Rahim, Y, Lindberg, C, Karason, K, et al. Loss of supervillin causes myopathy with myofibrillar disorganization and autophagic vacuoles. \u003Ci>Brain J Neurol\u003C/i>. (2020) 143:2406&#x2013;20. doi: 10.1093/brain/awaa206 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32779703\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/brain/awaa206\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Hedberg-Oldfors&#x00026;author=R+Meyer&#x00026;author=K+Nolte&#x00026;author=Y+Abdul+Rahim&#x00026;author=C+Lindberg&#x00026;author=K+Karason&#x00026;publication_year=2020&#x00026;title=Loss+of+supervillin+causes+myopathy+with+myofibrillar+disorganization+and+autophagic+vacuoles&#x00026;journal=Brain+J+Neurol&#x00026;volume=143&#x00026;pages=2406-20\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref76\" id=\"ref76\">\u003C/a>76. Olivotto, I, Girolami, F, Ackerman, MJ, Nistri, S, Bos, JM, Zachara, E, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. \u003Ci>Mayo Clin Proc\u003C/i>. (2008) 83:630&#x2013;8. doi: 10.1016/S0025-6196(11)60890-2 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18533079\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/S0025-6196(11)60890-2\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I+Olivotto&#x00026;author=F+Girolami&#x00026;author=MJ+Ackerman&#x00026;author=S+Nistri&#x00026;author=JM+Bos&#x00026;author=E+Zachara&#x00026;publication_year=2008&#x00026;title=Myofilament+protein+gene+mutation+screening+and+outcome+of+patients+with+hypertrophic+cardiomyopathy&#x00026;journal=Mayo+Clin+Proc&#x00026;volume=83&#x00026;pages=630-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref77\" id=\"ref77\">\u003C/a>77. Canepa, M, Fumagalli, C, Tini, G, Vincent-Tompkins, J, Day, SM, Ashley, EA, et al. Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: an analysis of the international Sarcomeric human cardiomyopathy registry. \u003Ci>Circ Heart Fail\u003C/i>. (2020) 13:e007230. doi: 10.1161/CIRCHEARTFAILURE.120.007230 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32894986\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCHEARTFAILURE.120.007230\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Canepa&#x00026;author=C+Fumagalli&#x00026;author=G+Tini&#x00026;author=J+Vincent-Tompkins&#x00026;author=SM+Day&#x00026;author=EA+Ashley&#x00026;publication_year=2020&#x00026;title=Temporal+trend+of+age+at+diagnosis+in+hypertrophic+cardiomyopathy:+an+analysis+of+the+international+Sarcomeric+human+cardiomyopathy+registry&#x00026;journal=Circ+Heart+Fail&#x00026;volume=13&#x00026;pages=e007230\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"ref78\" id=\"ref78\">\u003C/a>78. Marstrand, P, Han, L, Day, SM, Olivotto, I, Ashley, EA, Michels, M, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry. \u003Ci>Circulation\u003C/i>. (2020) 141:1371&#x2013;83. doi: 10.1161/CIRCULATIONAHA.119.044366 \u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32228044\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCULATIONAHA.119.044366\" target=\"_blank\">Crossref Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Marstrand&#x00026;author=L+Han&#x00026;author=SM+Day&#x00026;author=I+Olivotto&#x00026;author=EA+Ashley&#x00026;author=M+Michels&#x00026;publication_year=2020&#x00026;title=Hypertrophic+cardiomyopathy+with+left+ventricular+systolic+dysfunction:+insights+from+the+SHaRe+registry&#x00026;journal=Circulation&#x00026;volume=141&#x00026;pages=1371-83\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\n\u003C/div> \u003Cdiv class=\"thinLineM20\">\u003C/div> \u003Cdiv class=\"AbstractSummary\">\n\u003Cp>\u003Cspan>Keywords:\u003C/span> HCM, exome reanalysis, sarcomeric genes, non-sarcomeric genes, novel-associated genes, FHOD3, TRIM63, SVIL\u003C/p>\n\u003Cp>\u003Cspan>Citation:\u003C/span> Jaouadi H, Morel V, Martel H, Lindenbaum P, Lamy de la Chapelle L, Herbane M, Lucas C, Magdinier F, Habib G, Schott J-J, Zaffran S and Nguyen K (2024) Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5&#x2009;years after the initial analysis. \u003Ci>Front. Med\u003C/i>. 11:1480947. doi: 10.3389/fmed.2024.1480947\u003C/p>\n\u003Cp class=\"timestamps\">\u003Cspan>Received:\u003C/span> 14 August 2024; \u003Cspan>Accepted:\u003C/span> 09 October 2024;\u003Cbr> \u003Cspan>Published:\u003C/span> 31 October 2024.\u003C/p> \u003Cdiv>\n\u003Cp>Edited by:\u003C/p> \u003Ca href=\"https://loop.frontiersin.org/people/1570574/overview\">Simone Grassi\u003C/a>, University of Florence, Italy\u003C/div> \u003Cdiv>\n\u003Cp>Reviewed by:\u003C/p> \u003Ca href=\"https://loop.frontiersin.org/people/978038/overview\">Lilei Zhang\u003C/a>, Baylor College of Medicine, United States\u003Cbr> \u003Ca href=\"https://loop.frontiersin.org/people/557735/overview\">Oscar Campuzano\u003C/a>, University of Girona, Spain\u003Cbr> \u003Ca href=\"https://loop.frontiersin.org/people/2836618/overview\">Andrea Costantino\u003C/a>, Careggi University Hospital, Italy\u003C/div>\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x000A9; 2024 Jaouadi, Morel, Martel, Lindenbaum, Lamy de la Chapelle, Herbane, Lucas, Magdinier, Habib, Schott, Zaffran and Nguyen. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\n\u003Cp>\u003Cspan>&#x0002A;Correspondence:\u003C/span> Hager Jaouadi, \u003Ca id=\"encmail\">aGFqZXIuamFvdWFkaUB1bml2LWFtdS5mcg==\u003C/a>; St&#x000E9;phane Zaffran, \u003Ca id=\"encmail\">c3RlcGhhbmUuemFmZnJhbkB1bml2LWFtdS5mcg==\u003C/a>\u003C/p>\n\u003Cp>\u003Cspan>\u003Csup>&#x2020;\u003C/sup>\u003C/span>These authors have contributed equally to this work\u003C/p> \u003Cdiv class=\"clear\">\u003C/div> \u003C/div>","\u003Cul class=\"flyoutJournal\"> \u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h3\">Methods\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h6\">Data availability statement\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h7\">Ethics statement\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h8\">Author contributions\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h9\">Funding\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h10\">Conflict of interest\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h11\">Publisher&#x2019;s note\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h12\">Supplementary material\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h13\">Footnotes\u003C/a>\u003C/li> \u003Cli>\u003Ca href=\"#h14\">References\u003C/a>\u003C/li> \u003C/ul>",[694,699,705,708,714],{"name":695,"fileServerPackageEntryId":19,"fileServerId":696,"fileServerVersionNumber":671,"type":697},"EPUB.epub","1480947/epub",{"code":698,"name":698},"EPUB",{"name":700,"fileServerPackageEntryId":701,"fileServerId":702,"fileServerVersionNumber":671,"type":703},"fmed-11-1480947.pdf","fmed-11-1480947-r1/fmed-11-1480947.pdf","1480947/pubmed-zip",{"code":704,"name":704},"PDF",{"name":700,"fileServerPackageEntryId":19,"fileServerId":706,"fileServerVersionNumber":671,"type":707},"1480947/publishers-proof/pdf",{"code":704,"name":704},{"name":709,"fileServerPackageEntryId":710,"fileServerId":702,"fileServerVersionNumber":671,"type":711},"fmed-11-1480947.xml","fmed-11-1480947-r1/fmed-11-1480947.xml",{"code":712,"name":713},"NLM_XML","XML",{"name":715,"fileServerPackageEntryId":19,"fileServerId":716,"fileServerVersionNumber":374,"type":717},"Provisional PDF.pdf","1480947/provisional-pdf",{"code":704,"name":704},"v3",{"title":720,"link":721,"meta":725,"script":866},"Frontiers | Exome sequencing data reanalysis of 200 hypertrophic cardiomyopathy patients: the HYPERGEN French cohort 5â€‰years after the initial analysis",[722],{"rel":723,"href":724},"canonical","https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/full",[726,729,732,734,737,741,744,748,751,754,757,759,761,763,765,767,770,773,775,778,780,782,785,788,791,794,797,801,805,808,811,814,817,820,823,826,828,831,833,836,838,841,843,846,848,851,853,856,858,861,863],{"hid":727,"property":727,"name":727,"content":728},"description","Background: Approximately half of hypertrophic cardiomyopathy (HCM) patients lack a precise genetic diagnosis. The likelihood of identifying clinically relev...",{"hid":730,"property":730,"name":731,"content":720},"og:title","title",{"hid":733,"property":733,"name":727,"content":728},"og:description",{"hid":735,"name":735,"content":736},"keywords","HCM,Exome reanalysis,Sarcomeric Genes,non-sarcomeric genes,novelassociated genes,FHOD3,trim63,SVIL",{"hid":738,"property":738,"name":739,"content":740},"og:site_name","site_name","Frontiers",{"hid":742,"property":742,"name":367,"content":743},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1480947/fmed-11-1480947-HTML-r1/image_m/fmed-11-1480947-g001.jpg",{"hid":745,"property":745,"name":746,"content":747},"og:type","type","article",{"hid":749,"property":749,"name":750,"content":724},"og:url","url",{"hid":752,"name":752,"content":753},"twitter:card","summary_large_image",{"hid":755,"name":755,"content":756},"citation_volume","11",{"hid":758,"name":758,"content":116},"citation_journal_title",{"hid":760,"name":760,"content":740},"citation_publisher",{"hid":762,"name":762,"content":667},"citation_journal_abbrev",{"hid":764,"name":764,"content":668},"citation_issn",{"hid":766,"name":766,"content":518},"citation_doi",{"hid":768,"name":768,"content":769},"citation_firstpage","1480947",{"hid":771,"name":771,"content":772},"citation_language","English",{"hid":774,"name":774,"content":519},"citation_title",{"hid":776,"name":776,"content":777},"citation_keywords","HCM; Exome reanalysis; Sarcomeric Genes; non-sarcomeric genes; novelassociated genes; FHOD3; trim63; SVIL",{"hid":779,"name":779,"content":524},"citation_abstract",{"hid":781,"name":781,"content":532},"citation_article_type",{"hid":783,"name":783,"content":784},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/pdf",{"hid":786,"name":786,"content":787},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1480947/xml",{"hid":789,"name":789,"content":790},"citation_fulltext_world_readable","yes",{"hid":792,"name":792,"content":793},"citation_online_date","2024/10/09",{"hid":795,"name":795,"content":796},"citation_publication_date","2024/10/31",{"hid":798,"name":799,"content":800},"citation_author_0","citation_author","Jaouadi, Hager ",{"hid":802,"name":803,"content":804},"citation_author_institution_0","citation_author_institution","Aix Marseille UniversitÃ©, INSERM, Marseille Medical Genetics (MMG), U1251, France",{"hid":806,"name":799,"content":807},"citation_author_1","Morel, Victor ",{"hid":809,"name":803,"content":810},"citation_author_institution_1","Department of Medical Genetics, La Timone Hospital, AP-HM, La Timone Childrenâ€™s Hospital, France",{"hid":812,"name":799,"content":813},"citation_author_2","Martel, Helene ",{"hid":815,"name":803,"content":816},"citation_author_institution_2","Department of Cardiology, La Timone Hospital, AP-HM, France",{"hid":818,"name":799,"content":819},"citation_author_3","Lindenbaum, Pierre ",{"hid":821,"name":803,"content":822},"citation_author_institution_3","Nantes UniversitÃ©, CHU Nantes, CNRS, INSERM, lâ€™institut du Thorax, France",{"hid":824,"name":799,"content":825},"citation_author_4","Lamy de la Chapelle, Lorcan ",{"hid":827,"name":803,"content":804},"citation_author_institution_4",{"hid":829,"name":799,"content":830},"citation_author_5","Herbane, Marine ",{"hid":832,"name":803,"content":804},"citation_author_institution_5",{"hid":834,"name":799,"content":835},"citation_author_6","Lucas, Claire ",{"hid":837,"name":803,"content":816},"citation_author_institution_6",{"hid":839,"name":799,"content":840},"citation_author_7","Magdinier, FrÃ©dÃ©rique ",{"hid":842,"name":803,"content":804},"citation_author_institution_7",{"hid":844,"name":799,"content":845},"citation_author_8","Habib, Gilbert ",{"hid":847,"name":803,"content":816},"citation_author_institution_8",{"hid":849,"name":799,"content":850},"citation_author_9","Schott, Jean-Jacques ",{"hid":852,"name":803,"content":822},"citation_author_institution_9",{"hid":854,"name":799,"content":855},"citation_author_10","Zaffran, StÃ©phane ",{"hid":857,"name":803,"content":804},"citation_author_institution_10",{"hid":859,"name":799,"content":860},"citation_author_11","Nguyen, Karine ",{"hid":862,"name":803,"content":804},"citation_author_institution_11",{"hid":864,"name":864,"content":865},"dc.identifier","doi:10.3389/fmed.2024.1480947",[867,870,872,874,876],{"src":868,"body":13,"type":869,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":871,"body":13,"type":869,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":873,"body":13,"type":869,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":875,"body":13,"type":869,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fmed.2024.1480947?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":877,"body":13,"type":869,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":879,"articleHubArticlesList":880,"canJournalHasArticleHub":351,"articleDoiList":881},{},[],[],{"title":19,"image":-1,"breadcrumbs":883,"linksCollection":884,"metricsCollection":886},[],{"total":371,"items":885},[],{"total":371,"items":887},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fmed.2024.1480947?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>